


**Funding Opportunities Monthly Edition
July 2020 Due Dates**

Introduction

This funding opportunity packet contains information on funding opportunities with deadlines in July 2020. The opportunities are organized in the following order:

1. National Institutes of Health (NIH)
2. National Science Foundation (NSF)
3. Other Federal
4. Non Federal

Use the bookmarks to navigate to each section.



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
082323	Provocative Questions (PQs) in Multiple Myeloma Disparities Research (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-280	15-Jul-2020	275,000 USD
	Contact Name	Amy Kennedy, Ph.D., M.P.H.			
	Contact Telephone	240-781-3335			
	Contact Email	amy.kennedy@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Jul-2020 , 15-Nov-2020			
	Synopsis	<p>Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites R21 applications for exploratory/developmental research projects designed to solve specific problems and paradoxes in multiple myeloma (MM) and disparities research identified as the NCI Multiple Myeloma Disparities Provocative Questions (MMD PQs). These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in multiple myeloma research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of multiple myeloma and disparities research that are deemed important but have not received sufficient attention. The FOA includes six Multiple Myeloma PQs that represent diverse fields relevant to multiple myeloma disparities research, but all are framed to inspire interested scientists to conceive new approaches and/or feasible solutions. Each research project (application) proposed in response to this FOA must be focused on addressing one particular research problem defined by one specific MMD PQ selected from the list. Projects proposed to address specific MMD PQs may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. Transdisciplinary projects are encouraged as long as they serve the scientific focus of the specific PQ chosen.</p>			
082322	Provocative Questions (PQs) in Multiple Myeloma Disparities Research (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-279	15-Jul-2020	Not Specified
	Contact Name	Amy Kennedy, Ph.D., M.P.H.			
	Contact Telephone	240-781-3335			
	Contact Email	amy.kennedy@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Jul-2020 , 15-Nov-2020			
	Synopsis	<p>Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites R01 applications for research projects designed to solve specific problems and paradoxes in multiple myeloma (MM) and disparities research identified as the NCI Multiple Myeloma Disparities Provocative Questions (MMD PQs). These problems and paradoxes</p>			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>phrased as questions are not intended to represent the full range of NCI's priorities in multiple myeloma research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of multiple myeloma and disparities research that are deemed important but have not received sufficient attention. The FOA includes six Multiple Myeloma PQs that represent diverse fields relevant to multiple myeloma disparities research, but all are framed to inspire interested scientists to conceive new approaches and/or feasible solutions. Each research project (application) proposed in response to this FOA must be focused on addressing one particular research problem defined by one specific MMD PQ selected from the list. Projects proposed to address specific MMD PQs may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. Transdisciplinary projects are encouraged as long as they serve the scientific focus of the specific PQ chosen.</p>				
082789	Research Projects in Cancer Systems Biology (U01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-287	10-Jul-2020	2,000,000 USD
	Contact Name	Dr. Shannon K. Hughes			
	Contact Telephone	240-276-6224			
	Contact Email	shannon.hughes@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	10-Jul-2020 , 17-Nov-2020 , 09-Jul-2021 , 15-Nov-2021			
	Synopsis	<p>The National Cancer Institute's (NCI) Cancer Systems Biology Consortium (CSBC) supports systems biology approaches to cancer research and includes U54 CSBC Research Centers, a U24 CSBC Coordinating Center and, through this FOA, well-defined, discrete and circumscribed U01 Research Projects. CSBC Research Projects are expected to involve interdisciplinary teams of scientists, engineers, and cancer researchers who collaborate to advance our understanding of the mechanisms underlying cancer initiation, progression, and treatment. CSBC Research Projects proposed in response to this Funding Opportunity Announcement must be based upon explicit integration of experimental biology and computational modeling to test and validate novel hypotheses in cancer research.</p>			
067443	Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3) Clinical Trials Not Allowed	National Cancer Institute/NIH/DHHS	PAR-18-310	10-Jul-2020	750,000 USD
	Contact Name	Tracy G. Lively, Ph.D.			
	Contact Telephone	240-276-5944			
	Contact Email	livelyt@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
085282	NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-356	19-Jun-2020	275,000 USD

Deadline Dates (ALL) | 10-Jul-2020 , 08-Oct-2020

Synopsis | National Cancer Institute (NCI) invites applications to accelerate the adoption and validation of molecular/cellular/imaging markers and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA also includes the validation of pharmacodynamic markers and markers of toxicity. Applicants to this FOA must have an assay(s) whose performance has been analytically validated in specimens similar to those for the intended clinical use of the assay(s) and marker(s). As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance durability of anti-cancer responses, multiple assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously. The UH3 mechanism supports the clinical validation of established assays for up to 3 years using specimens from retrospective or prospective clinical trials or studies. This FOA may be used to validate existing assays for use in other trials, observational studies, or population studies. Efforts to harmonize clinical laboratory tests, including investigation into the performance and reproducibility of assays across multiple clinical laboratories, are also appropriate for this funding opportunity. Projects proposed for this FOA will require multi-disciplinary interaction and collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientists. This FOA is not intended to support early-stage development of technology or the conduct of clinical trials, but is intended for validation of assays to the point where they could be integrated into clinical trials/studies as investigational assays. This FOA will use the NIH UH3 Exploratory/Developmental Cooperative Agreement Phase II award mechanism.

Contact Name | William C. Timmer, Ph.D

Contact Telephone | 240-276-6130

Contact Email | william.timmer@nih.gov

Sponsor Website

Program URL | [Link to program URL](#)

Deadline Dates (ALL) | 19-Jun-2020 , 20-Jul-2020 , 20-Oct-2020 , 18-Dec-2020 , 19-Feb-2021 , 19-Mar-2021 , 21-Jun-2021 , 20-Jul-2021 , 20-Oct-2021 , 17-Dec-2021 , 22-Feb-2022 , 21-Mar-2022 , 21-Jun-2022 , 20-Jul-2022

Synopsis | This Funding Opportunity Announcement (FOA) supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; innovative preclinical studies, including the use of new clinically-relevant models and imaging technologies, which could lead to first-in-human clinical trials, and therapeutic outcome disparities, including biomarkers or genetic/epigenetic signatures, among diverse racial/ethnic populations, including genetically engineered mouse models, patient-derived xenograft models, organoids, and cell lines. The R21 mechanism is intended to encourage

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (pre-clinical or clinical).			
085717	RFA-CA-19-042 -- Informatics Technology for Cancer Research Education Resource (UE5 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	RFA-CA-19-042	30-Jun-2020 [Optional][LOI/Pre-App]	3,750,000 USD
	Contact Name	Elizabeth Hsu, Ph.D., M.P.H.			
	Contact Telephone	240-276-5733			
	Contact Email	hsuel@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	30-Jun-2020 [Optional][LOI/Pre-App], 31-Jul-2020			
	Synopsis	This UE5 FOA is a part of the NCI's Informatics Technology for Cancer Research (ITCR) program (https://itcr.cancer.gov/). The UE5 awardee to be supported under this FOA will serve as an ITCR Education Resource for educational activities that will help their participants to enhance the use and usability of the informatics tools and other resources developed and supported by the ITCR program.			
079034	Physical Sciences-Oncology Network (PS-ON): Physical Sciences-Oncology Projects (PS-OP) (U01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-101	30-Jul-2020	2,499,995 USD
	Contact Name	Nastaran Z. Kuhn, Ph.D.			
	Contact Telephone	240-276-7610			
	Contact Email	nas.zahir@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	30-Jul-2020			
	Synopsis	This Funding Opportunity Announcement (FOA) invites U01 cooperative agreement applications for Physical Science-Oncology Projects (PS-OP). The goal of the Physical Sciences-Oncology Network (PS-ON) is to foster the convergence of physical sciences approaches and perspectives with cancer research to advance our understanding of cancer biology and oncology by forming transdisciplinary teams of physical scientists and cancer biologists/physician scientists. Examples of physical scientists may include engineers, physicists, mathematicians, chemists, and computer scientists. The PS-OPs, individually and as a collaborative Network along with other PS-OPs and the Physical Sciences-Oncology Centers (PS-OC), will			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		support transdisciplinary research that: (1) establishes a physical sciences perspective within the cancer research community; (2) facilitates team science and field convergence at the intersection of physical sciences and cancer research; and (3) collectively tests physical sciences-based experimental and theoretical concepts of cancer and promotes innovative solutions to address outstanding questions in cancer research.			
045115	Short-Term Scientist Exchange Program	National Cancer Institute/NIH/DHHS		01-Jul-2020	Not Specified
	Contact Name	Dr. Vidya Vedham			
	Contact Telephone	240-276-7272			
	Contact Email	NCICenterforGlobalHe@mail.nih.gov			
	Sponsor Website	Link to sponsor website			
	Program URL				
	Deadline Dates (ALL)	01-Jul-2020 , 01-Oct-2020			
	Synopsis	The Short-Term Scientist Exchange Program (STSEP) promotes collaborative research between researchers at the National Cancer Institute (NCI) and scientists from low-, middle-, and upper-middle income countries.			
087537	Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-20-074	10-Jul-2020	450,000 USD
	Contact Name	Sumana Dey, Ph.D.			
	Contact Telephone	240-276-5748			
	Contact Email	sumana.dey@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	10-Jul-2020 , 27-Oct-2020 , 26-Feb-2021 , 13-Jul-2021 , 26-Oct-2021 , 28-Feb-2022 , 11-Jul-2022 , 28-Oct-2022			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI R01 research projects. The applicants should propose projects that are expected to accelerate the pace of translation of NCI-supported methods/assays/technologies (referred to as "assays") to the clinic. Specifically, the focus of applications submitted in response to this FOA should be on the adaption and clinical validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") for cancer detection, diagnosis, prognosis, monitoring, and prediction of response in treatment, as well as markers for cancer prevention and control. Applications may support the acquisition of well-annotated specimens from NCI-supported or other clinical trials or observational cohorts/consortia for the purpose of clinical validation of the assay. Research projects proposed in response to this FOA encourage multi-disciplinary interaction among scientific investigators, assay developers, clinicians, statisticians, and			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		clinical laboratory staff. Clinical laboratory scientist(s) and statistical experts are highly encouraged to comprise integral parts of the application. This FOA is not intended to support early-stage development of technology or the conduct of clinical trials, but rather the adaption and validation of assays to the point where they could be integrated into clinical trials as investigational assays/tools/devices.			
077749	Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-18-947	09-Jul-2020	1,250,000 USD
	Contact Name	Abhi Rao, Ph.D.			
	Contact Telephone	240-276-5715			
	Contact Email	abhi.rao@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	09-Jul-2020 , 09-Nov-2020 , 15-Mar-2021 , 11-Jul-2021			
	Synopsis	This Funding Opportunity Announcement (FOA) will support extramural research to investigate and mitigate challenges facing clinical assay development and subsequent analytical validation due to preanalytical variability in tumor tissue biopsies, blood biospecimens utilized as “liquid biopsies, or other biospecimens as described in this FOA. Extramural research funded under this FOA may include investigations of preanalytical variability associated with the procurement and study of small biopsies (core biopsies, small excision samples), blood utilized for liquid biopsies, tissue swabs, tissue secretions, pleural and esophageal aspirates, feces, or bodily fluids like sweat, urine, CSF, breast milk and saliva. Investigator-designed experiments will explore how different biospecimen preanalytical conditions affect emerging and clinically relevant biomarkers quantified by a variety of testing platforms. The results from this research program will improve the understanding of how analytical quantification of clinically relevant biomarkers is affected by variation in biospecimen collection, processing, and storage procedures. The overall goal is to expedite biomarker clinical assay development through evidence-based standardization of biopsy handling practices.			
090144	RFA-CA-20-033 -- SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-CA-20-033	03-Jul-2020 [Optional][LOI/Pre-App]	4,000,000 USD
	Contact Name	Jonathan Franca-Koh, PhD, MBA			
	Contact Telephone	240-276-7622			
	Contact Email	francakohjc@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	03-Jul-2020 [Optional][LOI/Pre-App], 03-Aug-2020			
	Synopsis	<p>This Funding Opportunity Announcement (FOA) solicits Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support the next stage of development for cancer-relevant projects that were previously funded under SBIR or STTR Phase II awards from any Federal agency. The purpose of this FOA is to facilitate the transition of SBIR or STTR Phase II projects to the commercialization stage. This FOA is expected to promote partnerships between Federally-funded SBIR or STTR Phase II awardees and third-party investors and/or strategic partners to facilitate and accelerate the capital-intensive steps that are required to commercialize new products and services. Applicants must submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the Phase IIB Bridge Award project period. It is expected that the level of this independent third-party funding will be equal to or greater than the NCI funds being requested throughout the Phase IIB Bridge Award project period. Proposed projects may address preclinical and/or clinical stages of technology development. Clinical trials may be proposed as appropriate but are not required.</p>			
083856	RFA-OD-19-022 -- Secondary Analyses of Existing Datasets of Tobacco Use and Health (R21 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	RFA-OD-19-022	21-May-2020 [Optional][LOI/Pre-App]	275,000 USD
	Contact Name	Rachel Grana Mayne, PhD			
	Contact Telephone	240-276-5899			
	Contact Email	granar@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	21-May-2020 [Optional][LOI/Pre-App], 20-Jul-2020 , 07-Jan-2021 [Optional][LOI/Pre-App], 08-Mar-2021			
	Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to invite R21 applications proposing the innovative analysis of existing (publicly available) nationally representative U.S. cross-sectional and longitudinal data, to investigate novel scientific ideas and/or to generate new models, systems, tools, methods, or technologies that have the potential for significant impact on biomedical or biobehavioral research in areas relevant to the Food and Drug Administration (FDA) - Center for Tobacco Products (CTP). Other publicly available data sets would be considered depending on the analyses to be conducted; however, nationally representative analyses will receive priority. Applications not using nationally representative data sets will need to provide justification why the data set is unique, and why the research questions cannot be answered from a (publicly available) nationally representative data set. This FOA encourages the analyses of public use datasets that may inform tobacco regulatory actions in the United States (U.S.). The awards under this FOA will be administered by NIH using funds that have been made available through FDA-CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.</p>			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP).

067444	Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-18-317	10-Jul-2020	1,025,000 USD
--------	--	------------------------------------	------------	-------------	---------------

Contact Name | Tracy G. Lively, Ph.D.
Contact Telephone | 240-276-5944
Contact Email | livelyt@mail.nih.gov
Sponsor Website |
Program URL | [Link to program URL](#)
Deadline Dates (ALL) | 10-Jul-2020 , 08-Oct-2020

Synopsis

National Cancer Institute (NCI) invites applications to support the validation of molecular/cellular/imaging markers and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA also includes the validation of pharmacodynamic markers and markers of toxicity. Applicants should have assays that work on human samples and whose importance is well justified for development into clinical assays. As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance durability of anti-cancer responses, multiple assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously. The UH2 phase of this FOA supports analytical validation of assays for these markers that must be achieved within 2 years before assays may undergo clinical validation. The UH3 phase of this FOA supports clinical validation of established assays for up to 3 years using specimens from retrospective or prospective clinical trials or studies. This FOA may be used to validate existing assays for use in other cancer clinical trials, observational studies, or population studies. Efforts to harmonize clinical laboratory tests, including investigation into the performance and reproducibility of assays across multiple clinical laboratories, are also appropriate for this funding opportunity. Projects proposed for this FOA will require multi-disciplinary interaction and collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientists. This FOA is not intended to support early-stage development of technology or the conduct of clinical trials, but is intended for validation of assays to the point where they could be integrated into clinical trials/studies as investigational assays. Investigators responding to this FOA must address both UH2 and UH3 phases. This FOA will use the NIH UH2/UH3 Phase Innovation Awards Cooperative Agreement award mechanism.

086016	RFA-OD-19-028--Tobacco Regulatory Science (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-OD-19-028	18-May-2020 [Optional][LOI/Pre-App]	900,000 USD
--------	---	------------------------------------	---------------	-------------------------------------	-------------

Contact Name | Rachel Grana Mayne, PhD

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 240-276-5899</p> <p>Contact Email granar@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 18-May-2020 [Optional][LOI/Pre-App], 17-Jul-2020 , 15-Dec-2020 [Optional][LOI/Pre-App], 13-Feb-2021</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to invite R01 applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). The awards under this FOA will be administered by NIH using funds that have been made available through FDA CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.</p>				
081994	Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Aggressive Cancer (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-264	10-Jul-2020	Not Specified
	<p>Contact Name Sudhir Srivastava, Ph.D., MPH</p> <p>Contact Telephone 240-276-7028</p> <p>Contact Email svrivasts@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-Jul-2020 , 10-Dec-2020 , 09-Jul-2021 , 10-Dec-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) will support the development of state-of-the-art projects that include imaging, biomarkers, digital pathomic and other -omic integration strategies for improving current approaches for the earliest detection of premetastatic aggressive cancer as well as identifying precancerous lesions that will subsequently demonstrate an aggressive phenotype. This FOA specifically attempts to address and improve diagnostic uncertainty in clinical decisions in a technology agnostic manner by improving sensitivity and specificity of applied tests. N-dimensional co-registered, cross-correlated imaging results integrated with multiplexed biomarker data and digital pathomics using analytic strategies such as artificial intelligence and virtual reality visualization for improving discovery are encouraged. The projects supported by this FOA will collectively participate in the existing Consortium for Imaging and Biomarkers (CIB) Research Program. The goals of the CIB are to: (1) improve diagnostic performance by developing methodology for the early identification of lethal cancer versus non-lethal disease, (2) to minimize/better manage overdiagnosis and (3) to reduce false positives and false negatives.</p>				
081438	Basic and Translational Research on Adducts in Cancer Risk Identification	National Cancer	PAR-	02-Jul-2020	275,000 USD

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	and Prevention (R21 Clinical Trial Optional)	Institute/NIH/DHHS	19-252		
	Contact Name	Wendy Wang, Ph.D. M.Sc.			
	Contact Telephone	240-276-7117			
	Contact Email	wangw@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	02-Jul-2020 , 06-Nov-2020 , 08-Jul-2021 , 08-Nov-2021			
	Synopsis	<p>The overall objective of this Funding Opportunity Announcement (FOA) is to support innovative research on adducts to cellular macromolecules as indicators of exposures to endogenous and exogenous cancer risk factors relevant to exposures in human populations. The priority is on projects that will focus on adductomic approaches, i.e., address some aspects of the totality of adducts. The ultimate goal is to discover and characterize the utility of adductomic-based exposure indicators for cancer detection, cancer prevention, and/or assessing cancer risks. In well-justified cases, innovative studies using the adductomic approaches in the context of cancer etiology and/or gene-environment interaction research may also be appropriate. For projects intended for NIEHS support, the focus may be on innovative technology and method development.</p>			
081437	Basic and Translational Research on Adducts in Cancer Risk Identification and Prevention (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-251	02-Jul-2020	Not Specified
	Contact Name	Wendy Wang, Ph.D. M.Sc.			
	Contact Telephone	240-276-7117			
	Contact Email	wangw@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	02-Jul-2020 , 06-Nov-2020 , 08-Jul-2021 , 08-Nov-2021			
	Synopsis	<p>The overall objective of this Funding Opportunity Announcement (FOA) is to support innovative research on adducts to cellular macromolecules as indicators of exposures to endogenous and exogenous cancer risk factors relevant to exposures in human populations. The priority is on projects that will focus on adductomic approaches, i.e., address some aspects of the totality of adducts. The ultimate goal is to discover and characterize the utility of adductomic-based exposure indicators for cancer detection, cancer prevention, and/or assessing cancer risks. In well-justified cases, innovative studies using the adductomic approaches in the context of cancer etiology and/or gene-environment interaction research may also be appropriate. For projects intended for NIEHS support, the focus may be on innovative technology and method development.</p>			
092377	RFA-CA-20-030 -- Utilizing Cohort Studies to Address Health Outcomes in	National Cancer	RFA-	07-Jun-2020	Not

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Cancer Survivors (UG3/UH3 Clinical Trial Not Allowed)		Institute/NIH/DHHS	CA-20-030 [Optional][LOI/Pre-App]	Specified
	Contact Name	Joanne Elena, Ph.D., M.P.H.,			
	Contact Telephone	240-276-6818			
	Contact Email	elenajw@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Jun-2020 [Optional][LOI/Pre-App], 07-Jul-2020			
	Synopsis	<p>Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications to support research in new and innovative cohort studies that identify clinical, lifestyle, genomic, and other factors that affect health outcomes (e.g., morbidity, mortality, quality of life, physical, social, and psychological outcomes) in cancer survivors (i.e., from diagnosis to the end of life). This FOA intends to support research that requires the creation of a new prospective cohort study that addresses a gap in knowledge pertaining to the health of cancer survivors. Applications must identify the scientific gap that the study addresses, which may include emerging treatments, less common cancer sites, and/or understudied populations of cancer survivors with disparities. Sample size and proposed data collection must be driven by the scientific questions proposed and should include information from all the following five domains in order to cover the full extent of the cancer survivor experience: 1) disease characteristics (e.g., type, stage, tumor biomarkers), 2) individual survivor characteristics (e.g., comorbidities, socioeconomic status [SES], social connections, information seeking, access to care measures), 3) treatment, treatment-related effects, and follow-up care (e.g. dose, adverse events, palliative care), 4) behavioral and lifestyle factors (e.g., diet, physical activity, adherence) and 5) quality of life outcomes (health-related quality of life (HRQOL), patient symptom reports). These domains may represent exposures and/or outcomes, depending on the research questions, and should be measured at multiple timepoints, when appropriate. The UG3/UH3 mechanism has two phases: the UG3 Planning-Exploratory Phase focused on the recruitment of study participants and data collection/utilization, and the UH3 Implementation Phase focused on completing the research agenda. Milestones to be accomplished in the UG3 phase for transition to the UH3 phase should be proposed by the Principal Investigator(s) (PIs), which will require NCI review and approval before the grant is awarded , and must include a timeline for recruitment and show feasibility for data collection and analysis. Recruitment is not required to be completed in the UG3 phase, but reasonable progress should be demonstrated to ensure that all aims will be completed in the UH3 phase.</p>			
090085	RFA-RM-20-010 -- Research Education Program Grants for CryoEM and CryoET Curriculum Development (R25 Clinical Trial Not Allowed)		National Eye Institute/NIH/DHHS	RFA- 25-Jun-2020 RM-20- [Optional][LOI/Pre-App] 010	345,000 USD
	Contact Name	Houmam Araj, Ph.D.			
	Contact Telephone	301-451-2020			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email arajh@nei.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 25-Jun-2020 [Optional][LOI/Pre-App], 24-Jul-2020</p> <p>Synopsis The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this Common Fund R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Curriculum or Methods Development To accomplish the stated overarching goal, this FOA will support creative educational activities with a primary focus on Curriculum or Methods Development in cryoelectron microscopy (cryoEM) and cryoelectron tomography (cryoET) for structural and cell biology research. Technical advances in cryoEM have resulted in its expanded use in generating reliable atomic models of complete and fully functional macromolecular complexes. An emerging related cryoEM method, cryoET, can image macromolecular assemblies in intact unstained frozen cells in three dimensions (3-D). Together, these methods enable high-resolution analysis of previously inaccessible levels of biological organization, ranging from below 100 kD to whole cells. Currently, demand for existing training opportunities exceeds capacity. Moreover, this demand is expected to rise as adoption of cryoEM and cryoET technology continues to increase. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on addressing instructional needs for new users of cryoEM and cryoET methods by supporting the development of online and computer-based instructional materials in these technologies.</p>				
085482	RFA-HL-20-024 -- Catalyze: Product Definition – Device Prototype Design and Testing, Diagnostic Disease Target Identification and Assay Development, and Research Tool Development (R61/R33 - Clinical Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-20-024	11-May-2020	500,000 USD
	<p>Contact Name Kathleen Rousche, Ph.D.</p> <p>Contact Telephone 301-827-7981</p> <p>Contact Email kathleen.rousche@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-May-2020 , 09-Jun-2020 [Optional][LOI/Pre-App], 09-Jul-2020 , 11-Aug-2020 , 09-Feb-2021 [Optional][LOI/Pre-App], 09-Mar-2021 , 11-May-2021 , 09-Jun-2021 [Optional][LOI/Pre-App], 09-Jul-2021 , 11-Aug-2021</p> <p>Synopsis This Catalyze Product Definition Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to develop and test device prototype designs, identify diagnostic disease targets and develop associated assays, and</p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		develop research tools for use in the treatment of HLBS diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical product optimization and characterization.			
085480	RFA-HL-20-022 -- Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-20-022	11-May-2020	600,000 USD
	Contact Name	Margaret Ochocinska, PhD			
	Contact Telephone	301-827-8285			
	Contact Email	ochocinm@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	11-May-2020 , 09-Jun-2020 [Optional][LOI/Pre-App], 09-Jul-2020 , 11-Aug-2020 , 09-Feb-2021 [Optional][LOI/Pre-App], 09-Mar-2021 , 11-May-2021 , 09-Jun-2021 [Optional][LOI/Pre-App], 09-Jul-2021 , 11-Aug-2021			
	Synopsis	This Funding Opportunity Announcement (FOA) solicits grant applications to further develop enabling technologies and transformative platforms to catalyze next-generation predictive, diagnostic and therapeutic products to address heart, lung, blood, and sleep (HLBS)-related disorders and diseases. This FOA solicits R33 applications where major feasibility gaps for the enabling technology or transformative platform have already been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage downstream demonstration, utilization and adoption.			
085481	RFA-HL-20-023 -- Catalyze: Product Definition for Small Molecules and Biologics - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 – Clinical Trials Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-20-023	11-May-2020	700,000 USD
	Contact Name	Kathleen Rousche, Ph.D.			
	Contact Telephone	301-827-7981			
	Contact Email	kathleen.rousche@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	11-May-2020 , 09-Jun-2020 [Optional][LOI/Pre-App], 09-Jul-2020 , 11-Aug-2020 , 09-Feb-2021 [Optional][LOI/Pre-App], 09-Mar-2021 , 11-May-2021 , 09-Jun-2021 [Optional][LOI/Pre-App], 09-Jul-2021 , 11-Aug-2021			
	Synopsis	This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to identify and			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

characterize potential therapeutic candidates (compound and lead series) to treat heart, lung, blood, and sleep diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical optimization and development of therapeutic candidates.

085485	RFA-HL-20-028 -- Catalyze: Product Definition – Device Prototype Testing and Design Modification, Diagnostic Disease Target Assay Development and Design Characterization, and Research Tool Testing and Validation (R33 - Clinical Trials Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-20-028	11-May-2020	500,000 USD
--------	---	--	---------------	-------------	-------------

Contact Name	Kathleen Rousche, Ph.D.
Contact Telephone	301-827-7981
Contact Email	kathleen.rousche@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	11-May-2020 , 09-Jun-2020 [Optional][LOI/Pre-App], 09-Jul-2020 , 11-Aug-2020 , 09-Feb-2021 [Optional][LOI/Pre-App], 09-Mar-2021 , 11-May-2021 , 09-Jun-2021 [Optional][LOI/Pre-App], 09-Jul-2021 , 11-Aug-2021
Synopsis	This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed for prototype testing/design modification, assay development for diagnostic disease targets, and development of research tools for use in the treatment of HLBS diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical product optimization and characterization.

085483	RFA-HL-20-027 -- Catalyze: Product Definition for Small Molecules and Biologics - Preliminary Product/Lead Series Identification (R33 - Clinical Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-20-027	11-May-2020	700,000 USD
--------	---	--	---------------	-------------	-------------

Contact Name	Kathleen Rousche, Ph.D.
Contact Telephone	301-827-7981
Contact Email	kathleen.rousche@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	11-May-2020 , 09-Jun-2020 [Optional][LOI/Pre-App], 09-Jul-2020 , 11-Aug-2020 , 09-Feb-2021 [Optional][LOI/Pre-App], 09-Mar-2021 , 11-May-2021 , 09-Jun-2021 [Optional][LOI/Pre-App], 09-Jul-2021 , 11-Aug-2021
Synopsis	This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to identify a lead

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		compound series toward development of potential therapeutic agents to treat heart, lung, blood, and sleep diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical optimization and development of therapeutic agents.			
074725	RFA-HL-19-018 -- NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-19-018	09-Jun-2020 [Optional][LOI/Pre-App]	3,000,000 USD
	Contact Name	Gary Robinson, Ph.D.			
	Contact Telephone	301-496-2149			
	Contact Email	NHLBI_SBIR@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	09-Jun-2020 [Optional][LOI/Pre-App], 09-Jul-2020			
	Synopsis	National Heart, Lung, and Blood Institute (NHLBI) invites applications to provide support to Phase II SBIR or STTR awardees that are developing NHLBI mission-related products that address a rare disease or young pediatric populations. The goal of this FOA is for these products to be further validated so that development can continue with private funding after NHLBI support ends. Applicants must submit a Commercialization Plan that includes details on any independent third-party funding that has already been secured or is anticipated during the project period. It is expected that the level of this independent third-party funding will be equal to or greater than one-third of the NHLBI funds being requested throughout the project period. Projects proposed in response to this FOA must require eventual Federal regulatory approval/clearance, and may address preclinical and/or clinical stages of technology development. Clinical trials may be proposed as appropriate, but are not required. This FOA will utilize the NIH R44 Small Business Innovation Research (SBIR) Grant - Phase II only.			
087129	RFA-HL-21-011 -- Stimulating T4 Implementation Research to Optimize Integration of Proven-effective Interventions for Heart, Lung, and Blood Diseases and Sleep Disorders into Practice (STIMULATE-2) (R61/R33 Clinical Trial Required)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-21-011	01-Jul-2020	2,425,000 USD
	Contact Name	Rebecca A. Roper, MS, MPH			
	Contact Telephone	301-496-1051			
	Contact Email	Rebecca.Roper@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 01-Jul-2020</p> <p>Synopsis This milestone-driven Funding Opportunity Announcement (FOA) invites applications for single-site, biphasic, late-stage implementation and translation (T4) research trials to identify and test pragmatic and sustainable implementation strategies that will increase the use of evidence-based practices (EBP), i.e., evidence-based guidelines or other well-accepted evidence-based interventions, for preventing and/or managing heart, lung, and blood diseases and/or sleep (HLBS) disorders. Clinical trials for this FOA must meet the NIH definition of a clinical trial (see NOT-OD-15-015). Applicants will be expected to address a planning phase (R61) of up to one year, and an implementation research phase (R33) of up to four years for the clinical trial. During the planning phase awardees will be expected to: finalize selection of the EBP; recruit participating organization(s); prepare the implementation protocol; develop milestones and a project timeline; and develop plans for data collection and management, and participant recruitment and retention. Robust plans for the implementation research clinical trial and the supporting implementation strategy dissemination package are required for the R33 phase of the application. Upon administrative review by the NHLBI, only meritorious R61 projects that meet the predetermined scientific milestones will be selected to transition to the R33 phase. Investigators with expertise in T4 clinical trials and hybrid studies for heart, lung, blood, or sleep conditions are expected to be part of the research team. In addition, applications proposing collaborative investigative teams combining expertise in qualitative methods, administration of T4 implementation clinical trials as appropriate at various levels (e.g., individual, clinical practice, facility, etc.), quality improvement, health economics, implementation of skills development programs, and robust experience in the adaptation and implementation of other established EBP will be encouraged. Personnel involved in the proposed strategy, e.g., nurse practitioners, patient, family members, respiratory therapists, pharmacists, hospital intensivists, etc., should be meaningfully engaged in the conceptualization and the planned execution of the proposed project. Applications proposing to establish a new EBP are not within the scope of this FOA.</p>				
088228	RFA-HG-20-008 -- Mendelian Genomics Data Coordinating Center (U24 Clinical Trial Not Allowed)	National Human Genome Research Institute/NIH/DHHS	RFA-HG-20-008	15-Jul-2020	Not Specified
	<p>Contact Name Lisa Helbling Chadwick, Ph.D.</p> <p>Contact Telephone 301-435-7275</p> <p>Contact Email lisa.chadwick@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Jul-2020</p> <p>Synopsis The purpose of this FOA is to solicit applications to develop and implement a Mendelian Genomics Data Coordination Center (MGDCC) for the Mendelian Genomics Research Consortium. The MGDCC will be responsible for managing the release of data and findings generated under the program, as well as program outreach, ensuring maximum utility for the research</p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

community. The MGDCC will also coordinate program logistics, supporting effective working groups and meetings. Finally, the MGDCC will oversee the program's Opportunity Fund, providing rapid turnaround short-term funding for functional follow-up studies to program findings.

088227	RFA-HG-20-007 -- Mendelian Genomics Research Centers (U01 - Clinical Trial Optional)	National Human Genome Research Institute/NIH/DHHS	RFA-HG-20-007	15-Jul-2020	2,000,000 USD
	Contact Name	Lisa Helbling Chadwick, Ph.D.			
	Contact Telephone	301-435-7275			
	Contact Email	lisa.chadwick@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Jul-2020			
	Synopsis	The purpose of this Funding Opportunity is to establish a consortium aimed at significantly increasing the proportion of Mendelian conditions with an identified genetic cause. A key objective of the Mendelian Genomics Research Centers is to develop and apply approaches to discover causal genes underlying Mendelian conditions for which a candidate gene was not identified using whole exome sequencing alone.			
068182	Global Infectious Disease Research Administration Development Award for Low-and Middle-Income Country Institutions (G11 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-18-335	31-Jul-2020	100,000 USD
	Contact Name	Paula S. Strickland, Ph.D., MPH			
	Contact Telephone	240-669-2922			
	Contact Email	pstricklan@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	31-Jul-2020			
	Synopsis	National Institute of Allergy and Infectious Diseases (NIAID) invites applications from research institutions in low- to middle-income countries (LMIC) to provide senior administrators from these institutions with advanced training in the management of NIH grants. The ultimate goal is to improve oversight of NIAID grant awards and compliance with NIH funding policies and Federal research funding requirements for NIAID-supported foreign institutions in low to middle-income countries. This FOA will use the NIH G11 Extramural Associate Research Development Award (EARDA) award mechanism.			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
088718	International Research in Infectious Diseases (R01 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-20-108	15-Jul-2020	625,000 USD
	Contact Name	Glen C. McGugan, Jr., Ph.D.			
	Contact Telephone	240-627-3314			
	Contact Email	gm233g@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Jul-2020 , 19-Aug-2020 , 15-Jul-2021 , 19-Aug-2021 , 15-Jul-2022 , 19-Aug-2022			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for support of high-priority, regionally relevant infectious disease research by international investigators in resource-constrained countries. Applicant organizations must be headquartered in foreign (non-U.S.) resource-constrained countries (i.e. low-income economies, lower-middle-income economies, and upper-middle-income economies by World Bank Classification). Eligibility status of applicant organizations will be determined by this World Bank Classification list at application submission date.			
090030	Integrated Preclinical / Clinical AIDS Vaccine Development Program (IPCAVD) (U19 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-20-120	28-Jul-2020	15,000,000 USD
	Contact Name	Sujata Vijh, Ph.D.			
	Contact Telephone	301-761-7713			
	Contact Email	vijhs@niaid.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	28-Jul-2020 , 09-Mar-2021 , 09-Mar-2022			
	Synopsis	The purpose of the Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD) Funding Opportunity Announcement (FOA) is to facilitate the translation of vaccine candidates into early clinical testing. The IPCAVD program is designed to enable a multi-disciplinary team to complete necessary steps from final down-selection of an advanced HIV-1 vaccine candidate through regulatory submissions needed for clinical trial(s). These steps include technology transfer, process development, optimization studies, assay development and qualification, analytical testing, Current Good Manufacturing Practice (CGMP) manufacture, quality assurance oversight, safety testing, product release and storage, drug substance and drug product stability testing program, IND-enabling studies, and regulatory submissions. This FOA will not provide funds for conducting the clinical studies; applicants are encouraged to collaborate with NIAID-supported clinical trial networks or to develop other relationships to support the clinical studies.			
090127	RFA-AI-20-010 -- Advancing Vaccine Science to Improve Tuberculosis	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-	29-Jun-2020	4,000,000 USD

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Treatment Outcomes for People Living With or Without HIV (R01 Clinical Trial Not Allowed)		Infectious Diseases/NIH/DHHS	20-010 [Optional][LOI/Pre-App]	USD
	Contact Name	Daniel Frank, Ph.D.			
	Contact Telephone	301-761-6256			
	Contact Email	daniel.frank@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	29-Jun-2020 [Optional][LOI/Pre-App], 28-Jul-2020			
	Synopsis	The purpose of this Funding Opportunity Announcement is to invite applications for innovative clinical, and preclinical/translational research to develop therapeutic vaccine strategies to improve treatment outcomes of active tuberculosis (TB) in the presence or absence of HIV co-infection.			
090164	RFA-AI-20-015 -- Engineering Immunity to HIV-1 Through Next Generation Vaccines (R61/R33 Clinical Trial Not Allowed)		National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-20-015 28-Jun-2020 [Optional][LOI/Pre-App]	Not Specified
	Contact Name	Patricia D'Souza, Ph.D.			
	Contact Telephone	240-627-3037			
	Contact Email	pdsouza@niaid.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	28-Jun-2020 [Optional][LOI/Pre-App], 28-Jul-2020			
	Synopsis	The objective of this Funding Opportunity Announcement (FOA) is to pair Bioengineers and Immunologists to leverage emerging innovative knowledge in physical and computational sciences for the design and development of an HIV-1 vaccine.			
090892	RFA-AI-20-024 --Long Acting Treatments for HIV and HIV-Associated Co-Infections (R61/R33 Clinical Trial Not Allowed)		National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-20-024 28-Jun-2020 [Optional][LOI/Pre-App]	Not Specified
	Contact Name	Marina N Protopopova, PhD			
	Contact Telephone	301-761-7653			
	Contact Email	marina.protopopova@nih.gov			
	Sponsor Website				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 28-Jun-2020 [Optional][LOI/Pre-App], 28-Jul-2020</p> <p>Synopsis The purpose of this Funding Opportunity is to stimulate new and innovative multidisciplinary research in the area of long acting therapeutics for HIV and HIV-associated tuberculosis (TB) and viral hepatitis B and C. Applications are sought that lead to new effective therapies for administration once per month or less frequently as oral, injectable, implantable, or transdermal products.</p>				
090891	RFA-AI-20-007 -- Asthma and Allergic Diseases Cooperative Research Centers (U19 Clinical Trial Optional)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-20-007	29-Jul-2020 [Optional][LOI/Pre-App]	4,500,000 USD
	<p>Contact Name Gang Dong, M.D., Ph.D.</p> <p>Contact Telephone 240-627-3508</p> <p>Contact Email gdong@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 29-Jul-2020 [Optional][LOI/Pre-App], 28-Aug-2020</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to invite applications from single institutions or consortia of institutions to participate in the Asthma and Allergic Diseases Cooperative Research Centers (AADCRC) program. The program will support centers that integrate clinical and translational research to conduct studies on the mechanisms underlying the onset and progression of diseases of interest, including asthma, rhinitis (allergic and non-allergic), chronic rhinosinusitis, atopic dermatitis, food allergy, and drug allergy. The overarching goal of the program is to improve the understanding of the pathogenesis of these conditions and to provide a rational foundation for new, effective treatments and prevention strategies.</p>				
091509	Innovation for HIV Vaccine Discovery (R01 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-20-158	28-Jul-2020	Not Specified
	<p>Contact Name Jon Warren, Ph.D.</p> <p>Contact Telephone 240-627-3032</p> <p>Contact Email JWarren@niaid.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 28-Jul-2020 , 28-Jul-2021 , 28-Jul-2022</p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support high risk, high impact, early discovery research on vaccine approaches to prevent acquisition of or ongoing infection by HIV. In keeping with the high risk, high impact nature of this research, this FOA supports a Go/No-Go approach to funding high risk research, which is significantly different from most R01 projects. Continued funding for the full award duration is dependent upon achieving negotiated "Go/No-Go" criteria by the end of Year 2.			
091964	RFA-AI-20-026 -- Limited Competition: National Biocontainment Laboratories (NBLs) Operations Support (UC7 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-20-026	17-Jun-2020 [Optional][LOI/Pre-App]	57,500,000 USD
	Contact Name	Nancy Boyd			
	Contact Telephone	240-292-4119			
	Contact Email	nboyd@niaid.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	17-Jun-2020 [Optional][LOI/Pre-App], 17-Jul-2020			
	Synopsis	The goal of this Funding Opportunity Announcement (FOA) is to continue to provide operations support for Biosafety Level 4 (BSL4) facilities to the National Biocontainment Laboratories at the University of Texas Medical Branch (UTMB) in Galveston, Texas and Boston University in Boston, Massachusetts. Operations support is provided in the following areas: facility maintenance and operations; biosecurity; environmental health and safety regulations and requirements; regulatory compliance; and specialized research support services. The NBLs will serve as a national resource for efforts in conducting pre-clinical and laboratory (in vitro and in vivo) research and testing on hazardous biological agents in support of NIAID's biodefense and emerging infectious diseases research efforts. Additionally, in times of a national biodefense or emerging infectious disease (EID) emergency, the NBLs may be expected to rapidly realign their activities to assist response efforts within the US under the direction of NIAID.			
071567	Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed)	National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS	PAR-18-597	20-Jul-2020	450,000 USD
	Contact Name	James Witter, M.D., Ph.D.			
	Contact Telephone	301-594-1963			
	Contact Email	witterj@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	20-Jul-2020 , 03-Nov-2020			
	Synopsis	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) invites applications to pursue clinical observational (CO) studies to obtain data necessary for designing clinical studies for musculoskeletal, rheumatic, or skin diseases or conditions. A future clinical study may include a clinical trial or an observational study. Research data from observational studies supported by this FOA can enhance clinical study design by providing essential information about disease symptoms, stages and timing of disease progression, comorbid conditions, availability of potential research participants, and outcomes that are important to patients. They also can facilitate efforts to develop and/or validate objective biomarkers or subjective outcome measures for use in a future clinical study. Applicants to this FOA are encouraged to propose studies that address significant obstacles or questions in the design of a clinical project, such as determining the appropriate primary or secondary outcome measures, or identifying the stages of disease during which patients are most likely to respond to an intervention. Only observational studies will be supported through this FOA. This program will use the NIH R01 Research Project Grant award mechanism.			
071544	NIAMS Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required)	National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS	PAR-18-594	02-Jul-2020	Not Specified
	Contact Name	Shahnaz Khan, MPH			
	Contact Telephone	301-451-9893			
	Contact Email	Khanshah@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	02-Jul-2020 , 03-Nov-2020			
	Synopsis	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) cooperative agreement (U01) applications for implementation of investigator-initiated interventional clinical trials (all phases). Applications for clinical trials submitted to the NIAMS are normally expected to go through a two-part process, which begins with an R34 planning phase (Part 1) followed by an application for the U01 (Part 2). Investigators who have completed all necessary pre-trial planning and preparation through other means may apply for a NIAMS U01 without having applied for a R34. The NIAMS expects trials to be hypothesis-driven and have the potential for high impact within the research mission of the NIAMS. This FOA will utilize the NIH U01 Research Project – Cooperative Agreements award mechanism.			
081811	RFA-AR-20-002 -- Mechanistic Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed)	National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS	RFA-AR-20-002	04-Jul-2020 [Optional][LOI/Pre-App]	400,000 USD
	Contact Name	Heiyoung Park, Ph.D.			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Telephone	301-594-5032				
Contact Email	parkh1@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	04-Jul-2020 [Optional][LOI/Pre-App], 03-Aug-2020 , 01-Nov-2020 [Optional][LOI/Pre-App], 01-Dec-2020				
Synopsis	<p>This Funding Opportunity Announcement (FOA) solicits applications that propose to conduct time-sensitive mechanistic ancillary studies related to the NIAMS mission in conjunction with privately or publicly funded, ongoing clinical projects. The ongoing “parent” clinical project can be an interventional clinical trial, or a clinical study such as an observational study that will be actively collecting patient samples or clinical data. The “parent” project(s) should provide a cohort of well-characterized patients, infrastructure, data, and biological samples for the ancillary study. Applications submitted in response to this FOA will undergo an accelerated review and award process. The objective of this FOA is to provide a flexible mechanism to leverage established resources and maximize the return on existing investments in parent projects. Successful ancillary studies will enhance the scientific content and value of the parent projects, improve the research community’s understanding of a disease or organ system in the NIAMS portfolio, and thus may identify novel targets for diagnosis, treatment, and prevention of disease.</p>				

081806	RFA-AR-20-001 -- Mechanistic Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed)	National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS	RFA-AR-20-001	04-Jul-2020 [Optional][LOI/Pre-App]	1,200,000 USD
--------	--	--	---------------	-------------------------------------	---------------

Contact Name	Heiyoung Park, Ph.D.				
Contact Telephone	301-594-5032				
Contact Email	parkh1@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	04-Jul-2020 [Optional][LOI/Pre-App], 03-Aug-2020 , 01-Nov-2020 [Optional][LOI/Pre-App], 01-Dec-2020				
Synopsis	<p>This Funding Opportunity Announcement (FOA) solicits applications that propose to conduct time-sensitive mechanistic ancillary studies related to the NIAMS mission in conjunction with privately or publicly funded, ongoing clinical projects. The ongoing “parent” clinical project can be an interventional clinical trial, or a clinical study such as an observational study that will be actively collecting patient samples or clinical data. The “parent” project(s) should provide a cohort of well-characterized patients, infrastructure, data, and biological samples for the ancillary study. Applications submitted in response to this FOA will undergo an accelerated review and award process. The objective of this FOA is to provide a flexible mechanism to leverage established resources and maximize the return on existing investments in parent projects. Successful ancillary studies will enhance the scientific content and value of the parent projects, improve the research community’s</p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		understanding of a disease or organ system in the NIAMS portfolio, and thus may identify novel targets for diagnosis, treatment, and prevention of disease.			
071545	Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R21 Clinical Trial Required)	National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS	PAR-18-595	02-Jul-2020	400,000 USD
	Contact Name	James Witter, M.D., Ph.D.			
	Contact Telephone	301-594-1963			
	Contact Email	witterj@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	02-Jul-2020 , 03-Nov-2020			
	Synopsis	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) invites applications designed to facilitate clinical trials that can be completed within a limited timeframe and budget. A broad range of types of exploratory studies may be submitted to this FOA. The trials must address research questions related to the mission and goals of the NIAMS and may evaluate interventions with drugs, biologics, devices, or surgical, dietary, behavioral or rehabilitation therapies. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.			
088239	NIAMS Clinical Trial Planning Grant (R34) - Clinical Trial Not Allowed	National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS	PAR-20-090	01-Jul-2020	300,000 USD
	Contact Name	NIAMS Clinical Research Team			
	Contact Telephone				
	Contact Email	NIAMScinicaltrials@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jul-2020 , 02-Nov-2020 , 01-Mar-2021 , 01-Jul-2021 , 01-Nov-2021 , 01-Mar-2022 , 01-Jul-2022 , 01-Nov-2022			
	Synopsis	This Funding Opportunity Announcement (FOA) will support planning grants for investigator-initiated clinical interventional trials. The R34 planning grant is designed to enable the necessary planning, design, and preparation of documentation prior to implementation of investigator-initiated clinical trials. Completion of the agreed upon milestones of an R34 planning grant or documentation that planning has been addressed is required prior to submission of an application through a NIAMS U01 clinical trial implementation application that will support the actual implementation and conduct of the study. The planning should facilitate the launching of a trial that is hypothesis-driven, milestone-defined, and has the potential for high impact			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

within the research mission of the NIAMS.

090141	RFA-AR-21-003 -- NIAMS Skin Biology and Diseases Resource-based Centers (P30 - Clinical Trial Not Allowed)	National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS	RFA-AR-21-003	12-Jul-2020 [Optional][LOI/Pre-App]	2,500,000 USD
--------	--	--	---------------	-------------------------------------	---------------

Contact Name	Ricardo Cibotti, Ph.D.
Contact Telephone	301-451-5888
Contact Email	ricardo.cibotti@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	12-Jul-2020 [Optional][LOI/Pre-App], 11-Aug-2020
Synopsis	The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) requests applications for the NIAMS Resource-based Centers Program (P30) for research areas within its mission in skin biology and diseases research. The Resource-based Centers will provide critical research infrastructure, shared facilities, services, and/or resources to groups of investigators conducting research on skin biology and diseases, enabling them to conduct their independently-funded individual and/or collaborative research projects more efficiently and/or more effectively, with the broad overall goal of accelerating, enriching, and enhancing the effectiveness of ongoing basic, translational, and clinical research and promoting new research within the NIAMS mission.

090211	RFA-AR-21-004 -- NIAMS Resource-based Centers for Bone, Muscle and Orthopaedic Research (P30 - Clinical Trial Not Allowed)	National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS	RFA-AR-21-004	12-Jul-2020 [Optional][LOI/Pre-App]	2,500,000 USD
--------	--	--	---------------	-------------------------------------	---------------

Contact Name	Aron Marquitz, Ph.D.
Contact Telephone	301-435-1240
Contact Email	aron.marquitz@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	12-Jul-2020 [Optional][LOI/Pre-App], 11-Aug-2020
Synopsis	The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) requests applications for the NIAMS Resource-based Centers Program (P30) for research areas within its mission in bone, muscle and orthopaedic research. The Resource-based Centers will provide critical research infrastructure, shared facilities, services, and/or resources to groups of investigators conducting research on bone, muscle and orthopaedic biology and diseases, enabling them to conduct their independently-funded individual and/or collaborative research projects more efficiently and/or more effectively, with the

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		broad overall goal of accelerating, enriching, and enhancing the effectiveness of ongoing basic, translational, and clinical research and promoting new research within these areas of NIAMS mission.			
091775	RFA-HD-21-017 -- Child Health Research Career Development Award (CHRCDA) Program [K12 Clinical Trials Not Allowed]	National Institute of Child Health and Human Development/NIH/DHHS	RFA-HD-21-017	30-Jun-2020 [Optional][LOI/Pre-App]	2,125,000 USD
	Contact Name	Andrew A Bremer, MD, PhD			
	Contact Telephone	301-402-7886			
	Contact Email	andrew.bremer@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	30-Jun-2020 [Optional][LOI/Pre-App], 30-Jul-2020			
	Synopsis	This funding opportunity announcement (FOA) invites applications for institutional research career development (K12) programs from applicant organizations that propose to support a program of mentored institutional career development programs for junior faculty investigators who have recently completed postgraduate clinical training in a subspecialty area of Pediatrics and are committed to launching an independent research career. The program provides supervised biomedical research training to assist the transition of junior faculty investigators into productive and independent physician-scientists. This Funding Opportunity Announcement (FOA) does not allow appointed Trainees to lead an independent clinical trial, but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.			
091878	RFA-HD-21-009 -- Intellectual and Developmental Disabilities Research Centers 2021 (P50 Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	RFA-HD-21-009	15-Jul-2020 [Optional][LOI/Pre-App]	4,000,000 USD
	Contact Name	Melissa A. Parisi, MD, PhD			
	Contact Telephone	301-435-6880			
	Contact Email	parisima@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Jul-2020 [Optional][LOI/Pre-App], 14-Aug-2020			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to seek applications for the Eunice Kennedy Shriver Intellectual and Developmental Disabilities Research Centers (IDDRCs). This FOA invites applications for research center grants designed to advance the diagnosis, prevention, treatment, and amelioration of intellectual and developmental disabilities (IDD). This FOA seeks applications from institutions that meet the qualifications for a multi-disciplinary program of			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		IDD research that will include: 1) Cores that facilitate interdisciplinary and translational research in IDD and its dissemination, and that support IDD-related projects funded by other sources; and 2) at least one specific research project related to one of several focus themes identified as an area of research need in IDD. Funds for the majority of outside research projects using these core facilities come from independent sources including Federal, State, and private organizations.			
092506	RFA-HD-21-007 -- Development of Fertility Regulation Methods by Small Business (R43/R44 Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	RFA-HD-21-007	30-Jun-2020 [Optional][LOI/Pre-App]	Not Specified
	Contact Name	Christopher C. Lindsey, Ph.D.			
	Contact Telephone	301-435-6907			
	Contact Email	chris.lindsey@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	30-Jun-2020 [Optional][LOI/Pre-App], 30-Jul-2020			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to invite SBIR applications to support and facilitate the development of new and/or improved non-hormonal contraceptive products for men and women.			
090419	RFA-DE-20-007 -- Defining Lineage Plasticity and Endogenous Regeneration Capacity of Dental, Oral, and Craniofacial Tissues (R21 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	RFA-DE-20-007	08-Jun-2020 [Optional][LOI/Pre-App]	275,000 USD
	Contact Name	Nadya Lumelsky, PhD			
	Contact Telephone	301-594-7703			
	Contact Email	nadyal@nidcr.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	08-Jun-2020 [Optional][LOI/Pre-App], 08-Jul-2020 , 31-Jul-2020			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to encourage high risk high reward studies that will interrogate the capacity of cells residing in the postnatal Dental, Oral, and Craniofacial tissues to acquire developmental plasticity to undergo lineage reprogramming in vivo in response to injury and other types of environmental stress, and to generate functionally-competent cells of alternative lineage(s). The end goal of this initiative is to develop approaches that will explore new opportunities for capitalizing on this developmental plasticity for obtaining needed cells to promote endogenous regeneration of DOC tissues affected by disease or injury and to achieve the goals of regenerative medicine. This Initiative will aid in building a basic science foundation for developing clinically relevant, minimally invasive strategies for			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

overcoming limitations of the currently available regenerative medicine methodologies.

090417	RFA-DE-20-006 -- Defining Lineage Plasticity and Endogenous Regeneration Capacity of Dental, Oral, and Craniofacial Tissues (R01 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	RFA-DE-20-006	08-Jun-2020 [Optional][LOI/Pre-App]	Not Specified
--------	--	---	---------------	-------------------------------------	---------------

Contact Name	Nadya Lumelsky, PhD
Contact Telephone	301-594-7703
Contact Email	nadyal@nidcr.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	08-Jun-2020 [Optional][LOI/Pre-App], 08-Jul-2020 , 31-Jul-2020
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to encourage studies that will interrogate the capacity of cells residing in the postnatal Dental, Oral, and Craniofacial tissues to acquire developmental plasticity to undergo lineage reprogramming in vivo in response to injury and other types of environmental stress, and to generate functionally-competent cells of alternative lineage(s). The end goal of this initiative is to develop approaches for capitalizing on this developmental plasticity for obtaining needed cells to promote endogenous regeneration of Dental, Oral, and Craniofacial tissues affected by disease or injury for? achieving the goals of regenerative medicine. This Initiative will build a basic science foundation for developing clinically relevant, minimally invasive strategies for overcoming limitations of the currently available regenerative medicine methodologies.

083080	Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01 Clinical Trial Not Allowed)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-19-294	14-Jul-2020	Not Specified
--------	--	---	------------	-------------	---------------

Contact Name	Aaron C. Pawlyk, Ph.D.
Contact Telephone	301-451-7299
Contact Email	pawlykac@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	14-Jul-2020 , 12-Nov-2020 , 14-Jul-2021 , 12-Nov-2021
Synopsis	The goal of this Funding Opportunity Announcement (FOA) is to support translational research that provides strong justification for later-phase therapeutics discovery and development efforts in health-related outcomes relevant to the National Institute of Diabetes and Digestive and Kidney Diseases. This includes outcomes relevant to obesity, diabetes and related aspects of endocrinology and metabolism, digestive diseases, liver diseases, nutrition, kidney and urological diseases,

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>and hematology. Additional information concerning programmatic areas at NIDDK is available at www.niddk.nih.gov/research-funding/research-programs/Pages/default.aspx and applicants are strongly encouraged to discuss research priorities with the Scientific Contact. The objective of this FOA is to stimulate early-stage preclinical validation of therapeutic leads (that need not be finalized therapeutics, henceforth called "therapeutic leads") such as small molecules or non-viral biologics that are not currently a focus within the biotechnology and pharmaceutical industries. It is expected that there is significant novelty in the target, small molecule, or non-viral biologic and in how the resulting therapeutic would differentiate from existing therapies. This must be articulated clearly in the application. It is not intended to support research focused on understanding normal biology, disease processes, generating lists of putative new targets, or identifying new therapeutic uses for existing compounds. At the end of the project period, a successful project will have provided a significant contribution to the data supporting the validity around a therapeutic such that it can advance further through other funding mechanisms, such as the small business program (https://sbir.nih.gov/niddk/index).</p>			
076166	Time-Sensitive Obesity Policy and Program Evaluation (R01 Clinical Trial Not Allowed)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-18-854	11-May-2020	Not Specified
	Contact Name	Mary Evans, Ph.D.			
	Contact Telephone	301-594-4578			
	Contact Email	evansmary@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	11-May-2020 , 10-Jun-2020 , 10-Jul-2020 , 11-Aug-2020 , 10-Sep-2020 , 14-Oct-2020 , 10-Nov-2020 , 11-Dec-2020 , 11-Jan-2021 , 10-Feb-2021 , 10-Mar-2021 , 09-Apr-2021 , 10-May-2021 , 11-Jun-2021 , 09-Jul-2021 , 10-Aug-2021 , 10-Sep-2021			
	Synopsis	<p>National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for time-sensitive research to evaluate a new policy or program that is likely to influence obesity related behaviors (e.g., dietary intake, physical activity, or sedentary behavior) and/or weight outcomes in an effort to prevent or reduce obesity. This FOA is intended to support research where opportunities for empirical study are, by their very nature, only available through expedited review and funding. All applications submitted to this FOA must demonstrate that the evaluation of an obesity related policy and /or program offers an uncommon and scientifically compelling research opportunity that will only be available if the research is initiated with minimum delay. For these reasons, applications submitted to this time-sensitive FOA are not eligible for re-submission. It is intended that eligible applications selected for funding will be awarded within 4 months of the application due date. However, administrative requirements and other unforeseen circumstances may delay issuance dates beyond that timeline. This FOA will utilize the NIH R01 Research Project Grant award mechanism.</p>			
090389	RFA-DK-20-006 -- Kidney Technology Development Research Education Program (R25 - Independent Clinical Trial Not Allowed)	National Institute of Diabetes and Digestive and Kidney	RFA-DK-20-	22-Jun-2020 [Optional][LOI/Pre-	650,000 USD

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
			Diseases/NIH/DHHS	006 App]	
	Contact Name	Daniel Gossett, Ph.D.			
	Contact Telephone	301-594-7723			
	Contact Email	daniel.gossett@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	22-Jun-2020 [Optional][LOI/Pre-App], 22-Jul-2020			
	Synopsis	<p>The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that help recruit individuals with specific specialty or disciplinary backgrounds to research careers in biomedical, behavioral and clinical sciences. To accomplish the stated overarching goal, this FOA will support creative educational activities with a primary focus on: Research Experiences This FOA encourages applications from institutions that propose to establish research experiences in kidney technology development.</p> <p>Successful programs should include a collaborative capstone research or design project(s), innovative and/or ground-breaking technology development, multidisciplinary/interdisciplinary teamwork, education in entrepreneurship, product development and navigating regulatory pathways, and clinical immersion. Applications must include plans to recruit undergraduate students as participants and to engage students from engineering and other quantitative scientific and technical backgrounds, but applicants may also propose the inclusion of medical students, graduate students and/or dual-degree students (e.g., M.D./Ph.D.; Pharm.D./Ph.D.) prior to their qualifying exams and selection of Ph.D. mentor.</p>			
081424	Environmental Influences on Aging: Effects of Extreme Weather and Disaster Events on Aging Populations (R01 Clinical Trial Optional)	National Institute of Environmental Health Sciences/NIH/DHHS	PAR-19-250	07-Jul-2020	Not Specified
	Contact Name	Symma Finn, PhD			
	Contact Telephone	984-287-3259			
	Contact Email	finns@niehs.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Jul-2020 , 09-Nov-2020 , 08-Mar-2021			
	Synopsis	<p>The purpose of this funding opportunity announcement is to advance our understanding of the impact of extreme weather and disaster events in aging human populations. Together with the companion FOA (PAR- 19-XXX) that focuses on underlying mechanisms of aging utilizing animal models, these two FOAs will help to explicate the behavioral, biological, and socioecological processes that occur during extreme weather or disaster events and that affect aging processes. Through the integration of the population studies and the companion mechanistic studies FOA, the ultimate goal is to improve the health</p>			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
					and well-being of older adults via increased knowledge about extreme weather and disaster preparedness, response, and recovery.
084593	RFA-ES-19-011 -- Mechanism for Time-Sensitive Research Opportunities in Environmental Health Sciences (R21 Clinical Trial Not Allowed)	National Institute of Environmental Health Sciences/NIH/DHHS	RFA-ES-19-011	01-Jun-2020	275,000 USD
	Contact Name	Martha I. Barnes, MS			
	Contact Telephone	919-541-3335			
	Contact Email	barnes@niehs.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2020 , 01-Jul-2020 , 03-Aug-2020 , 01-Sep-2020 , 01-Oct-2020 , 02-Nov-2020 , 01-Dec-2020 , 04-Jan-2021 , 01-Feb-2021 , 01-Mar-2021 , 01-Apr-2021 , 03-May-2021 , 01-Jun-2021 , 01-Jul-2021 , 02-Aug-2021 , 01-Sep-2021 , 01-Oct-2021 , 01-Nov-2021 , 01-Dec-2021 , 03-Jan-2022 , 01-Feb-2022 , 01-Mar-2022 , 01-Apr-2022 , 02-May-2022 , 01-Jun-2022 , 01-Jul-2022 , 01-Aug-2022 , 01-Sep-2022 , 03-Oct-2022			
	Synopsis	This funding opportunity announcement (FOA) is intended to support novel environmental health research in which an unpredictable event or policy change provides a limited window of opportunity to collect human biological samples or environmental exposure data. The primary motivation of the FOA is to understand the consequences of natural and human-made disasters, emerging environmental public health threats, and policy changes in the U.S. and abroad. A distinguishing feature of an appropriate study is the need for rapid review and funding, substantially shorter than the typical NIH grant review/award cycle, for the research question to be addressed and swiftly implemented. The shortened timeframe will be achieved by more frequent application due dates and expediting peer review, council concurrence and award issuance. The entire cycle, from submission to award, is expected to be within 3-4 months.			
093639	RFA-ES-20-011 -- Superfund Research Program Occupational Health and Safety Education Programs on Emerging Technologies (R25 - Clinical Trial Not Allowed)	National Institute of Environmental Health Sciences/NIH/DHHS	RFA-ES-20-011	03-Jul-2020 [Optional][LOI/Pre-App]	1,250,000 USD
	Contact Name	Danielle Carlin, Ph.D., DABT			
	Contact Telephone	984-287-3244			
	Contact Email	danielle.carlin@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	03-Jul-2020 [Optional][LOI/Pre-App], 03-Aug-2020			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Courses for Skills Development Research Experiences Curriculum or Methods Development The intent of this announcement is to provide an opportunity to Institutions of Higher Education to develop and offer continuing education courses, research experiences, and academic curricula on occupational health and safety management and laboratory practices in the areas of emerging technologies, emerging contaminants, and/or disaster response. Target participants include industrial hygienists, graduate students, postdoctorates, and professionals involved in the research, evaluation, management, and handling of hazardous substances. The Superfund Research Program also expects that such programs will provide a unique educational opportunity to those professionals involved in the training of other personnel for careers in these new industries. These programs are also meant to expand and complement existing educational programs in occupational health and safety and industrial hygiene.</p>			
091401	NIH Science Education Partnership Award (SEPA) (R25 - Clinical Trial Not Allowed)	National Institute of General Medical Sciences/NIH/DHHS	PAR-20-153	14-Jul-2020	1,250,000 USD
	Contact Name	Tony Beck, Ph.D.			
	Contact Telephone	301-480-4623			
	Contact Email	beckl@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	14-Jul-2020 , 13-Jul-2021 , 13-Jul-2022			
	Synopsis	<p>The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Courses for Skills Development Research Experiences Mentoring Activities Curriculum or Methods Development Outreach Information on current SEPA projects can be found at: https://www.nigms.nih.gov/Research/crcb/sepa/Pages/default.aspx and https://www.nihsepa.org Applicants are strongly encouraged to consult with the SEPA Scientific/Research Contact to be advised on the appropriateness of the intended project for SEPA program objectives and the priorities of the NIGMS.</p>			
087290	RFA-MH-20-401-- Implementing and Sustaining Evidence-Based Mental Health Practices in Low-Resource Settings to Achieve Equity in Outcomes (R34 Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	RFA-MH-20-401	25-Jul-2020 [Optional][LOI/Pre-App]	450,000 USD
	Contact Name	Denise Juliano-Bult			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Telephone 301-443-1638
Contact Email djuliano@mail.nih.gov
Sponsor Website
Program URL [Link to program URL](#)
Deadline Dates (ALL) 25-Jul-2020 [Optional][LOI/Pre-App], 25-Aug-2020
Synopsis This Funding Opportunity Announcement (FOA) supports pilot work for subsequent studies testing the effectiveness of strategies to deliver evidence-based mental health services, treatment interventions, and/or preventive interventions (EBPs) in low-resource mental health specialty and non-specialty settings within the United States. The FOA targets settings where EBPs are not currently delivered or delivered with fidelity, such that there are disparities in mental health and related functional outcomes (e.g., employment, educational attainment, stable housing, integration in the community, treatment of comorbid substance use disorders, etc.) for the population(s) served. Implementation strategies should identify and use innovative approaches to remediate barriers to provision, receipt, and/or benefit from EBPs and generate new information about factors integral to achieving equity in mental health outcomes for underserved populations. Research generating new information about factors causing/reducing disparities is strongly encouraged, including due consideration for the needs of individuals across the life span. Applications proposing definitive tests of an implementation strategy should respond to the companion R01 announcement RFA-MH-20-400 .

087289	RFA-MH-20-400 -- Effectiveness of Implementing Sustainable Evidence-Based Mental Health Practices in Low-Resource Settings to Achieve Mental Health Equity for Traditionally Underserved Populations (R01 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	RFA-MH-20-400	25-Jul-2020 [Optional][LOI/Pre-App]	Not Specified
--------	--	--	---------------	-------------------------------------	---------------

Contact Name Denise Juliano-Bult
Contact Telephone 301-443-1638
Contact Email djuliano@mail.nih.gov
Sponsor Website
Program URL [Link to program URL](#)
Deadline Dates (ALL) 25-Jul-2020 [Optional][LOI/Pre-App], 25-Aug-2020
Synopsis This Funding Opportunity Announcement (FOA) encourages studies that develop and test the effectiveness of strategies for implementation and sustainable delivery of evidence-based mental health treatments and services to improve mental health outcomes for underserved populations in under-resourced settings in the United States. Studies should identify and use innovative approaches to remediate barriers to provision, receipt, and/or benefit from evidence-based practices (EBPs) and generate new information about factors integral to achieving equity in mental health outcomes for underserved populations. Research generating new information about factors causing/reducing disparities are strongly encouraged, including due

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

consideration of the needs of individuals across the life span. This FOA is published in parallel to a companion R34 RFA-MH-20-401 that supports pilot studies in preparation for the larger-scale studies described here.

072264	Clinical Validation of a Candidate Biomarker for Neurological Disease (U01 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18-664	07-May-2020	Not Specified
--------	---	--	------------	-------------	---------------

Contact Name	Mary Ann Pellemounter, PhD
Contact Telephone	301-496-1779
Contact Email	mary.pellemounter@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2020 , 20-Jul-2020 , 07-Sep-2020
Synopsis	National Institute of Neurological Disorders and Stroke (NINDS) invites applications for rigorous clinical validation of a candidate biomarker using retrospective and/or prospective methods in a manner that is consistent with the purpose of the biomarker. This FOA assumes that: 1) a candidate biomarker has already been identified, 2) an analytical method has been developed and validated that is consistent with the purpose of the biomarker and 3) a working hypothesis regarding context of use is in place. The goal of this FOA is to facilitate the advancement of robust and reliable biomarkers of diseases that fall within the mission of NINDS to application in clinical trials and practice (Phase II clinical trials and beyond). This FOA will utilize the NIH U01 Research Project – Cooperative Agreements award mechanism.

070605	Analytical Validation of a Candidate Biomarker for Neurological Disease (U01) (Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18-550	07-May-2020	Not Specified
--------	---	--	------------	-------------	---------------

Contact Name	Mary Ann Pellemounter, PhD
Contact Telephone	301-496-1779
Contact Email	mary.pellemounter@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2020 , 20-Jul-2020 , 07-Sep-2020
Synopsis	National Institute of Neurological Disorders and Stroke (NINDS) invites applications to perform rigorous analytical validation of candidate biomarker measures or endpoints in a manner that is consistent with FDA guidelines. Analytical validation establishes that the performance characteristics of the biomarker measurement or endpoint are acceptable for its intended use. This FOA assumes that 1) a candidate biomarker has already been identified, 2) assay technology has already been developed, and 3) a working hypothesis regarding context of use is in place. The goal of this FOA is to facilitate the advancement of robust and reliable biomarkers of diseases that fall within the mission of NINDS to application in clinical trials

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

and practice (Phase II clinical trials and beyond). This FOA will utilize the NIH U01 Research Project – Cooperative Agreements award mechanism.

070597	Clinical Validation of a Candidate Biomarker for Neurological Disease (U44 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18-548	07-May-2020	Not Specified
--------	---	--	------------	-------------	---------------

Contact Name	Mary Ann Pellemounter, PhD
Contact Telephone	301-496-1779
Contact Email	mary.pellemounter@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2020 , 20-Jul-2020 , 07-Sep-2020
Synopsis	National Institute of Neurological Disorders and Stroke (NINDS) invites applications for Small Business Innovation Research (SBIR) from small business concerns (SBCs) to support rigorous clinical validation of a candidate biomarker using retrospective and/or prospective methods in a manner that is consistent with the purpose of the biomarker. This FOA assumes that: 1) a candidate biomarker has already been identified, 2) an analytical method has been developed and validated that is consistent with the purpose of the biomarker and 3) a working hypothesis regarding context of use is in place. The goal of this FOA is to facilitate the advancement of robust and reliable biomarkers of diseases that fall within the mission of NINDS to application in clinical trials and practice (Phase II clinical trials and beyond). This FOA will utilize the NIH U44 Small Business Innovation Research (SBIR) Cooperative Agreement – Fast Track mechanism.

070598	Analytical Validation of a Candidate Biomarker for Neurological Disease (U44 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18-549	07-May-2020	Not Specified
--------	---	--	------------	-------------	---------------

Contact Name	Mary Ann Pellemounter, PhD
Contact Telephone	301-496-1779
Contact Email	mary.pellemounter@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2020 , 20-Jul-2020 , 07-Sep-2020
Synopsis	National Institute of Neurological Disorders and Stroke (NINDS) invites applications for Small Business Innovation Research (SBIR) from small business concerns (SBCs) to perform rigorous analytical validation of candidate biomarker measures or endpoints in a manner that is consistent with FDA guidelines. Analytical validation establishes that the performance characteristics of the biomarker measurement or endpoint are acceptable for its intended use. This FOA assumes that 1) a candidate biomarker has already been identified, 2) assay technology has already been developed, and 3) a working

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		hypothesis regarding context of use is in place. The goal of this FOA is to facilitate the advancement of robust and reliable biomarkers of diseases that fall within the mission of NINDS to application in clinical trials and practice (Phase II clinical trials and beyond). This FOA will utilize the NIH U44 Small Business Innovation Research (SBIR) Cooperative Agreement – Fast Track mechanism.			
083919	Discovery of Biomarkers and Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-19-315	07-May-2020	Not Specified
	Contact Name	Mary Ann Pellemounter, PhD			
	Contact Telephone	301-496-1779			
	Contact Email	mary.pellemounter@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2020 , 20-Jul-2020 , 07-Sep-2020 , 17-Feb-2021 , 07-May-2021 , 19-Jul-2021 , 07-Sep-2021 , 14-Feb-2022 , 07-May-2022			
	Synopsis	The overarching purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and/or early evaluation of strong candidate biomarkers and biomarker signatures that can be used as tools to facilitate the clinical development of neurotherapeutics and their use in clinical practice. Specifically, the focus of this FOA is on the identification and initial biological, analytical and clinical evaluation of biomarkers and biomarker signatures for neurological and neuromuscular disorders/diseases. Although research supported by this FOA can include animal studies, it must also include preliminary human evaluation using carefully standardized human samples or datasets. The goal of this initiative is to deliver candidate biomarkers or biomarker signatures that are ready for definitive analytical and clinical validation studies.			
070229	RFA-NS-18-014 -- BRAIN Initiative: Targeted BRAIN Circuits Planning Projects - TargetedBCPP (R34 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-18-014	01-Jun-2020 [Optional][LOI/Pre-App]	450,000 USD
	Contact Name	James Gnad, PhD			
	Contact Telephone	301-496-9964			
	Contact Email	BRAINcircuits@NIH.GOV			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2020 [Optional][LOI/Pre-App], 01-Jul-2020 , 11-Oct-2020 [Optional][LOI/Pre-App], 10-Nov-2020			
	Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications that offer a limited scope of aims and an approach that will establish feasibility, validity, or other technically qualifying results that, if successful, would			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		support, enable, and/or lay the groundwork for a potential, subsequent Targeted Brain Circuits Projects - TargetedBCP R01, as described in the companion FOA (RFA-NS-18-009, SPIN # 67290). Applications should be exploratory research projects that use innovative, methodologically-integrated approaches to understand how circuit activity gives rise to mental experience and behavior. This FOA will use the NIH R34 Planning Grant award mechanism.			
070586	CREATE Bio Development Track: Nonclinical and Early-Phase Clinical Development for Biologics (U44 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18-543	07-May-2020	Not Specified
	Contact Name	Chris Boshoff, Ph.D.			
	Contact Telephone	301-496-1779			
	Contact Email	chris.boshoff@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2020 , 20-Jul-2020 , 07-Sep-2020 , 12-Feb-2021 , 07-May-2021			
	Synopsis	National Institute of Neurological Disorders and Stroke (NINDS) invites applications for the development of therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene therapies, cell therapies, and novel emerging therapies) for disorders identified under the NINDS mission. An identified clinical candidate with sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application, is required for entry to this CREATE Bio Development Track. Therefore, this FOA supports Investigational New Drug (IND)-enabling studies for a therapeutic candidate and the inclusion of an optional small delayed-onset first in human Phase I clinical trial. At the end of the funding period, a successful project should have at least an IND application submitted to the U.S. Food and Drug Administration (FDA). This program will use the NIH U44 Small Business Innovation Research (SBIR) Cooperative Agreement – Fast-track only.			
065641	CREATE Bio Optimization Track for Biologics (U01)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-17-456	07-May-2020	2,500,000 USD
	Contact Name	Chris Boshoff, Ph.D.			
	Contact Telephone	301-496-1779			
	Contact Email	chris.boshoff@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2020 , 20-Jul-2020 , 07-Sep-2020 , 12-Feb-2021 , 07-May-2021			
	Synopsis	National Institute of Neurological Disorders and Stroke (NINDS) invites applications for the optimization of potential therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene and cell therapies) for			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

disorders identified under the NINDS mission. This track supports the further characterization and optimization of therapeutic lead(s) that showed promise as a potential therapeutic agent as evidenced by convincing animal proof-of-concept studies. Therefore, at the end of this funding period, successful projects will have delivered and optimized therapeutic candidate with demonstrated bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and should be eligible for entry into the CREATE Bio Development track. The CREATE Bio Development track is a later stage program focused on the development of optimized therapeutic candidates through Investigational New Drug (IND)-enabling studies and submission of an IND package to the Food and Drug Administration (FDA). This program will use the NIH U01 Research Project Cooperative Agreements award mechanism.

065643	CREATE Bio Optimization Track for Biologics (SBIR-U44)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-17-457	07-May-2020	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name	Chris Boshoff, Ph.D.
Contact Telephone	301-496-1779
Contact Email	chris.boshoff@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2020 , 20-Jul-2020 , 07-Sep-2020 , 12-Feb-2021 , 07-May-2021

Synopsis National Institute of Neurological Disorders and Stroke (NINDS) invites SBIR applications for the optimization of potential therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene therapies, cell therapies, and novel emerging modalities) for disorders identified under the NINDS mission. This track supports the further characterization and optimization of therapeutic agent(s) that showed promise as evidenced by relevant, rigorous, convincing in vivo studies. Therefore, at the end of this funding period, successful projects will have delivered an optimized therapeutic candidate with demonstrated bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and should be eligible for entry into the CREATE Bio Development track. This program will use the NIH U44 Small Business Innovation Research (SBIR) Cooperative Agreements - Phase II, and Fast-Track award mechanism.

070582	CREATE Bio Development Track: Nonclinical and Early-Phase Clinical Development for Biologics (U01 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18-542	07-May-2020	7,500,000 USD
--------	--	--	------------	-------------	---------------

Contact Name	Hao Wang, Ph.D.
Contact Telephone	301-496-1779
Contact Email	CREATEinquiries@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-May-2020 , 20-Jul-2020 , 07-Sep-2020 , 12-Feb-2021 , 07-May-2021			
	Synopsis	National Institute of Neurological Disorders and Stroke (NINDS) invites applications for the development of therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene therapies, cell therapies, and novel emerging therapies) for disorders identified under the NINDS mission. An identified clinical candidate with sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application, is required for entry to this CREATE Bio Development Track. Therefore, this FOA supports Investigational New Drug (IND)-enabling studies for a therapeutic candidate and the inclusion of an optional small delayed-onset first in human Phase I clinical trial. At the end of the funding period, a successful project should have at least an IND application submitted to the U.S. Food and Drug Administration (FDA). This program will use the NIH U01 Research Project – Cooperative Agreements award mechanism.			
081489	Limited Competition: Modular Budget Research Project Grant for NIH Nurse Scientist Scholars (R01 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PAR-19-256	08-Jul-2020	1,250,000 USD
	Contact Name	David Banks, PhD, MPH, RN			
	Contact Telephone	301-496-9558			
	Contact Email	david.banks@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	08-Jul-2020 , 02-Oct-2020 , 06-Jul-2021 , 04-Oct-2021 , 06-Jul-2022			
	Synopsis	The purpose of this funding opportunity announcement (FOA) is to encourage modular budget R01 grant applications from nurse scientists who are currently or were supported within the last 3 years by an NIH Career Development (K) award. This opportunity is limited to those K awardee nurse scientists who have NIH New Investigator status. Through this opportunity, NINR seeks to enhance the transition of nurse scientists to independent investigator status.			
081422	Environmental Influences on Aging: Effects of Extreme Weather and Disaster Events on Aging Processes (R01 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PAR-19-249	07-Jul-2020	Not Specified
	Contact Name	Ronald A. Kohanski, Ph.D.			
	Contact Telephone	301-496-6402			
	Contact Email	kohanskir@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Jul-2020 , 09-Nov-2020 , 08-Mar-2021			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	Synopsis	The purpose of this funding opportunity announcement (FOA) is to support research to explore the impacts of extreme weather and disaster events on the basic biology of aging. Together with the companion FOA (PAR-19-250) that focuses on how extreme weather and disaster events impact older adults, these complementary FOAs will help to explicate the behavioral, biological, epigenetic, genetic, neurological and socioecological processes that affect the aging process. Through integration of this and the companion population studies FOA, the ultimate goal is to improve the health and well-being of older adults via increased knowledge about extreme weather and disaster preparedness, response, and recovery.			
--	----------	--	--	--	--

070974	Emotional Function in Normal Aging and/or MCI and AD/ADRD (R21 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PAR-18-582	22-Jul-2020	275,000 USD
--------	--	--------------------------------------	------------	-------------	-------------

	Contact Name	Lis Nielsen, Ph.D.			
	Contact Telephone	301-402-4156			
	Contact Email	nielsenli@nia.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	22-Jul-2020			

	Synopsis	National Institute on Aging (NIA) invites applications for foundational research demonstrating generally improved emotional function and emotion regulation with aging, to further clarify the trajectories of change in emotion processing and linked neurobiological factors in adults who are aging normally, as well as in individuals with mild cognitive impairment (MCI), Alzheimer's disease (AD), and Alzheimer's disease-related dementias (ADRD). The goal is three-fold: to advance understanding of (1) normative maturational shifts in emotional processes, (2) how dysfunction in the integrative neural-behavioral mechanisms of emotional function might manifest in MCI and the early stages of AD/ADRD, and/or (3) how such dysfunction might account for any of the neuropsychiatric symptoms observed in AD/ADRD. Such studies may identify novel targets for interventions or prevention efforts, or provide clues to intervention strategies that might be applied to normalize emotion dysregulation or strengthen emotional resilience at different life stages in normal aging or disease stages in MCI and AD/ADRD. The R21 Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.			
--	----------	--	--	--	--

070970	Emotional Function in Normal Aging and/or MCI and AD/ADRD (R01 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-18-581	08-Jul-2020	Not Specified
--------	---	--------------------------------------	------------	-------------	---------------

	Contact Name	Lis Nielsen, Ph.D.			
	Contact Telephone	301-402-4156			
	Contact Email	nielsenli@nia.nih.gov			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	08-Jul-2020			
	Synopsis	National Institute on Aging (NIA) invites applications for foundational research demonstrating generally improved emotional function and emotion regulation with aging, to further clarify the trajectories of change in emotion processing and linked neurobiological factors in adults who are aging normally, as well as in individuals with mild cognitive impairment (MCI), Alzheimer's disease (AD), and Alzheimer's disease-related dementias (ADRD). The goal is three-fold: to advance understanding of (1) normative maturational shifts in emotional processes, (2) how dysfunction in the integrative neural-behavioral mechanisms of emotional function might manifest in MCI and the early stages of AD/ADRD, and/or (3) how such dysfunction might account for any of the neuropsychiatric symptoms observed in AD/ADRD. Such studies may identify novel targets for interventions or prevention efforts, or provide clues to intervention strategies that might be applied to normalize emotion dysregulation or strengthen emotional resilience at different life stages in normal aging or disease stages in MCI and AD/ADRD. This FOA invites Stage 0 (basic research) or Stage I (intervention development/modification) clinical trials, in line with the NIH Stage Model. This FOA will use the NIH Research Project (R01) award mechanism.			
089645	RFA-AG-21-006 -- Alzheimer's Disease Sequencing Project Functional Genomics Consortium (U01 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	RFA-AG-21-006	01-Jun-2020 [Optional][LOI/Pre-App]	5,000,000 USD
	Contact Name	Alison Yao, Ph.D.			
	Contact Telephone	301-827-7264			
	Contact Email	alison.yao@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2020 [Optional][LOI/Pre-App], 01-Jul-2020			
	Synopsis	This Funding Opportunity Announcement (FOA) supports concerted efforts that take a multipronged, team-science strategy and apply high-throughput, genome-wide approaches to systematically discover and characterize functional genomic and epigenomic elements and elucidate and validate their functional roles and mechanisms of action underpinning the heterogeneity, pathogenesis, and progression of Alzheimer's disease and related dementias (AD/ADRD).			
078596	Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PAR-19-071	09-Jul-2020	275,000 USD
	Contact Name	Robin A. Barr, D.Phil.			
	Contact Telephone	301-402-7715			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email BarrR@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 09-Jul-2020 , 12-Nov-2020 , 11-Mar-2021 , 09-Jul-2021 , 12-Nov-2021</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing new tests, animal models, techniques, etc. to advance research on Alzheimer's disease and its related dementias and which need additional preliminary data with broader dissemination to establish them for more general use in this research field. The priority topics will be announced through a series of Notices published subsequent to this FOA.</p>				
089594	RFA-AG-21-016 -- Planning Projects for Clinical Trials on Effects of Sustained Reductions in Caloric Intake and Related Dietary Practices in Younger and Older Persons (U01 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	RFA-AG-21-016	23-Jul-2020	Not Specified
	<p>Contact Name Giovanna Zappalà, Ph.D., MPH</p> <p>Contact Telephone 301-827-6240</p> <p>Contact Email giovanna.zappala@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 23-Jul-2020 , 01-Oct-2020</p> <p>Synopsis This funding opportunity announcement (FOA) invites applications for 3-year planning projects for trials in either of two age ranges (25 to <50 or ≥50 years of age) to determine the effects of sustained (e.g. 5-year) caloric restriction (CR) and other interventions that modify the amount, timing, or composition of nutrient intake on risk factors for aging-related conditions and mechanisms that may influence health span and longevity. Proposed projects must plan for trials with a minimum of three arms: a control group; a CR group; and at least one other nutritional intervention that modifies level, timing, or composition of nutrient intake. Narrower age ranges within the younger and older age groups may be proposed. The projects will support organizational, planning, and protocol development activities, addressing elements such as selection and design of interventions, recruitment, eligibility criteria, selection of pre-specified study outcomes, outcome ascertainment, behavioral interventions to achieve and maintain adherence, adherence measurement, and outcome analysis. The projects will also support pilot studies and data analyses needed for these planning activities.</p>				
070587	Basic and Translational Research on Decision Making in Aging and Alzheimer's Disease (R01 - Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-18-544	08-Jul-2020	Not Specified
	<p>Contact Name Lis Nielsen, Ph.D.</p> <p>Contact Telephone 301-402-4156</p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email nielsenli@nia.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Jul-2020</p> <p>Synopsis National Institute on Aging (NIA) invites applications for basic research to better characterize the affective, cognitive, social, and motivational parameters of impaired and intact decision making in both normal aging and Alzheimer's disease (AD). Research is sought that will characterize the extent to which basic behavioral and neural processes involved in decision making are differentially impacted in normal aging and AD, investigate the influence of social factors on decision making, and investigate the decision-making factors that render older adults (with or without cognitive impairment) vulnerable to financial exploitation and other forms of mistreatment and abuse. The FOA also invites applications to apply basic research on the processes involved in decision making to the design of decision-supportive interventions for midlife and older adults with and without AD. Specific opportunities include the development of decision-supportive interventions to leverage cognitive, emotional and motivational strengths of these populations; tools to assess decisional capacity; strategies for simplifying choices and offering better defaults; and the promotion of timely adoption of optimal delegation practices (e.g., power of attorney, living wills, etc.). This FOA will use the NIH Research Project (R01) award mechanism.</p>				
070550	Basic and Translation Research on Decision Making in Aging and Alzheimer's Disease (R21 - Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-18-538	22-Jul-2020	275,000 USD
	<p>Contact Name Lis Nielsen, Ph.D.</p> <p>Contact Telephone 301-402-4156</p> <p>Contact Email nielsenli@nia.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 22-Jul-2020</p> <p>Synopsis National Institute on Aging (NIA) invites applications for basic research to better characterize the affective, cognitive, social, and motivational parameters of impaired and intact decision making in both normal aging and Alzheimer's disease (AD). Research is sought that will characterize the extent to which basic behavioral and neural processes involved in decision making are differentially impacted in normal aging and AD, investigate the influence of social factors on decision making, and investigate the decision-making factors that render older adults (with or without cognitive impairment) vulnerable to financial exploitation and other forms of mistreatment and abuse. The FOA also invites applications to apply basic research on the processes involved in decision making to the design of decision-supportive interventions for midlife and older adults with and without AD. Specific opportunities include the development of decision-supportive interventions to leverage cognitive, emotional and motivational strengths of these populations; tools to assess decisional capacity; strategies for</p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		simplifying choices and offering better defaults; and the promotion of timely adoption of optimal delegation practices (e.g., power of attorney, living wills, etc.). This FOA will use the NIH Exploratory/Developmental (R21) grant mechanism.			
071939	Supplements to Advance Research (STAR) from Projects to Programs (Admin Supp Clinical Trial Optional)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-18-647	01-Jul-2020	300,000 USD
	Contact Name	Abraham P. Bautista, Ph.D.			
	Contact Telephone	301-443-9737			
	Contact Email	bautista@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jul-2020 , 01-Mar-2021			
	Synopsis	National Institute on Alcohol Abuse and Alcoholism (NIAAA) invites administrative supplement applications to promote innovation and novel high-risk projects by early established investigators (EIs). The supplement will allow EIs to expand and explore new opportunities within the scope of the currently funded R01 grant, and to facilitate the transition from a single, structured research project to a research program. This FOA will use the NIH Administrative Supplement award mechanism.			
080453	Behavioral & Integrative Treatment Development Program (R01 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PAR-19-212	23-Jul-2020	Not Specified
	Contact Name	Will M. Aklin, Ph.D.			
	Contact Telephone	301-827-5909			
	Contact Email	aklinwm@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	23-Jul-2020 , 23-Mar-2021 , 23-Jul-2021 , 23-Mar-2022			
	Synopsis	The purpose of this funding opportunity announcement (FOA) is to encourage behavioral intervention development research. Specifically, test efficacy, conduct clinical trials, examine mechanisms of behavior change, determine dose-response, treatment optimization, and/or ascertain best sequencing of behavioral, combined, sequential, or integrated behavioral and pharmacological treatments. Research of interest includes but is not limited to Stage II and Stage III efficacy research, including: (1) drug abuse treatment interventions, including interventions for patients with comorbidities; (2) drug abuse treatment and adherence interventions; (3) drug abuse treatment and adherence interventions that utilize technologies to boost effects and increase implementability and sustainability; (4) interventions to prevent the acquisition or transmission of HIV infection among individuals in drug abuse treatment; (5) interventions to promote adherence to drug abuse treatment, HIV and addiction medications; and (6) interventions to treat substance misuse and chronic pain			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
080458	Behavioral & Integrative Treatment Development Program (R34 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PAR-19-213	23-Jul-2020	450,000 USD
	Contact Name	Will M. Aklin, Ph.D.			
	Contact Telephone	301-827-5909			
	Contact Email	aklinwm@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	23-Jul-2020 , 23-Mar-2021 , 23-Jul-2021 , 23-Mar-2022			
	Synopsis	The purpose of this funding opportunity announcement (FOA) is to encourage behavioral intervention development research. Specifically, test efficacy, conduct clinical trials, examine mechanisms of behavior change, determine dose-response, treatment optimization, and/or ascertain best sequencing of behavioral, combined, sequential, or integrated behavioral and pharmacological treatments. Research of interest includes but is not limited to Stage I research, including: (1) drug abuse treatment interventions, including interventions for patients with comorbidities; (2) drug abuse treatment and adherence interventions; (3) drug abuse treatment and adherence interventions that utilize technologies to boost effects and increase implementability and sustainability; (4) interventions to prevent the acquisition or transmission of HIV infection among individuals in drug abuse treatment; (5) interventions to promote adherence to drug abuse treatment, HIV and addiction medications; and (6) interventions to treat substance misuse and chronic pain.			
069802	Multi-Site Pilot & Feasibility Studies for System-Level Implementation of Substance Use Prevention and Treatment Services (R34 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PAR-18-223	17-Jul-2020	450,000 USD
	Contact Name	Tisha Wiley, Ph.D.			
	Contact Telephone	301-594-4381			
	Contact Email	tisha.wiley@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	17-Jul-2020 , 13-Nov-2020			
	Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for the development and testing of interventions, models, and/or frameworks that examine system-level implementation of evidence-based interventions, guidelines, or principles to improve the delivery, uptake, quality, and sustainability of substance use prevention and treatment interventions and services. This FOA will use the NIH R34 Planning Grant award mechanism.			
072841	RFA-DA-18-022 -- Advancing Exceptional Research on HIV/AIDS and	National Institute on Drug	RFA-	22-Jul-2020	Not

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Substance Abuse (R01 Clinical Trial Optional)		Abuse/NIH/DHHS	DA-18-022 [Optional][LOI/Pre-App]	Specified
	Contact Name	Jacques Normand, Ph.D.			
	Contact Telephone	301-443-1470			
	Contact Email	jnormand@nida.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	22-Jul-2020 [Optional][LOI/Pre-App], 21-Aug-2020			
	Synopsis	<p>National Institute on Drug Abuse (NIDA) invites highly innovative R01 applications on HIV/AIDS and drug abuse and complements the Avant-Garde Award Program for HIV/AIDS and Drug Use Research and the Avenir Award Program for Research on Substance Abuse and HIV/AIDS. The Avant-Garde award supports individuals who conduct high-risk, high-reward research and does not require a detailed research plan. The Avenir award is similar to the Avant-Garde award but focuses on support for early stage investigators. Applications submitted under this FOA are required to have a detailed research plan and preliminary data. This FOA focuses on innovative research projects that have the potential to open new areas of HIV/AIDS research and/or lead to new avenues for prevention and treatment of HIV/AIDS among substance abusers. The nexus with drug abuse should be clearly described. This FOA is open to both individual researchers and research teams and is not limited to any one area of research on HIV and substance use, but all studies must focus on NIH HIV/AIDS Research Priorities https://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-137.html. This FOA will use the NIH Research Project (R01) award mechanism.</p>			
070007	RFA-DA-18-019 -- NIDA Avant-Garde Award Program for HIV/AIDS and Drug Use Research (DP1, Clinical Trial Optional)		National Institute on Drug Abuse/NIH/DHHS	RFA-DA-18-019 15-Jul-2020 [Optional][LOI/Pre-App]	2,500,000 USD
	Contact Name	Jacques Normand, Ph.D., Director			
	Contact Telephone	301-443-1470			
	Contact Email	jnormand@nida.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Jul-2020 [Optional][LOI/Pre-App], 14-Aug-2020			
	Synopsis	<p>The NIDA Avant-Garde Award Program for HIV/AIDS Research supports individual scientists of exceptional creativity who propose high-impact research that will open new areas of HIV/AIDS research relevant to drug abuse and/or lead to new avenues for prevention and treatment of HIV/AIDS among drug abusers. The term “avant-garde” is used to describe highly</p>			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>innovative approaches that have the potential to be transformative. The proposed research should reflect approaches and ideas that are substantially different from those already being pursued by the investigator or others and should support the NIH HIV/AIDS Research Priorities https://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-137.html. The NIDA Avant-Garde award supports innovative, basic research that may lead to improved preventive interventions or therapies; creative, new strategies to prevent disease transmission; novel approaches to improve disease outcomes; and creative approaches to eradicating HIV or improving the lives of those living with HIV. This FOA will utilize the NIH DP1 NIH Director's Pioneer Award (NDPA) mechanism.</p>			
073437	Exploring Epigenomic or Non-Coding RNA Regulation in the Development, Maintenance, or Treatment of Chronic Pain (R61/R33 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PAR-18-742	17-Jul-2020	Not Specified
	Contact Name	John Satterlee Ph.D.			
	Contact Telephone	301-435-1020			
	Contact Email	satterleej@nida.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	17-Jul-2020 , 13-Nov-2020 , 11-Feb-2021			
	Synopsis	<p>National Institute on Drug Abuse (NIDA) and National Center for Complementary and Integrative Health (NCCIH) invite applications for research that investigates the role of epigenetic or non-coding RNA regulatory pathways in the development, maintenance, or treatment of chronic pain. Ultimately research in the area will provide foundational knowledge that can be exploited to develop novel and non-addictive pain medications or to develop biomarkers that predict chronic pain progression or treatment response. This FOA will use the NIH R61/R33 Exploratory/Developmental Phased Award mechanism.</p>			
070283	Device-Based Treatments for Substance Use Disorders (UG3/UH3, Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PAR-18-494	24-Jul-2020	Not Specified
	Contact Name				
	Contact Telephone				
	Contact Email				
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	24-Jul-2020			
	Synopsis	<p>National Institutes of Health (NIH) and its participating Institutes and Centers invite applications to accelerate the development of devices to treat Substance Use Disorders (SUDs). The continuing advances in technologies offer</p>			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

unprecedented opportunities to develop neuromodulatory or neurophysiological devices that are safe and effective SUD treatments. The objective is to move devices to their next step in the FDA approval process, with the ultimate goal of generating new, FDA approved device-based treatments for SUDs. Applications may focus on the pre-clinical and/or clinical development and testing of new devices or existing devices approved for other indications. Applications may evaluate the mechanism of action of a device. The UG3/UH3 Cooperative Agreement involves 2 phases. The UG3 phase, for up to 2 years, is designed to support a project with specific milestones to be accomplished by the end of the period. The UH3 phase is to provide funding for up to 3 additional years following successful completion of the UG3. UG3 projects that meet their milestones will be administratively considered by NIDA and prioritized for transition to the UH3 phase. Investigators submitting to this FOA must address both UG3 and UH3 phases in the application. This FOA will use the NIH UG3/UH3 Phase Innovation Awards Cooperative Agreement award mechanism.

089603	RFA-DA-21-004 -- Exploring the Roles of Biomolecular Condensates (BMCs) in HIV Replication, Latency, or Pathogenesis in the Context of Substance Use Disorders (R21/R33 Clinical Trial Not Allowed)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-21-004	20-Jun-2020 [Optional][LOI/Pre-App]	1,000,000 USD
--------	---	---	---------------	-------------------------------------	---------------

Contact Name	John Satterlee, Ph.D.
Contact Telephone	301-435-1020
Contact Email	satterleej@nida.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	20-Jun-2020 [Optional][LOI/Pre-App], 20-Jul-2020
Synopsis	To support research projects exploring the roles of biomolecular condensates (BMCs) and their regulators in processes relevant to HIV/SIV infection, replication, latency, or pathogenesis in the context of substance use disorders. These processes could include studies exploring BMC involvement in HIV infection, HIV replication (including viral gene expression), HIV latency formation or maintenance (including chromatin structure), or HIV pathogenesis (including neurodegenerative processes). Studies could also include investigation of roles for BMCs or their regulators on host cell functions in the context of HIV infection, antiretroviral therapy, and/or exposure to addictive substances.

081730	NIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Not Allowed)	National Institute on Drug Abuse/NIH/DHHS	PAR-19-258	22-Jul-2020	1,750,000 USD
--------	--	---	------------	-------------	---------------

Contact Name	Belinda E. Sims, Ph.D.
Contact Telephone	301-402-1533
Contact Email	bsims@nida.nih.gov
Sponsor Website	

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 22-Jul-2020 , 07-Sep-2020 , 22-Jul-2021 , 07-Sep-2021</p> <p>Synopsis The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NIDA R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. This FOA is intended to support research education activities that enhance the knowledge of substance use (SU) and substance use disorder (SUD) research. The program is intended for those in clinically focused careers and/or those training for careers as clinicians/health service providers, clinical researchers, or optimally a combination of the two. This mechanism may not be used to support non-research-related clinical training. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development and Research Experiences. The proposed research education programs must include both courses for skills development and research experiences with primary emphasis on research experiences. Proposed courses should be developed in conjunction with and support research experiences to enhance skills development.</p>				
082413	Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PAR-19-282	10-Jul-2020	Not Specified
	<p>Contact Name Vani Pariyadath, Ph.D.</p> <p>Contact Telephone 301-443-3209</p> <p>Contact Email vani.pariyadath@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-Jul-2020 , 07-Sep-2020 , 10-Mar-2021 , 07-May-2021 , 13-Oct-2021 , 07-Jan-2022 , 11-Jul-2022 , 07-Sep-2022 , 10-Mar-2023 , 07-May-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) uses a R61/R33 Phased Innovation Award mechanism to support clinical research applications that are exploratory and developmental in nature and focus on understanding the neurobiological mechanisms underlying Substance Use Disorders (SUD), including fundamental brain function relevant to substance use. For projects not requiring a phased research approach, applicants are encouraged to apply under a different funding mechanism (e.g., Neuroscience Research on Drug Abuse (R01 Clinical Trial Optional)).</p>				
092380	RFA-DA-21-001 -- Reducing Stigma Related to Drug Use in Human Service Settings (R34 Clinical Trial Required)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-21-001	11-Jul-2020 [Optional][LOI/Pre-App]	450,000 USD
	Contact Name Richard A. Jenkins PhD				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-443-1923</p> <p>Contact Email jenkinsri@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-Jul-2020 [Optional][LOI/Pre-App], 11-Aug-2020</p> <p>Synopsis One of the most important barriers to the provision and utilization of HIV prevention and care services is stigma, which is defined as an identity marked by disgrace, disapproval or shame, which often leads to discriminatory treatment by others. This RFA will support pilot or feasibility studies of new or adapted interventions to reduce stigma that impedes the provision and utilization of HIV care and prevention services.</p>				
092379	RFA-DA-21-002 -- Reducing Stigma Related to Drug Use in Human Service Settings (R21 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	RFA- DA-21-002	11-Jul-2020 [Optional][LOI/Pre-App]	275,000 USD
	<p>Contact Name Richard A. Jenkins PhD</p> <p>Contact Telephone 301-443-1923</p> <p>Contact Email jenkinsri@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-Jul-2020 [Optional][LOI/Pre-App], 11-Aug-2020</p> <p>Synopsis One of the most important barriers to the provision and utilization of HIV prevention and care services is stigma, which is defined as an identity marked by disgrace, disapproval or shame, which often leads to discriminatory treatment by others. This funding opportunity supports formative research to support the development of stigma reduction interventions, as well as pilot or feasibility studies of new or adapted interventions to reduce stigma that impedes the provision and utilization of HIV care and prevention services.</p>				
091073	Exploiting In Vivo or In Situ Imaging Approaches to Understand HIV- Relevant Processes in the Context of Substance Use Disorders (R61/R33 Clinical Trials Optional)	National Institute on Drug Abuse/NIH/DHHS	RFA- DA-21-005	13-Jul-2020 [Optional][LOI/Pre-App]	2,050,000 USD
	<p>Contact Name Vasundhara Varthakavi, DVM, PhD</p> <p>Contact Telephone 301-443-2146</p> <p>Contact Email vasundhara.varthakavi@nih.gov</p> <p>Sponsor Website</p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 13-Jul-2020 [Optional][LOI/Pre-App], 13-Aug-2020</p> <p>Synopsis The purpose of this initiative is to support projects that further develop or exploit advances using in situ or in vivo imaging or related technologies to investigate HIV/SIV infection, latent reservoirs, the pathogenic consequences of HIV/SIV infection, or the effects of substance use, substance use disorders (SUDs), or HIV or SUD therapies on these processes. Applicants may propose primate or human studies to investigate blood, lymphoid, or brain tissues.</p>				
072241	RFA-DA-19-003 -- Exploiting Omics Assays to Investigate Molecular Regulation of Persistent HIV in Individuals with Substance Use Disorder (R61/R33 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-19-003	17-Jun-2020 [Optional][LOI/Pre-App]	2,650,000 USD
	<p>Contact Name John Satterlee Ph.D.</p> <p>Contact Telephone 301-435-1020</p> <p>Contact Email satterleej@nida.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 17-Jun-2020 [Optional][LOI/Pre-App], 17-Jul-2020</p> <p>Synopsis National Institute on Drug Abuse (NIDA) invites applications for projects that exploit Omics assays to address outstanding questions regarding molecular regulation of persistent HIV (e.g. latency or reservoirs) in the context of chronic substance use or substance use disorder (SUD). This FOA will use the NIH R61/R33 Exploratory/Developmental Phased Award award mechanism.</p>				
069798	Multi-Site Studies for System-Level Implementation of Substance Use Prevention and Treatment Services (R01 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PAR-18-222	17-Jul-2020	2,500,000 USD
	<p>Contact Name Tisha Wiley, Ph.D.</p> <p>Contact Telephone 301-594-4381</p> <p>Contact Email tisha.wiley@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 17-Jul-2020 , 13-Nov-2020</p> <p>Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for the development and testing of interventions, models, and/or frameworks that examine system-level implementation of evidence-based interventions, guidelines, or principles to improve the delivery, uptake, quality, and sustainability of substance use prevention</p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

and treatment interventions and services. This FOA will use the NIH Research Project (R01) award mechanism.

086925	Building Population Health Research Capacity in the U.S. Affiliated Pacific Islands (U24 – Clinical Trial Not Allowed)	National Institute on Minority Health and Health Disparities/NIH/DHHS	PAR-20-048	15-Jul-2020	2,000,000 USD
--------	--	---	------------	-------------	---------------

Contact Name	Jennifer Alvidrez, PhD
Contact Telephone	301-594-9567
Contact Email	alvidrezjl@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	15-Jul-2020 , 15-Jul-2021 , 15-Jul-2022
Synopsis	The purpose of this initiative is to build the capacity of organizations in the US-Affiliated Pacific Islands to conduct ongoing population health research in this region.

075328	BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Required)	National Institutes of Health/DHHS	PAR-18-813	07-May-2020	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name	Edmund (Ned) Talley, PhD
Contact Telephone	301-496-1917
Contact Email	talleye@ninds.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2020 , 12-Jul-2020 , 07-Sep-2020 , 12-Nov-2020 , 07-Jan-2021 , 12-Mar-2021 , 07-May-2021 , 07-Sep-2021
Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for the NIH BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program. The purpose of this program is to enhance workforce diversity in the neuroscience workforce and maintain a strong cohort of new and talented, NIH-supported, independent investigators from diverse backgrounds in BRAIN Initiative research areas. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. This FOA will use the NIH K99/R00 Career Transition Award/Research Transition Award mechanism.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
075927	Investigator Initiated Research in Computational Genomics and Data Science (R21 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-18-843	16-Jul-2020	275,000 USD
	Contact Name	Daniel Gilchrist, Ph.D.			
	Contact Telephone	301-496-7531			
	Contact Email	daniel.gilchrist@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Jul-2020 , 07-Sep-2020 , 16-Nov-2020 , 07-Jan-2021 , 16-Jul-2021 , 07-Sep-2021			
	Synopsis	<p>National Human Genome Research Institute (NHGRI) invites applications for a broad range of research efforts in computational genomics, data science, statistics, and bioinformatics relevant to one or both of basic or clinical genomic science, and broadly applicable to human health and disease. This FOA supports fundamental genomics research developing innovative analytical methodologies and approaches, early stage development of tools and software, and refinement or hardening of software and tools of high value to the biomedical genomics community. Work supported under this FOA should be enabling for genomics and be generalizable or broadly applicable across diseases and biological systems. All applications should address how the methods would scale to address larger and larger data sets. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p>			
075924	Investigator Initiated Research in Computational Genomics and Data Science (R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-18-844	16-Jul-2020	Not Specified
	Contact Name	Daniel Gilchrist, Ph.D.			
	Contact Telephone	301-496-7531			
	Contact Email	daniel.gilchrist@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Jul-2020 , 07-Sep-2020 , 16-Nov-2020 , 07-Jan-2021 , 16-Jul-2021 , 07-Sep-2021			
	Synopsis	<p>National Human Genome Research Institute (NHGRI) invites applications for a broad range of research efforts in computational genomics, data science, statistics, and bioinformatics relevant to one or both of basic or clinical genomic science, and broadly applicable to human health and disease. This FOA supports fundamental genomics research developing innovative analytical methodologies and approaches, early stage development of tools and software, and refinement or hardening of software and tools of high value to the biomedical genomics community. Work supported under this FOA should be enabling for genomics and be generalizable or broadly applicable across diseases and biological systems. All applications should address how the methods would scale to address larger and larger data sets. This FOA will use the NIH Research</p>			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Project (R01) award mechanism.

088861	RFA-OD-20-010 -- Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 - Independent Clinical Trial Required)	National Institutes of Health/DHHS	RFA-OD-20-010	09-May-2020 [Optional][LOI/Pre-App]	Not Specified
--------	---	------------------------------------	---------------	-------------------------------------	---------------

Contact Name	Sergei Radaev, PhD
Contact Telephone	240-276-5630
Contact Email	sergei.radaev@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	09-May-2020 [Optional][LOI/Pre-App], 08-Jul-2020 , 10-Dec-2020 [Optional][LOI/Pre-App], 08-Feb-2021 , 09-Aug-2021 [Optional][LOI/Pre-App], 08-Oct-2021 , 09-May-2022 [Optional][LOI/Pre-App], 08-Jul-2022
Synopsis	The purpose of the Pathway to Independence Award in Tobacco Regulatory Research (K99/R00) is to increase and maintain a strong cohort of new and talented independent investigators conducting research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. This program will provide independent research support during this transition in order to help awardees launch competitive, independent research careers. Research projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP) as mandated by the Family Smoking Prevention and Tobacco Control Act (FSPTCA), Public Law 111-31. The awards under this FOA will be administered by NIH using funds made available through the CTP and the FSPTCA (P.L. 111-31). This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (RFA-OD-20-009).

088855	RFA-OD-20-008 -- Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 - Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-OD-20-008	09-May-2020 [Optional][LOI/Pre-App]	Not Specified
--------	---	------------------------------------	---------------	-------------------------------------	---------------

Contact Name	Sergei Radaev, PhD
Contact Telephone	240-276-5630
Contact Email	sergei.radaev@nih.gov

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Sponsor Website

Program URL [Link to program URL](#)

Deadline Dates (ALL) 09-May-2020 [Optional][LOI/Pre-App], 08-Jul-2020 , 10-Dec-2020 [Optional][LOI/Pre-App], 08-Feb-2021 , 09-Aug-2021 [Optional][LOI/Pre-App], 08-Oct-2021 , 09-May-2022 [Optional][LOI/Pre-App], 08-Jul-2022

Synopsis The purpose of the Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01) is to provide support and protected time (three, four, or five years) for an intensive, supervised career development experience in biomedical, behavioral, and social science research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing and that will lead to research independence. Research projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP) as mandated by the Family Smoking Prevention and Tobacco Control Act (FSPTCA), Public Law 111-31. The awards under this FOA will be administered by NIH using funds made available through the CTP and the FSPTCA (P.L. 111-31). This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (RFA-OD-20-011).

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

089643	National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders, Substance Use Disorders, or Alcohol Use Disorder (U19 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-20-119	27-Jul-2020	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name Linda Brady, Ph.D., Director

Contact Telephone 301-443-3563

Contact Email lbrady@mail.nih.gov

Sponsor Website

Program URL [Link to program URL](#)

Deadline Dates (ALL) 27-Jul-2020 , 25-Nov-2020 , 25-Mar-2021 , 26-Jul-2021 , 26-Nov-2021 , 25-Mar-2022

Synopsis The purpose of this FOA is to: accelerate innovative drug and device discovery; develop pharmacologic and neuromodulatory tools for basic and clinical research on mental health, substance use disorders (SUDs) or alcohol use disorder (AUD); develop and validate tools (pharmacologic or neurostimulation) in support of experimental therapeutic studies of innovative new candidates for mental disorders, SUDs or AUD; and support early-stage human studies to rapidly assess the safety,

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

tolerability, and pharmacodynamics of promising drug candidates/devices and new indications for novel Investigational New Drug (IND)-ready agents or Investigational Device Exemption (IDE)-ready devices for the treatment of mental disorders, SUDs or AUD. This FOA encourages applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders, SUDs or AUD, and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. Partnerships between academia and industry are strongly encouraged. This FOA supports a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach. Projects seeking support for a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies should consider the companion FOA at PAR-20-118.

089640	National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental or Substance Use Disorders or Alcohol Disorder (U01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-20-118	27-Jul-2020	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

Contact Name	Linda Brady, Ph.D., Director
Contact Telephone	301-443-3563
Contact Email	lbrady@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	27-Jul-2020 , 25-Nov-2020 , 25-Mar-2021 , 26-Jul-2021 , 26-Nov-2021 , 25-Mar-2022

Synopsis The purpose of this Funding Opportunity Announcement is to accelerate innovative drug and device therapies translation from discovery to early human studies. Studies appropriate for this FOA will develop pharmacologic and neuromodulatory tools for basic and clinical research on mental health disorders, substance use disorders (SUDs) or alcohol addiction; develop and validate tools (pharmacologic or neurostimulation) in support of experimental therapeutic studies of innovative new candidates for mental disorders; and support early-stage human studies to rapidly assess the safety, tolerability, and pharmacodynamics of promising drug candidates/devices and new indications for novel Investigational New Drug (IND)-ready agents or Investigational Device Exemption (IDE)-ready devices for the treatment of mental disorders, SUDs or alcohol addiction. This FOA encourages applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders or SUDs or alcohol addiction, and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. Partnerships between academia and industry are strongly encouraged. Projects seeking support for a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach should consider the companion FOA at PAR-20-119 . This FOA supports a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

representing his or her specific interest and competencies.

088687	Developmental Centers for AIDS Research (P30 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-20-107	28-Jul-2020	5,000,000 USD
--------	--	------------------------------------	------------	-------------	---------------

Contact Name	Candice Beaubien, M.P.H.
Contact Telephone	240-627-3098
Contact Email	candice.beaubien@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	28-Jul-2020 , 28-Jul-2021 , 28-Jul-2022
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for the Developmental Centers for AIDS Research (D-CFAR) program to provide administrative and shared research support to enhance HIV/AIDS research. D-CFARs provide core facilities, expertise, resources, and services not readily obtained otherwise through more traditional funding mechanisms. Additionally, D-CFARs provide support to assist investigators in the development of a competitive standard CFAR. The program emphasizes interdisciplinary collaboration across all areas of HIV/AIDS research.

088686	Centers for AIDS Research (P30 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-20-106	28-Jul-2020	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

Contact Name	Candice Beaubien, M.P.H.
Contact Telephone	240-627-3098
Contact Email	candice.beaubien@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	28-Jul-2020 , 28-Jul-2021 , 28-Jul-2022
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for the Centers for AIDS Research (CFAR) program to provide administrative and shared research support to enhance HIV/AIDS research. CFARs provide core facilities, expertise, resources, and services not readily obtained otherwise through more traditional funding mechanisms. The program emphasizes interdisciplinary collaboration across all areas of HIV/AIDS research.

090082	RFA-AT-21-002 -- Exploring the Mechanisms Underlying Modulation of Glymphatic-Lymphatic Systems by Complementary and Integrative Health Approaches (R21 Clinical Trial Optional)	National Institutes of Health/DHHS	RFA-AT-21-002	09-Jun-2020 [Optional][LOI/Pre-App]	275,000 USD
--------	--	------------------------------------	---------------	-------------------------------------	-------------

Contact Name | Yisong Wang, Ph.D.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-480-9483</p> <p>Contact Email yisong.wang@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 09-Jun-2020 [Optional][LOI/Pre-App], 09-Jul-2020</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages research applications that explore the impact of and the mechanisms by which complementary and integrative health approaches regulate the activities of glymphatic and lymphatic systems, or investigate the effect of complementary and integrative health approaches on the interactions between glymphatic/lymphatic functions and physiological/pathological processes. Proposed mechanistic studies may be in relevant animal models and/or human research participants. This FOA will not support clinical trials aiming to assess efficacy or effectiveness of clinical outcomes.</p>				
090067	RFA-AT-21-001 -- Exploring the Mechanisms Underlying Modulation of Glymphatic-Lymphatic Systems by Complementary and Integrative Health Approaches (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	RFA-AT-21-001	09-Jun-2020 [Optional][LOI/Pre-App]	2,500,000 USD
	<p>Contact Name Yisong Wang, Ph.D.</p> <p>Contact Telephone 301-480-9483</p> <p>Contact Email yisong.wang@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 09-Jun-2020 [Optional][LOI/Pre-App], 09-Jul-2020</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages research applications that explore the impact of and the mechanisms by which complementary and integrative health approaches regulate the activities of glymphatic/lymphatic systems, or investigate the effect of complementary and integrative health approaches on the interactions between glymphatic/lymphatic functions and physiological/pathological processes. Proposed mechanistic studies may be in relevant animal models and/or human research participants. This FOA will not support clinical trials aiming to assess efficacy or effectiveness of clinical outcomes.</p>				
090136	RFA-AI-20-016 -- Harnessing Natural Killer (NK) Cells to Prevent, Control, or Eradicate HIV (R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-AI-20-016	29-Jun-2020 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Cesar Boggiano, Ph.D.</p> <p>Contact Telephone 240-627-3038</p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Email	boggianoca@niaid.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	29-Jun-2020 [Optional][LOI/Pre-App], 28-Jul-2020			
	Synopsis	This Funding Opportunity Announcement (FOA) will support basic, translational, and clinical research to improve the understanding of the effector or immunoregulatory potentials of NK cells for HIV prevention, control and/or eradication.			
078592	Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-19-070	09-Jul-2020	Not Specified
	Contact Name	Robin A. Barr, D.Phil.			
	Contact Telephone	301-402-7715			
	Contact Email	BarrR@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	09-Jul-2020 , 12-Nov-2020 , 11-Mar-2021 , 09-Jul-2021 , 12-Nov-2021			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing research on current topics in Alzheimer's disease and its related dementias. Further information on the high-priority topics of interest will be announced through a series of Notices published subsequent to this FOA.			
090789	RFA-HD-21-005 -- Genomic Predictors of Pregnancy Loss (R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-HD-21-005	30-Jun-2020 [Optional][LOI/Pre-App]	5,000,000 USD
	Contact Name	Lisa M. Halvorson, MD			
	Contact Telephone	301-480-1646			
	Contact Email	lisa.halvorson@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	30-Jun-2020 [Optional][LOI/Pre-App], 30-Jul-2020			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support studies which utilize emerging genomic technologies to identify variants which predict risk for pregnancy loss in subsequent pregnancies beyond standard karyotype approaches.			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
091112	Big Data Analysis Challenge: Creating New Paradigms for Heart Failure Research	National Institutes of Health/DHHS	NOT-HL-20-758	28-Jul-2020 [Optional][LOI/Pre-App]	50,000 USD
	Contact Name				
	Contact Telephone				
	Contact Email				
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	28-Jul-2020 [Optional][LOI/Pre-App], 28-Aug-2020			
	Synopsis	NHLBI invites submissions for the Big Data Analysis Challenge: Creating New Paradigms for Heart Failure Research. The Challenge is designed to foster innovation and address the need for new open-source models that can define sub-categorizations of adult heart failure. These models will support new research hypotheses that further advancements in the management of this disorder.			
086488	Integrative Research on Polysubstance Abuse and Disorder (R61/R33 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-20-035	17-Jul-2020	2,100,000 USD
	Contact Name	Shelley Su, Ph.D.			
	Contact Telephone	301-402-3869			
	Contact Email	shelley.su@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	17-Jul-2020 , 17-Nov-2020 , 17-Mar-2021 , 19-Jul-2021 , 17-Nov-2021 , 17-Mar-2022 , 19-Jul-2022 , 07-Nov-2022			
	Synopsis	This Funding Opportunity Announcement (FOA) is supported by Collaborative Research on Addiction (CRAN) at the National Institutes of Health (NIH), a trans-NIH partnership composed of the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the National Institute on Drug Abuse (NIDA), and the National Cancer Institute (NCI). The intent of this FOA is two-fold: (1) characterize how the neurobiological alterations, associated behaviors, and public health consequences arising from polysubstance use differ from, or are similar to, those observed in single drug use; (2) promote integrative polysubstance research along a translational pipeline, consisting of basic science research in animals, human-based laboratory investigations, and epidemiological studies. These dual objectives will be accomplished with an Exploratory/Developmental Phased Award (R61/R33) mechanism, where polysubstance research can occur in any of these translational stages during the R61 phase and these findings will be rapidly back- or forward-integrated into another stage during the R33 phase, permitting accelerated bi-directional research exchange.			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
090063	Native American Research Centers for Health (NARCH) (S06 Clinical Trials Optional)	National Institutes of Health/DHHS	PAR-20-125	24-Jun-2020	4,000,000 USD
	Contact Name	Sheila A. Caldwell, PhD			
	Contact Telephone				
	Contact Email	caldwells@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	24-Jun-2020 , 24-Jul-2020 , 24-Jun-2021 , 23-Jul-2021			
	Synopsis	The National Institute of General Medical Sciences, in conjunction with the Institutes/Centers of the National Institutes of Health (NIH) listed above in the "Components of Participating Organizations" section and the Indian Health Service (IHS), invites applications from federally recognized Tribes and Tribal organizations for the Native American Research Centers for Health (NARCH) initiative. The objective of the NARCH initiative is to support biomedical research and career enhancement opportunities to meet health needs prioritized by American Indian/Alaska Native (AI/AN) communities. The NARCH initiative also supports research capacity building and the development of research infrastructure to enhance the biomedical research capabilities of AI/AN communities.			
091934	Mechanisms and Consequences of Sleep Disparities in the U.S. (R01 - Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-20-164	14-Jul-2020	Not Specified
	Contact Name	Rina Das, Ph.D.			
	Contact Telephone	301-496-3996			
	Contact Email	dasr2@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	14-Jul-2020 , 14-Jul-2021 , 14-Jul-2022			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to promote research to understand the underlying mechanisms of sleep deficiencies among U.S. populations that experience health disparities and how sleep deficiencies may lead to disparities in health outcomes.			
092529	RFA-AI-20-023 -- Limited Competition: International Epidemiology Databases to Evaluate AIDS (IeDEA) (U01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-AI-20-023	03-Jul-2020 [Optional][LOI/Pre-App]	Not Specified
	Contact Name	Lori Zimand, MBA, MPH			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone	240-627-3212			
	Contact Email	izimand@niaid.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	03-Jul-2020 [Optional][LOI/Pre-App], 04-Aug-2020			
	Synopsis	<p>This Funding Opportunity Announcement (FOA) solicits applications to continue the International epidemiology Databases to Evaluate AIDS (IeDEA) Program. The IeDEA program is comprised of 7 regional data center awards, which bring together clinical and research data within regions, and in collaboration monitor and guide the response to the HIV/AIDS epidemic. This research includes work on the long-term impact of HIV and its treatment, the epidemiology of common co-infections (e.g., hepatitis and tuberculosis). Research also evaluates health care utilization including medications, procedures, and vaccines, studies of co-morbidities such as cancer, disruption of physiological and metabolic processes leading to end organ impairment, mental health and alcohol and substance use. Data sources include clinical care, surveillance or research protocols as well as a Sentinel Research Network which collects data in a more intensive prospective cohort to understand the impact of non-communicable disease in HIV and allow for inferences across the network. This funding announcement also asks IeDEA to include a cohort of persons with tuberculosis (TB) to evaluate TB treatment outcomes. IeDEA facilitates access to data working with data consumers at the clinic, national, and global level and creating data tools.</p>			

088856	RFA-OD-20-009 -- Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 - Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-OD-20-009	09-May-2020 [Optional][LOI/Pre-App]	Not Specified
--------	--	------------------------------------	---------------	-------------------------------------	---------------

	Contact Name	Sergei Radaev, PhD			
	Contact Telephone	240-276-5630			
	Contact Email	sergei.radaev@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	09-May-2020 [Optional][LOI/Pre-App], 08-Jul-2020 , 10-Dec-2020 [Optional][LOI/Pre-App], 08-Feb-2021 , 09-Aug-2021 [Optional][LOI/Pre-App], 08-Oct-2021 , 09-May-2022 [Optional][LOI/Pre-App], 08-Jul-2022			
	Synopsis	<p>The purpose of the Pathway to Independence Award in Tobacco Regulatory Research (K99/R00) is to increase and maintain a strong cohort of new and talented independent investigators conducting research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. This program will provide independent NIH research support during this transition in order to help awardees launch competitive, independent</p>			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>research careers. Research projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP) as mandated by the Family Smoking Prevention and Tobacco Control Act (FSPTCA), Public Law 111-31. The awards under this FOA will be administered by NIH using funds made available through the CTP and the FSPTCA (P.L. 111-31). This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (RFA-OD-20-010).</p>			

088863	RFA-OD-20-011 -- Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 - Independent Clinical Trial Required)	National Institutes of Health/DHHS	RFA-OD-20-011	09-May-2020 [Optional][LOI/Pre-App]	Not Specified
--------	--	------------------------------------	---------------	-------------------------------------	---------------

Contact Name	Sergei Radaev, PhD				
Contact Telephone	240-276-5630				
Contact Email	sergei.radaev@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	09-May-2020 [Optional][LOI/Pre-App], 08-Jul-2020 , 10-Dec-2020 [Optional][LOI/Pre-App], 08-Feb-2021 , 09-Aug-2021 [Optional][LOI/Pre-App], 08-Oct-2021 , 09-May-2022 [Optional][LOI/Pre-App], 08-Jul-2022				
Synopsis	<p>The purpose of the Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01) is to provide support and protected time (three, four, or five years) for an intensive, supervised career development experience in biomedical, behavioral, and social science research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing and that will lead to research independence. Research projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP) as mandated by the Family Smoking Prevention and Tobacco Control Act (FSPTCA), Public Law 111-31. The awards under this FOA will be administered by NIH using funds made available through the CTP and the FSPTCA (P.L. 111-31). This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial or proposing to gain research experience in a clinical trial led by another investigator, must apply to (RFA-OD-20-008).</p>				

091783	RFA-NS-20-029 -- BRAIN Initiative: Exploratory Team-Research BRAIN Circuit Programs - eTeamBCP (U01 Clinical Trials Optional)	National Institutes of Health/DHHS	RFA-NS-20-029	14-Jun-2020 [Optional][LOI/Pre-App]	Not Specified
--------	---	------------------------------------	---------------	-------------------------------------	---------------

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		Contact Name Karen K David, Ph.D. Contact Telephone 301-496-9964 Contact Email BRAINCircuits@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 14-Jun-2020 [Optional][LOI/Pre-App], 14-Jul-2020 , 15-Jun-2021 Synopsis This funding opportunity announcement (FOA) is designed to support teams of investigators that seek to cross boundaries of interdisciplinary collaboration to elucidate the contributions of dynamic circuit activity to a specific behavioral or neural system. Applications are encouraged to propose adventurous and challenging goals that can only be tackled by a synergistic team-based approach and have the potential to be transformative and/or to enable significant advances. These studies at the exploratory stage are intended for the development of experimental capabilities and/or theoretical frameworks in preparation for a future competition for larger-scale or extended efforts, including the BRAIN TargetedBCP R01 or the multi-component, Team-Research BRAIN Circuit Programs (U19). The overall goal of this FOA is to enable a large-scale analysis of neural systems and circuits within the context and during the simultaneous measurement of an ethologically relevant behavior. Toward this end, teams are expected to assemble and leverage multi-disciplinary expertise, and to integrate experimental with computational and theoretical approaches. Teams are expected to bridge fields by incorporating rich information on cell-types, on circuit functionality and connectivity, in conjunction with sophisticated analyses of an ethologically relevant behavior of an organism or a well-defined neural system. Teams are also expected to aim for a mechanistic understanding of the circuits of the central nervous system (CNS) by applying cutting-edge methods such as those for large-scale recording, manipulation, and analysis of neural circuits across multiple regions of the CNS.			
078618	Data Science Research: Personal Health Libraries for Consumers and Patients (R01 Clinical Trial Optional)	National Library of Medicine/NIH/DHHS	PAR-19-072	30-Jun-2020 [Optional][LOI/Pre-App]	1,000,000 USD
		Contact Name Alan VanBiervliet, Ph.D. Contact Telephone 301-594-4882 Contact Email vanbiervliet@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 30-Jun-2020 [Optional][LOI/Pre-App], 31-Jul-2020 , 18-Dec-2020 [Optional][LOI/Pre-App], 19-Jan-2021 , 30-Jun-2021 [Optional][LOI/Pre-App], 30-Jul-2021 Synopsis The National Library of Medicine seeks applications for novel informatics and data science approaches that can help individuals gather, manage and use data and information about their personal health. A goal of this program is to advance			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

research and application by patients and the research community through broadly sharing the results via publication, and through open source mechanisms for data or resource sharing.

076604	Short-term Mentored Career Enhancement Awards in Mobile and Wireless Health Technology and Data Analytics: Cross-Training at the intersection of Behavioral and Social Sciences and STEM Disciplines (K18 Independent Clinical Trial Not Allowed)	Office of Behavioral and Social Sciences Research/NIH/DHHS	PAR-18-881	12-Jul-2020	Not Specified
--------	---	--	------------	-------------	---------------

Contact Name Dana Wolff-Hughes, Ph.D
Contact Telephone 301-496-0979
Contact Email dana.wolff@nih.gov
Sponsor Website
Program URL [Link to program URL](#)
Deadline Dates (ALL) 12-Jul-2020

Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications to support the development of research capability in mobile and wireless health technology (e.g., wearable devices, mobile applications, electronic health records, data analytics). Special emphasis will be given to independent behavioral and social sciences investigators who seek to train in a STEM discipline (e.g., big data analysis, computational modeling, engineering, computer science, and mathematics) or to STEM scientists who which to train in a behavioral and social science discipline. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. This FOA will use the NIH K18 Career Enhancement Award mechanism.

076613	Short-term Mentored Career Enhancement Awards in Mobile and Wireless Health Technology and Data Analytics: Cross-Training at the intersection of Behavioral and Social Sciences and STEM Disciplines (K18 Independent Clinical Trial Required)	Office of Behavioral and Social Sciences Research/NIH/DHHS	PAR-18-882	12-Jul-2020	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name Dana Wolff-Hughes, Ph.D
Contact Telephone 301-496-0979
Contact Email dana.wolff@nih.gov
Sponsor Website
Program URL [Link to program URL](#)
Deadline Dates (ALL) 12-Jul-2020

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis

National Institutes of Health (NIH) and its participating Institutes and Centers invite applications to support the development of research capability in mobile and wireless health technology (e.g., wearable devices, mobile applications, electronic health records, data analytics). Special emphasis will be given to independent behavioral and social sciences investigators who seek to train in a STEM discipline (e.g., big data analysis, computational modeling, engineering, computer science, and mathematics) or to STEM scientists who wish to train in a behavioral and social science discipline. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. This FOA will use the NIH K18 Career Enhancement Award mechanism.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
092508	NSF Convergence Accelerator Phase I and II	National Science Foundation	20-565	11-May-2020 [LOI/Pre-App]	Not Specified
	Contact Name	Linda Molnar			
	Contact Telephone	703-292-8316			
	Contact Email	lmolnar@nsf.gov			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	11-May-2020 [LOI/Pre-App], 10-Jul-2020 [LOI/Pre-App], 17-May-2021			
	Synopsis	<p>The goals of NSF's convergence accelerator effort are to support and accelerate use-inspired convergence research in areas of national importance within particular topics (tracks). NSF Convergence Accelerator tracks can be related to Industries of the Future (IoF), NSF's Big Ideas, or other topics, that may not relate directly to an IoF or Big Idea, however, they must have the potential for significant national impact. The 2020 NSF Convergence Accelerator is a two-phase program. Both phases are described in this solicitation. Phase I awardees receive significant resources to further develop their convergence research ideas and identify crucial partnerships and resources to accelerate their projects, leading to deliverable research prototypes in Phase II. This solicitation invites proposals for the following Tracks: Quantum Technology (Track C); AI-Driven Innovation via Data and Model Sharing (Track D).</p>			
092037	Civic Innovation Challenge	National Science Foundation	20-562	01-Jul-2020	1,000,000 USD
	Contact Name	David Corman			
	Contact Telephone	703-292-8754			
	Contact Email	dcorman@nsf.gov			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jul-2020, 31-Mar-2021			
	Synopsis	<p>The Civic Innovation Challenge (CIVIC) is a research and action competition in the Smart and Connected Communities (S&CC) domain designed to build a more cohesive research-to-innovation pipeline and foster a collaborative spirit. Building on the NSF S&CC program and the extensive S&CC ecosystem, CIVIC aims to accelerate the impact of S&CC research, and deepen cooperation and information sharing across sectors and regions. CIVIC will lay a foundation for a broader and more fluid exchange of research interests and civic priorities that will create new instances of collaboration and introduce new areas of technical and social scientific discovery. CIVIC will fund projects that can produce significant community impact within 12 months (following a four-month planning phase) — in contrast to many community-university partnerships that take years to</p>			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

provide tangible benefits to communities — and have the potential for lasting impact beyond the period of the CIVIC award.

092046	Disrupting Operations of Illicit Supply Networks (D-ISN)	National Science Foundation	20-561	01-Jul-2020	1,000,000 USD
--------	--	-----------------------------	--------	-------------	---------------

Contact Name	Georgia-Ann Klutke
Contact Telephone	703-292-2443
Contact Email	d-isn@nsf.gov
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	01-Jul-2020
Synopsis	This solicitation is the first of what is envisioned to be a three-year program, based on availability of funds, to support the research needed to inform the economy, security, and resilience of the Nation and the world in responding to the global threat posed by illicit supply networks. The solicitation calls for fundamental research across engineering, computer and information science, and social science with two proposal submission tracks. Track 1 research proposals should address at least one or more of the five focus domain areas listed below. Under Track 2, D-ISN calls for proposals for planning grants to support activities leading to convergence research team formation and capacity-building within the research communities interested in addressing larger-scope challenges in the future.

089592	Navigating the New Arctic Community Office (NNA-CO)	National Science Foundation	20-549	10-Jul-2020	2,500,000 USD
--------	---	-----------------------------	--------	-------------	---------------

Contact Name	
Contact Telephone	703-292-8030
Contact Email	nna@nsf.gov
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	10-Jul-2020
Synopsis	NSF invites proposals to establish a Navigating the New Arctic Community Office (NNA-CO). Launched in 2016, NNA has been building a growing portfolio of research and planning grants at the intersection of the built, social, and natural environments to improve understanding of Arctic change and its local and global effects. Each NNA-funded project is responsible for its own performance, including its core research and broader impacts. However, an NNA community office is required to coordinate the activities of funded NNA projects; engage new PIs; and promote research, education, and outreach activities. The NNA-CO will also provide centralized representation of ongoing NNA activities to the broader scientific community and the public.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		The lead PI of the successful NNA-CO proposal will serve as the Office Director and will work with the research community to develop and implement appropriate communication networks and support for investigators, stakeholders, and research teams pursuing NNA research. NNA research is inherently convergent, seeking new knowledge at the intersection of the natural, built, and social environments. NNA research also inherently involves diverse stakeholders, from local to international. The NNA-CO will need to demonstrate the ability to work with these types of research teams and audiences.			
085491	Inclusion Across the Nation of Communities of Learners of Underrepresented Discoverers in Engineering and Science (NSF INCLUDES)	National Science Foundation	19-600	13-Jul-2020	100,000 USD
	Contact Name				
	Contact Telephone	703-292-4635			
	Contact Email	nsfincludes@nsf.gov			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	13-Jul-2020			
	Synopsis	Through this solicitation, NSF Inclusion across the Nation of Communities of Learners of Underrepresented Discoverers in Engineering and Science (NSF INCLUDES) will support Planning Grants to build capacity for the development of collaborative infrastructure to: (a) facilitate innovative partnerships, networks, and theories of action for broadening participation in science, technology, engineering, and mathematics (STEM) at scale and (b) lead to the establishment of future centers, alliances, or other large-scale networks to address a broadening participation challenge. While this solicitation is open to all, NSF INCLUDES Design and Development Launch Pilots are especially encouraged to apply, as a Planning Grant could serve as an intermediate conduit for bringing their exploratory pilot work to scale.			
092802	NSF Program on Fairness in Artificial Intelligence in Collaboration with Amazon (FAI)	National Science Foundation	20-566	13-Jul-2020	1,250,000 USD
	Contact Name	Todd Leen			
	Contact Telephone	703-292-8930			
	Contact Email	tleen@nsf.gov			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	13-Jul-2020			
	Synopsis	NSF has long supported transformative research in artificial intelligence (AI) and machine learning (ML). The resulting innovations offer new levels of economic opportunity and growth, safety and security, and health and wellness, intended to			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

be shared across all segments of society. Broad acceptance and adoption of large-scale deployments of AI systems rely critically on their trustworthiness which, in turn, depends on the ability to assess and demonstrate the fairness (including broad accessibility and utility), transparency, explainability, and accountability of such systems. For example, the behavior of algorithms for face recognition, speech, and language, especially when integrated into decision support systems applied across different segments of society, would benefit from new foundational research in fairness of AI systems. NSF and Amazon are partnering to jointly support computational research focused on fairness in AI, with the goal of contributing to trustworthy AI systems that are readily accepted and deployed to tackle grand challenges facing society. Specific topics of interest include, but are not limited to transparency, explainability, accountability, potential adverse biases and effects, mitigation strategies, algorithmic advances, fairness objectives, validation of fairness, and advances in broad accessibility and utility. Funded projects will enable broadened acceptance of AI systems, helping the U.S. further capitalize on the potential of AI technologies. Although Amazon provides partial funding for this program, it will not play a role in the selection of proposals for award. Advancing AI is a highly interdisciplinary endeavor drawing on fields such as computer science, information science, engineering, statistics, mathematics, cognitive science, and psychology. As such, NSF and Amazon expect these varied perspectives to be critical for the study of fairness in AI. NSF's ability to bring together multiple scientific disciplines uniquely positions the agency in this collaboration, while building AI that is fair and unbiased is an important aspect of Amazon's AI initiatives. This program supports the conduct of fundamental computer science research into theories, techniques, and methodologies that go well beyond today's capabilities and are motivated by challenges and requirements in real systems. NSF's mission calls for the broadening of opportunities and expanding participation of groups, institutions, and geographic regions that are underrepresented in STEM disciplines, which is essential to the health and vitality of science and engineering. Consistent with this principle of diversity and particularly suitable for the thrust of this program, NSF and Amazon encourage proposals (either independently or in multi-institution collaborations) from investigators at institutions that serve groups historically underrepresented in STEM disciplines.

089058	Historically Black Colleges and Universities - Excellence in Research (HBCU- EiR)	National Science Foundation	20-542	23-Jul-2020 [LOI/Pre-App]	Not Specified
--------	---	-----------------------------	--------	---------------------------	---------------

Contact Name	Claudia Rankins
Contact Telephone	703-292-8109
Contact Email	crankins@nsf.gov
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	23-Jul-2020 [LOI/Pre-App], 06-Oct-2020
Synopsis	The Historically Black Colleges and Universities - Excellence in Research (HBCU-EiR) program was established in response to direction provided in the Senate Commerce and Justice, Science and Related Agencies Appropriations Subcommittee Report

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>(Senate Report 115-139), and is built on prior and continuing efforts by the National Science Foundation (NSF) to strengthen research capacity at Historically Black Colleges and Universities (HBCUs). This report provided guidance to NSF to establish the HBCU Excellence in Research program "to provide opportunities for both public and private HBCUs, particularly for those who have not been successful in larger NSF Research & Related Activities competitions, in order to stimulate sustainable improvement in their research and development capacity" (https://congress.gov/congressional-report/115th-congress/senate-report/139/1). EiR supports such capacity building by funding research projects aligned with NSF's research programs. The program aims to establish stronger connections between researchers at HBCUs and NSF's research programs.</p>				
087457	Faculty Early Career Development (CAREER) Program	National Science Foundation	20-525	27-Jul-2020	400,000 USD
	Contact Name				
	Contact Telephone	703-292-5111			
	Contact Email	info@nsf.gov			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	27-Jul-2020			
	Synopsis	<p>CAREER: The Faculty Early Career Development (CAREER) Program is a Foundation-wide activity that offers the National Science Foundation's most prestigious awards in support of early-career faculty who have the potential to serve as academic role models in research and education and to lead advances in the mission of their department or organization. Activities pursued by early-career faculty should build a firm foundation for a lifetime of leadership in integrating education and research. NSF encourages submission of CAREER proposals from early-career faculty at all CAREER-eligible organizations and especially encourages women, members of underrepresented minority groups, and persons with disabilities to apply. Each year NSF selects nominees for the Presidential Early Career Awards for Scientists and Engineers (PECASE) from among the most meritorious recent CAREER awardees. Selection for this award is based on two important criteria: 1) innovative research at the frontiers of science and technology that is relevant to the mission of NSF, and 2) community service demonstrated through scientific leadership, education, or community outreach. These awards foster innovative developments in science and technology, increase awareness of careers in science and engineering, give recognition to the scientific missions of the participating agencies, enhance connections between fundamental research and national goals, and highlight the importance of science and technology for the Nation's future. Individuals cannot apply for PECASE. These awards are initiated by the participating federal agencies. At NSF, up to twenty nominees for this award are selected each year from among the PECASE-eligible CAREER awardees most likely to become the leaders of academic research and education in the twenty-first century. The White House Office of Science and Technology Policy makes the final selection and announcement of the awardees.</p>			
090458	Historically Black Colleges and Universities Undergraduate Program (HBCU-UP)	National Science	20-	28-Jul-2020 [LOI/Pre-	Not Specified

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Foundation 559 App]

Contact Name	Claudia Rankins
Contact Telephone	703-292-8109
Contact Email	crankins@nsf.gov
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	28-Jul-2020 [LOI/Pre-App], 08-Sep-2020 [LOI/Pre-App], 06-Oct-2020 , 12-Nov-2020 , 22-Mar-2022 [LOI/Pre-App], 22-Nov-2022
Synopsis	HBCU-UP provides awards to strengthen STEM undergraduate education and research at HBCUs.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
093267	Neurofibromatosis Research Program--Investigator- Initiated Research Award	Department of the Army	W81XWH-20-NFRP-IIRA	25-Jun-2020 [LOI/Pre-App]	Not Specified
	Contact Name				
	Contact Telephone	301-682-5507			
	Contact Email	help@eBRAP.org			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	25-Jun-2020 [LOI/Pre-App], 09-Jul-2020			
	Synopsis	The vision of the FY20 NFRP is to decrease the clinical impact of NF. Toward this end, the NFRP seeks to support innovative, high-impact research that will foster new directions for and address neglected issues in NF research; sponsor multidisciplinary and multi-institutional collaborations that will bring new perspectives to the field; promote translational and clinical studies to move promising ideas from bench to bedside; and develop a balanced portfolio of meritorious research related to all aspects of NF1, NF2, and schwannomatosis. The NFRP Investigator-Initiated Research Award supports highly rigorous, high-impact research projects that have the potential to make an important contribution to NF research and/or patient care. Research projects may focus on any phase of research, excluding clinical trials. The rationale for a research idea may be derived from laboratory discovery, population-based studies, a clinician's firsthand knowledge of patients, or anecdotal data. Applications must include preliminary and/or published data that are relevant to NF and the proposed research project			
092168	Prostate Cancer Research Program--Population Science and Outcomes Research Award	Department of the Army	W81XWH-20-PCRP-PSORA	25-Jun-2020 [LOI/Pre-App]	Not Specified
	Contact Name				
	Contact Telephone	301-682-5507			
	Contact Email	help@eBRAP.org			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	25-Jun-2020 [LOI/Pre-App], 16-Jul-2020			
	Synopsis	The PCRP seeks to promote highly innovative, groundbreaking research; high-impact research with near-term clinical relevance; the next generation of prostate cancer investigators through mentored research; and resources that will facilitate translational research. The proposed research must be relevant to active duty Service members, Veterans, military beneficiaries, and/or the American public. The mission of the FY20 PCRP is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of Service members, Veterans, and all the men and their families			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>who are experiencing the impact of the disease. Within this context, the PCRP is interested in supporting research that addresses specific gaps in prostate cancer research and clinical care, with an emphasis on investing in research that will benefit patients diagnosed with lethal prostate cancer or improve quality of life for men diagnosed with this disease. Therefore, applications are required to address one or more of the following FY20 PCRP Overarching Challenges: • Improve the quality of life for survivors of prostate cancer • Develop treatments that improve outcomes for men with lethal prostate cancer--Applications must be directly relevant to lethal prostate cancer, which includes patients with metastatic disease; treatment-resistant disease; oligo-metastases; neuroendocrine disease; high-risk localized or locoregional disease, etc. • Reduce lethal prostate cancer in people of African descent, Veterans, and high-risk and underserved populations--High-risk populations include, but are not limited to, people of African descent (including Caribbean Americans), genetically predisposed populations, Service members, and Veterans. Underserved populations include, but are not limited to, men with limited access to clinical care and resources (in both rural and urban settings), and sexual and/or gender minorities with, or at risk for, prostate cancer. • Define the biology of lethal prostate cancer to reduce death--Applications must be directly relevant to lethal prostate cancer, which includes patients with metastatic disease; treatment-resistant disease; oligo-metastases; neuroendocrine disease; high-risk localized or locoregional disease; etc. Applications should not focus on topics such as differentiation between low risk and intermediate risk prostate cancer.</p>			
092182	Prostate Cancer Research Program--Health Disparity Research Award	Department of the Army	W81XWH-20-PCRP-HDRA	25-Jun-2020 [LOI/Pre-App]	Not Specified

Contact Name	
Contact Telephone	301-682-5507
Contact Email	help@eBRAP.org
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	25-Jun-2020 [LOI/Pre-App], 16-Jul-2020
Synopsis	<p>The PCRP seeks to promote highly innovative, groundbreaking research; high-impact research with near-term clinical relevance; the next generation of prostate cancer investigators through mentored research; and resources that will facilitate translational research. The proposed research must be relevant to active duty Service members, Veterans, military beneficiaries, and/or the American public. The mission of the FY20 PCRP is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of Service members, Veterans, and all the men and their families who are experiencing the impact of the disease. Within this context, the PCRP is interested in supporting research that addresses specific gaps in prostate cancer research and clinical care, with an emphasis on investing in research that will benefit patients diagnosed with lethal prostate cancer or improve quality of life for men diagnosed with this disease. Therefore, applications are required to address one or more of the following FY20 PCRP Overarching Challenges: • Improve the quality of life for survivors of prostate cancer • Develop treatments that improve outcomes for men with lethal prostate</p>

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
					<p>cancer--Applications must be directly relevant to lethal prostate cancer, which includes patients with metastatic disease; treatment-resistant disease; oligo-metastases; neuroendocrine disease; high-risk localized or locoregional disease, etc. • Reduce lethal prostate cancer in people of African descent, Veterans, and high-risk and underserved populations--High-risk populations include, but are not limited to, people of African descent (including Caribbean Americans), genetically predisposed populations, Service members, and Veterans. Underserved populations include, but are not limited to, men with limited access to clinical care and resources (in both rural and urban settings), and sexual and/or gender minorities with, or at risk for, prostate cancer. • Define the biology of lethal prostate cancer to reduce death--Applications must be directly relevant to lethal prostate cancer, which includes patients with metastatic disease; treatment-resistant disease; oligo-metastases; neuroendocrine disease; high-risk localized or locoregional disease; etc. Applications should not focus on topics such as differentiation between low risk and intermediate risk prostate cancer. The FY20 PCRP Health Disparity Research Award supports promising research ideas that have high potential to make a significant impact in eliminating disparities in prostate cancer incidence, morbidity, mortality, and survivorship.</p>
090989	Peer Reviewed Cancer Research Program--Behavioral Health Science Award	Department of the Army	W81XWH-20-PRCRP-BHSA	30-Jul-2020 [LOI/Pre-App]	Not Specified
	Contact Name				
	Contact Telephone	301-682-5507			
	Contact Email	help@eBRAP.org			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	30-Jul-2020 [LOI/Pre-App], 27-Aug-2020			
	Synopsis	<p>The BHSA supports innovative research and high-reward studies that span the spectrum of behavioral health science including prevention, quality of life, symptom management, resilience, and psychosocial issues related to cancer diagnosis, treatment, and survivorship. Studies are expected to address one or more of these critical issues in at least one of the FY20 PCRP Topic Areas. Proposed research should focus on at least one of the stages of survivorship as characterized by the American Society for Clinical Oncology: acute, extended, and/or permanent. The overall goal of the BHSA is to advance behavioral health cancer science and fill gaps in the understanding of survivorship, including investigations into the psychological health and well-being of those affected by cancer (e.g., patients, family members). This may include investigations into studies that improve mental health and/or cancer related outcomes in defined populations. Studies also may assess the relationship(s) between behavioral and social functioning in relation to cancer initiation, progression, detection, treatment, and rehabilitation. Applications may propose behavioral science that examines quality of life studies, decision making and/or cognitive function research, development and testing of educational interventions, and symptom management (e.g., toxicity of treatment, palliative care, psychological distress and anxiety). Applications may target development of evidence-based practices, behavioral health science interventions and surveillance, and identification of</p>			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	psychosocial patient outcomes.				

092188	Prostate Cancer Research Program - Clinical Trial Award	Department of the Army	W81XWH-20-PCRP-CTA	25-Jun-2020 [LOI/Pre-App]	Not Specified
--------	---	------------------------	--------------------	---------------------------	---------------

Contact Name	
Contact Telephone	301-682-5507
Contact Email	help@eBRAP.org
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	25-Jun-2020 [LOI/Pre-App], 16-Jul-2020
Synopsis	<p>The mission of the FY20 PCRP is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of Service members, Veterans, and all the men and their families who are experiencing the impact of the disease. Within this context, the PCRP is interested in supporting research that addresses specific gaps in prostate cancer research and clinical care, with an emphasis on investing in research that will benefit patients diagnosed with lethal prostate cancer or improve quality of life for men diagnosed with this disease. Therefore, applications are required to address one or more of the following FY20 PCRP Overarching Challenges:</p> <ul style="list-style-type: none"> • Improve the quality of life for survivors of prostate cancer • Develop treatments that improve outcomes for men with lethal prostate cancer--Applications must be directly relevant to lethal prostate cancer, which includes patients with metastatic disease; treatment-resistant disease; oligo-metastases; neuroendocrine disease; high-risk localized or locoregional disease, etc. • Reduce lethal prostate cancer in people of African descent, Veterans, and high-risk and underserved populations--High-risk populations include, but are not limited to, people of African descent (including Caribbean Americans), genetically predisposed populations, Service members, and Veterans. Underserved populations include, but are not limited to, men with limited access to clinical care and resources (in both rural and urban settings), and sexual and/or gender minorities with, or at risk for, prostate cancer. • Define the biology of lethal prostate cancer to reduce death--Applications must be directly relevant to lethal prostate cancer, which includes patients with metastatic disease; treatment-resistant disease; oligo-metastases; neuroendocrine disease; high-risk localized or locoregional disease; etc. Applications should not focus on topics such as differentiation between low risk and intermediate risk prostate cancer.

091435	Neurofibromatosis Research Program--Exploration – Hypothesis Development Award	Department of the Army	W81XWH-20-NFRP-EHDA	25-Jun-2020 [LOI/Pre-App]	100,000 USD
--------	--	------------------------	---------------------	---------------------------	-------------

Contact Name	
Contact Telephone	301-682-5507
Contact Email	help@eBRAP.org

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 25-Jun-2020 [LOI/Pre-App], 09-Jul-2020</p> <p>Synopsis The vision of the FY20 NFRP is to decrease the clinical impact of NF. Toward this end, the NFRP seeks to support innovative, high-impact research that will foster new directions for and address neglected issues in NF research; sponsor multidisciplinary and multi-institutional collaborations that will bring new perspectives to the field; promote translational and clinical studies to move promising ideas from bench to bedside; and develop a balanced portfolio of meritorious research related to all aspects of NF1, NF2, and schwannomatosis. The NFRP Exploration - Hypothesis Development Award supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in NF research. Studies supported by this award mechanism are expected to lay the groundwork for future avenues of scientific investigation. The proposed research project should include a wellformulated, testable hypothesis based on strong scientific rationale and study design. The presentation of preliminary and/or published data is encouraged, but not required.</p>				
090990	Peer Reviewed Cancer Research Program--Translational Team Science Award	Department of the Army	W81XWH-20-PRCRP-TTSA	30-Jul-2020 [LOI/Pre-App]	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 301-682-5507</p> <p>Contact Email help@eBRAP.org</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 30-Jul-2020 [LOI/Pre-App], 27-Aug-2020</p> <p>Synopsis The goal of the PRCRP is to improve quality of life by decreasing the impact of cancer on active duty Service members, their families, Veterans, and the American public. The PRCRP is charged by Congress with the mission to investigate cancer risks and knowledge gaps that may be relevant to active duty Service members, their families, other military beneficiaries, and the American public. The FY20 PRCRP Translational Team Science Award (TTSA) supports hypothesis-driven translational studies. These studies should be associated with clinical trial. The proposed project should focus on research for the next-phase clinical trial or future clinical application. The TTSA is intended to support advanced translational studies that are based on results from clinical investigations. While funding for clinical trials is allowed, the TTSA is intended to support multi-investigator, multidisciplinary teams to perform clinical research studies and not only to fund a clinical trial. Research projects funded by the TTSA should address critical knowledge gaps in clinical outcomes, validate key research results, expand upon potentially game-changing results, or investigate novel clinical findings.</p>				
091443	Neurofibromatosis Research Program--Early Investigator Research Award	Department of the Army	W81XWH-20-NFRP-EIRA	25-Jun-2020 [LOI/Pre-App]	450,000 USD

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Name				
	Contact Telephone	301-682-5507			
	Contact Email	help@eBRAP.org			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	25-Jun-2020 [LOI/Pre-App], 09-Jul-2020			
	Synopsis	<p>The vision of the FY20 NFRP is to decrease the clinical impact of NF. Toward this end, the NFRP seeks to support innovative, high-impact research that will foster new directions for and address neglected issues in NF research; sponsor multidisciplinary and multi-institutional collaborations that will bring new perspectives to the field; promote translational and clinical studies to move promising ideas from bench to bedside; and develop a balanced portfolio of meritorious research related to all aspects of NF1, NF2, and schwannomatosis. The Early Investigator Research Award supports NF-focused research opportunities for individuals in the early stages of their careers, under the guidance of a designated Mentor. This opportunity allows for early-stage investigators to develop a research project, investigate a problem or question in NF research, and further their intellectual development as an NF researcher of the future. The postdoctoral investigator is considered the Principal Investigator (PI) of the application and must exhibit strong potential for, and commitment to, pursuing a career as an investigator at the forefront of NF research; however, the PI is not required to have previous NF research experience. Applications must include at least one Mentor, appropriate to the proposed research project, who has experience in NF research and mentoring as demonstrated by a record of active funding, recent publications, and successful mentorship. The primary Mentor can be a junior faculty member, in which case the PI is encouraged to include a secondary Mentor with a more robust track record in NF research and mentorship. The selected Mentor(s) should also demonstrate a clear commitment to the development of the PI toward independence as an NF researcher.</p>			
091487	Neurofibromatosis Research Program--New Investigator Award	Department of the Army	W81XWH-20-NFRP-NIA	25-Jun-2020 [LOI/Pre-App]	450,000 USD
	Contact Name				
	Contact Telephone	301-682-5507			
	Contact Email	help@eBRAP.org			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	25-Jun-2020 [LOI/Pre-App], 09-Jul-2020			
	Synopsis	<p>The vision of the FY20 NFRP is to decrease the clinical impact of NF. Toward this end, the NFRP seeks to support innovative, high-impact research that will foster new directions for and address neglected issues in NF research; sponsor</p>			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>multidisciplinary and multi-institutional collaborations that will bring new perspectives to the field; promote translational and clinical studies to move promising ideas from bench to bedside; and develop a balanced portfolio of meritorious research related to all aspects of NF1, NF2, and schwannomatosis. The intent of the NFRP New Investigator Award is to support the continued development of promising early-stage investigators and/or the transition of established investigators from other research fields into a career in the field of NF research. Prior experience in NF research is not required. However, Principal Investigators (PIs) with a limited background in NF research are strongly encouraged to have a collaborator who is experienced in the NF field.</p>				
093266	Neurofibromatosis Research Program--Synergistic Idea Award	Department of the Army	W81XWH-20-NFRP-SIA	25-Jun-2020 [LOI/Pre-App]	Not Specified
	Contact Name				
	Contact Telephone	301-682-5507			
	Contact Email	help@eBRAP.org			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	25-Jun-2020 [LOI/Pre-App], 09-Jul-2020			
	Synopsis	<p>The vision of the FY20 NFRP is to decrease the clinical impact of NF. Toward this end, the NFRP seeks to support innovative, high-impact research that will foster new directions for and address neglected issues in NF research; sponsor multidisciplinary and multi-institutional collaborations that will bring new perspectives to the field; promote translational and clinical studies to move promising ideas from bench to bedside; and develop a balanced portfolio of meritorious research related to all aspects of NF1, NF2, and schwannomatosis. The NFRP Synergistic Idea Award supports new ideas that represent synergistic approaches to neurofibromatosis research involving two or three Principal Investigators (PIs). These investigators should utilize their complementary and synergistic perspectives to address a central problem or question in neurofibromatosis research. This award is designed to support both new and pre-existing partnerships, and encourages participation of PIs from other research fields.</p>			
092239	Peer Reviewed Medical Research Program--Clinical Trial Award	Department of the Army	W81XWH-20-PRMRP-CTA	29-Jul-2020 [LOI/Pre-App]	Not Specified
	Contact Name				
	Contact Telephone	301-682-5507			
	Contact Email	help@eBRAP.org			
	Sponsor Website				
	Program URL	Link to program URL			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	29-Jul-2020 [LOI/Pre-App], 13-Aug-2020			
	Synopsis	<p>The vision of the FY20 PRMRP is to improve the health, care, and well-being of all military Service members, Veterans, and beneficiaries, and its mission is to encourage, identify, select, and manage medical research projects of clear scientific merit and direct relevance to military health. Thus, the proposed research must be relevant to active duty Service members, Veterans, military beneficiaries, and/or the American public. The PRMRP challenges the scientific and clinical communities to address at least one of the FY20 PRMRP Topic Areas with original ideas that foster new directions along the entire spectrum of research and clinical care. The program seeks applications in laboratory, clinical, behavioral, epidemiologic, and other areas of research to advance knowledge in disease etiology, improve prevention, detection, diagnosis, treatment, and quality of life for those affected by a relevant disease or condition, and to develop and validate clinical care or public health guidelines. The PRMRP Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on a disease or condition addressed in at least one of the Congressionally directed FY20 PRMRP Topic Areas. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first in human, Phase 0), to demonstrate feasibility or inform the design of more advanced trials, through large-scale trials to determine efficacy in relevant patient populations.</p>			
092173	DoD Prostate Cancer Research Program - Translational Science Award	Department of the Army	W81XWH-20-PCRP-TSA	25-Jun-2020 [LOI/Pre-App]	Not Specified
	Contact Name				
	Contact Telephone	301-682-5507			
	Contact Email	help@eBRAP.org			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	25-Jun-2020 [LOI/Pre-App], 16-Jul-2020			
	Synopsis	<p>The PCRP seeks to promote highly innovative, groundbreaking research; high-impact research with near-term clinical relevance; the next generation of prostate cancer investigators through mentored research; and resources that will facilitate translational research. The proposed research must be relevant to active duty Service members, Veterans, military beneficiaries, and/or the American public. The mission of the FY20 PCRP is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of Service members, Veterans, and all the men and their families who are experiencing the impact of the disease. Within this context, the PCRP is interested in supporting research that addresses specific gaps in prostate cancer research and clinical care, with an emphasis on investing in research that will benefit patients diagnosed with lethal prostate cancer or improve quality of life for men diagnosed with this disease. Therefore, applications are required to address one or more of the following FY20 PCRP Overarching Challenges: • Improve the quality of life for survivors of prostate cancer • Develop treatments that improve outcomes for men with lethal prostate</p>			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>cancer--Applications must be directly relevant to lethal prostate cancer, which includes patients with metastatic disease; treatment-resistant disease; oligo-metastases; neuroendocrine disease; high-risk localized or locoregional disease, etc. • Reduce lethal prostate cancer in people of African descent, Veterans, and high-risk and underserved populations--High-risk populations include, but are not limited to, people of African descent (including Caribbean Americans), genetically predisposed populations, Service members, and Veterans. Underserved populations include, but are not limited to, men with limited access to clinical care and resources (in both rural and urban settings), and sexual and/or gender minorities with, or at risk for, prostate cancer. • Define the biology of lethal prostate cancer to reduce death--Applications must be directly relevant to lethal prostate cancer, which includes patients with metastatic disease; treatment-resistant disease; oligo-metastases; neuroendocrine disease; high-risk localized or locoregional disease; etc. Applications should not focus on topics such as differentiation between low risk and intermediate risk prostate cancer.</p>			

088421	Amyotrophic Lateral Sclerosis Research Program--Therapeutic Development Award	Department of the Army	W81XWH-20-ALSRP-TDA	23-Jul-2020	1,000,000 USD
--------	---	------------------------	---------------------	-------------	---------------

Contact Name	
Contact Telephone	301-682-5507
Contact Email	help@cdmrp.org
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	23-Jul-2020
Synopsis	<p>The FY20 ALSRP Therapeutic Development Award supports research ranging from validation of therapeutic leads through U.S. Food and Drug Administration (FDA) Investigational New Drug (IND)-enabling studies. The proposed studies are expected to be empirical in nature and product-driven. Preliminary data are required, including efficacy in at least one ALS-relevant model system with a lead molecule/class of compounds. The availability of validated biomarkers or biomarker development/characterization, in parallel to the main therapeutic effort and for use in eventual clinical trials, is a critical component of the FY20 ALSRP Therapeutic Development Award. Applicants with limited ALS experience are strongly encouraged to include collaborators with substantial expertise in the relevant ALS model systems, endpoints, and pathophysiology.</p>

088417	Amyotrophic Lateral Sclerosis Research Program--Therapeutic Idea Award	Department of the Army	W81XWH-20-ALSRP-TIA	23-Jul-2020	Not Specified
--------	--	------------------------	---------------------	-------------	---------------

Contact Name	
Contact Telephone	301-682-5507
Contact Email	help@eBRAP.org

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 23-Jul-2020 Synopsis The FY20 ALSRP Therapeutic Idea Award supports hypothesis-driven therapeutic development and is designed to promote new ideas aimed at drug or treatment discovery that are still in the early stages of development. Development and/or modification of preclinical model systems or the application of high-throughput screens to define or assess lead compounds for ALS treatment may also be proposed. All research projects should include a well-formulated, testable hypothesis based on strong scientific rationale that holds translational potential to improve ALS treatment and/or advance a novel treatment modality. Preliminary data are not required. While the inclusion of preliminary data is not prohibited, the strength of the application should not rely on preliminary data, but on the innovative approach. Projects that focus primarily on investigating the pathophysiology of ALS, without consideration of therapeutic development, are not within the scope of this Funding Opportunity.				
091048	Lung Cancer Research Program--Clinical Translational Research Partnership Award	Department of the Army	W81XWH-20-LCRP-CTRPA	15-Jul-2020 [LOI/Pre-App]	Not Specified
	Contact Name Contact Telephone 301-682-5507 Contact Email help@eBRAP.org Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 15-Jul-2020 [LOI/Pre-App], 29-Jul-2020 Synopsis The vision of the FY19 LCRP is to eradicate deaths and suffering from lung cancer to better the health and welfare of military Service members, Veterans, and the American public. As such, the LCRP will support and integrate research from multiple disciplines for risk assessment, prevention, early detection, diagnosis, and treatment for the control and cure of lung cancer. The proposed research must be relevant to active duty Service members, Veterans, military beneficiaries, and/or the American public. The FY20 LCRP Clinical Translational Research Partnership Award mechanism supports partnerships between clinicians and research scientists that will accelerate the movement of promising ideas in lung cancer into clinical applications. This award supports the development of translational research collaborations between two independent, faculty-level (or equivalent) investigators to address a critical problem or question in lung cancer in a manner that would be less readily achievable through separate efforts. One partner in the collaboration must be a research scientist and the other must be a clinician. In addition, one partner in the collaboration is strongly encouraged to be an active duty Service member or Federal employee from a Department of Defense (DoD) military treatment facility or laboratory, or a Department of Veterans Affairs (VA) medical center or research laboratory. It should be clear that both have had equal intellectual input into				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		the design of the research project. Multi-institutional partnerships are encouraged but not required. At least one member of the partnership must have experience either in lung cancer research or lung cancer patient care. A proposed project in which the clinical partner merely supplies tissue samples or access to patients will not meet the intent of this award mechanism.			
090408	Lung Cancer Research Program--Investigator-Initiated Translational Research Award	Department of the Army	W81XWH-20-LCRP-IITRA	06-May-2020 [LOI/Pre-App]	400,000 USD
	Contact Name				
	Contact Telephone	301-682-5507			
	Contact Email	help@eBRAP.org			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	06-May-2020 [LOI/Pre-App], 29-Jul-2020			
	Synopsis	<p>The FY20 LCRP Investigator-Initiated Translational Research Award mechanism supports translational research that will develop promising ideas in lung cancer into clinical applications. Translational research may be defined as an integration of basic science and clinical observations. Observations that drive a research idea may originate from a laboratory discovery, population-based studies, or a clinician's firsthand knowledge of patient care. The ultimate goal of translational research is to move a concept or observation forward into clinical application. However, Principal Investigators (PIs) should not view translational research as a one-way continuum from bench to bedside. The research plan must involve a reciprocal flow of ideas and information between basic and clinical science. This mechanism is intended to fund a broad range of translational studies, including, but not limited to, the following:</p> <ul style="list-style-type: none"> · Studies advancing/translating in vitro and/or animal studies to applications with human samples/cohorts. · Late-stage preclinical work leading to/preparing for a clinical trial, e.g., Investigational New Drug (IND) application submission. · Correlative studies that are associated with an open/ongoing or completed clinical trial and projects that develop endpoints for clinical trials. Preliminary lung cancer relevant data to support the feasibility of the research hypotheses and research approaches are required. 			
091489	Neurofibromatosis Research Program--Clinical Trial Award	Department of the Army	W81XWH-20-NFRP-CTA	25-Jun-2020 [LOI/Pre-App]	Not Specified
	Contact Name				
	Contact Telephone	301-682-5507			
	Contact Email	help@eBRAP.org			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	25-Jun-2020 [LOI/Pre-App], 09-Jul-2020			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The vision of the FY20 NFRP is to decrease the clinical impact of NF. Toward this end, the NFRP seeks to support innovative, high-impact research that will foster new directions for and address neglected issues in NF research; sponsor multidisciplinary and multi-institutional collaborations that will bring new perspectives to the field; promote translational and clinical studies to move promising ideas from bench to bedside; and develop a balanced portfolio of meritorious research related to all aspects of NF1, NF2, and schwannomatosis. The NFRP Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of NF. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first in human, Phase 0), to demonstrate feasibility or inform the design of more advanced trials, through large-scale trials to determine efficacy in relevant patient populations.			
091680	Tuberous Sclerosis Complex Research Program--Idea Development Award	Department of the Army	W81XWH-20-TSCR-IDA	18-Jun-2020 [LOI/Pre-App]	450,000 USD
	Contact Name				
	Contact Telephone	301-682-5507			
	Contact Email	help@eBRAP.org			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	18-Jun-2020 [LOI/Pre-App], 09-Jul-2020			
	Synopsis	The Idea Development Award promotes ideas that have the potential to yield high-impact findings and new avenues of investigation. This award mechanism supports conceptually innovative research that could ultimately lead to critical discoveries in TSC research and/or improvements in patient care. Research projects should include a well-formulated, testable hypothesis based on strong preliminary data and scientific rationale. The following are important aspects of the Idea Development Award: --Impact: Applications should articulate both the short- and long-term impact of the proposed research. High-impact research will, if successful, significantly advance TSC research and/or patient care. --Innovation: Innovative research may introduce a new paradigm, challenge existing paradigms, look at existing problems from new perspectives, or exhibit other uniquely creative qualities that may include high-risk/potentially high-gain approaches to TSC research. Research that is merely an incremental advance (the next logical step) is not considered innovative. --Preliminary Data: Unpublished results from the laboratory of the Principal Investigator (PI) or collaborators named on this application, and/or data from the published literature that are relevant to TSC and the proposed research project, are expected.			
090969	Peer Reviewed Cancer Research Program--Virtual Cancer Center Director Award	Department of the Army	W81XWH-20-PRCRP-VCCDA	30-Jul-2020 [LOI/Pre-App]	Not Specified
	Contact Name				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-682-5507</p> <p>Contact Email help@eBRAP.org</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 30-Jul-2020 [LOI/Pre-App], 20-Aug-2020</p> <p>Synopsis The goal of the PRCRP is to improve quality of life by decreasing the impact of cancer on active duty Service members, their families, Veterans, and the American public. The PRCRP is charged by Congress with the mission to investigate cancer risks and knowledge gaps that may be relevant to active duty Service members, their families, other military beneficiaries, and the American public. The Virtual Cancer Center Director Award (VCCDA) mechanism is a unique, interactive virtual cancer center (VCC) focused on bringing together two established investigators (Director and Deputy Director) and up to nine early career investigators (Scholars) to interrogate the commonalities of cancer. Candidates for Scholars will apply to a separate funding opportunity (W81XWH-20-PRCRP-CDA). The Director and Deputy Director will catalyze the growth and professional development of the Scholars in collaboration with the Scholars' Career Guides, assess the progress of the Scholars, promote the cross pollination of different cancer disciplines, and facilitate communication and collaboration amongst all of the VCC members. The overarching goal of the VCC is to develop successful, highly productive Scholars in a collaborative research and career developmental environment. The VCC will provide intensive mentoring, national networking, collaborations, and a peer group for junior faculty. The VCC will give Scholars opportunities to operate in a collegial, highly dynamic, and cutting edge center to lead cancer research to a new frontier. It is the intention that through the VCC, collaborations will foster new growth in different cancers and spur an integrated cancer center to ensure the research advancements across different cancers.</p>				
090910	Peer Reviewed Cancer Research Program--Career Development Award	Department of the Army	W81XWH-20-PRCRP-CDA	30-Jul-2020 [LOI/Pre-App]	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 301-682-5507</p> <p>Contact Email help@eBRAP.org</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 30-Jul-2020 [LOI/Pre-App], 20-Aug-2020</p> <p>Synopsis The PRCRP is seeking to advance cancer research through development of early career investigators. Dependent on the accomplishments of candidates, the PRCRP will offer two distinct early career development options: the Fellow Option (CDA-FO) and the Virtual Cancer Center Scholar Option (CDA-SO). Under this award mechanism, the early-career investigator is considered the Principal Investigator (PI), and the application should focus on the PI's research and career development.</p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Preliminary data are not required. However, logical reasoning and a sound scientific rationale for the proposed research must be demonstrated. This award supports impactful research projects with an emphasis on discovery.					
092630	RFA-FD-21-003 -- Smoking Machine Adaptor Design Project for ENDS, Cigars, and Heated Tobacco Products (UC2) Clinical Trials Not Allowed	Food and Drug Administration/DHHS	RFA-FD-21-003	08-May-2020 [Optional][LOI/Pre-App]	5,000,000 USD
	Contact Name	Christi Wakefield			
	Contact Telephone				
	Contact Email	Christi.Wakefield@fda.hhs.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	08-May-2020 [Optional][LOI/Pre-App], 10-Jul-2020			
	Synopsis	FDA's CTP is seeking to develop a smoking machine adaptor for use with electronic nicotine delivery system (ENDS), cigars, and heated tobacco products that will require significant collaboration and research efforts with outside organizations. The selected organization(s) will develop a single universal adaptor, or standardized family of adaptors, for the attachment of ENDS, cigars, and heated tobacco products to existing smoking machines originally designed for use with cigarettes and make available to tobacco stakeholders, contract and government laboratories, and academic institutions.			
071586	Vet-LIRN Network Capacity-Building Projects	Food and Drug Administration/DHHS	PAR-18-604	13-Jul-2020	2,500,000 USD
	Contact Name	Dr. Olgica Ceric			
	Contact Telephone	240-402-5419			
	Contact Email	olgica.ceric@fda.hhs.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	13-Jul-2020 , 15-Jan-2021 , 15-Apr-2021 , 12-Jul-2021 , 15-Jan-2022 , 15-Apr-2022 , 11-Jul-2022 , 15-Jan-2023 , 15-Apr-2023 , 10-Jul-2023			
	Synopsis	Food and Drug Administration (FDA) invites applications from FDA's Veterinary Laboratory Investigation and Response Network laboratories for research related to emerging public food safety issues identified by the Vet-LIRN network office (VPO), for equipment and personnel necessary to expand laboratory capability and capacity, and for other related activities. This cooperative agreement program is intended to build domestic laboratory capacity as put forth in the Food Safety Modernization Act (FSMA), by developing the Vet-LIRN laboratory Network capabilities and capacity to investigate			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		potential animal foodborne illness outbreaks. This FOA will use the NIH U18 Research Demonstration – Cooperative Agreements award mechanism.			
089296	ROSES 2020: Ecological Forecasting	National Aeronautics & Space Administration	NNH20ZDA001N-ECOF	17-Jul-2020 [LOI/Pre-App]	Not Specified
	Contact Name	Woody Turner			
	Contact Telephone	202-358-1662			
	Contact Email	Woody.Turner@nasa.gov			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	17-Jul-2020 [LOI/Pre-App], 14-Aug-2020			
	Synopsis	<p>Ecological Forecasting is an applications area in the NASA Earth Science Division’s Applied Sciences Program. This program element seeks proposals for Applications Projects that develop and demonstrate applications of Earth observations for the conservation of nature. In particular, this program element focuses on two approaches to nature conservation: 1) measuring and monitoring protected area outcomes and 2) promoting sustainable rewilding for ecosystem restoration.</p> <p>Details are below on the types of proposals sought to address these two approaches. The goal of Applications Projects in the Applied Sciences Program is to transition applications developed by the funded projects to public or private partner organizations (i.e., end users) for their sustained use in decision-making and the provision of services. Please Note: This solicitation has numerous required components detailed in the text that must be addressed for full consideration. Please ensure review and have addressed all requirements before submitting.</p>			
093101	ROSES 2020: Advanced Component Technology	National Aeronautics & Space Administration	NNH20ZDA001N-ACT	21-Jul-2020	Not Specified
	Contact Name	Amber E. Emory			
	Contact Telephone	301--614-6274			
	Contact Email	amber.emory@nasa.gov			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	21-Jul-2020			
	Synopsis	<p>The Advanced Component Technology (ACT) program seeks proposals for technology development leading to new components- as well as subsystem-level spaceborne and/or airborne measurement techniques to be developed in support of the Science Mission Directorate’s Earth Science Division. The ACT program is managed by NASA's Earth Science Technology Office (ESTO). ESTO supports the development of a range of advanced observation and information systems technologies to</p>			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
091603	HERO Appendix F: NASA Human Research Program Omnibus Opportunity	National Aeronautics & Space Administration	80JSC019N0001-OMNIBUS3	30-Jul-2020	150,000 USD

meet the demand of future Earth science measurements and activities addressing the full scientific measurement process. This includes, but is not limited to, instruments needed to make specific observations, data systems, and information products that render observations useful to the scientific community in a timely manner.

Contact Name	Jennifer Fogarty, Ph.D. Chief Scientist, Human Research Program
Contact Telephone	281-483-6089
Contact Email	jennifer.fogarty-1@nasa.gov
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	30-Jul-2020
Synopsis	To expedite progress in various research areas in a short period of time, NASA is requesting proposals for short-term investigations or technology development projects that provide innovative approaches to any of the risks and associated knowledge gaps contained in the Human Research Program (HRP) Integrated Research Plan (IRP). Proposers may access the most current Web-based version of the IRP at the Human Research Roadmap (HRR) Web site at https://humanresearchroadmap.nasa.gov . The results of these short-term investigations are anticipated to deliver new tools, techniques, or knowledge that could lead to novel breakthroughs addressing one or more of the risks and gaps in the IRP. These short-term investigations may provide initial results testing a new scientific approach, or they may provide the initial proof-of-concept for a new technology or method that has not yet been proven as a means to address a risk or gap in the IRP. All short-term investigations are expected to produce novel scientific knowledge or technology development that can stand alone to address a risk or gap in the IRP, but these investigations may also provide the necessary preliminary results to justify a full proposal to a future NASA solicitation.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
032818	Research Grant Program		A-T Children's Project	01-Jul-2020 [LOI/Pre-App]	150,000 USD
	Contact Name	Cynthia Rothblum-Oviatt			
	Contact Telephone	703-765-1223			
	Contact Email	cynthia@atcp.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jul-2020 [LOI/Pre-App], 01-Sep-2020			
	Synopsis	<p>The sponsors greatest interest is in funding translational and clinical research projects, particularly those projects focused on the neurological problems faced by all patients with A-T. They are desperate to deliver new ideas from A-T research with practical relevance for patients into the hands of experts involved in drug discovery and clinical development. They have interest in disease-modifying strategies that would prevent, slow, or stop the progression of the disease as well as symptom-improving strategies that address neural circuit function, immune system health and lung function. The sponsor may occasionally support earlier-stage discovery research, but only if the results of those early-stage projects will clearly (a) reveal and accelerate a path to new treatments (such as validating a drug target) or (b) produce a tool or resource that will help accelerate the development of treatments (such as an A-T animal model that has an obvious neurological impairment, a viral vector that can carry the ATM gene, or a validated disease biomarker that can more quickly measure or predict the efficacy of treatments for the neurological problems of A-T).</p>			
002780	Post Doctoral Fellowship		A-T Children's Project	01-Jul-2020 [LOI/Pre-App]	80,000 USD
	Contact Name				
	Contact Telephone	954-481-6611			
	Contact Email	grants@atcp.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jul-2020 [LOI/Pre-App], 01-Sep-2020			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis | The Post Doctoral Fellowship Award provides competitive support for clinical and translational research related to A-T.

055305	Program to Accelerate Clinical Trials (PACT)	Alzheimer's Drug Discovery Foundation		08-May-2020	3,000,000 USD
--------	--	---------------------------------------	--	-------------	---------------

Contact Name	
Contact Telephone	212-901-8019
Contact Email	grants@alzdiscovery.org
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	08-May-2020 , 10-Jul-2020 [LOI/Pre-App], 07-Aug-2020 , 09-Oct-2020 [LOI/Pre-App], 06-Nov-2020
Synopsis	The true test for new Alzheimer's drugs is in human clinical trials. Numerous treatments for Alzheimer's disease have been shown to be safe and to have some positive effect when tested in animal models of Alzheimer's disease. However, many of these potentially successful treatments have not been brought to human trials because of the increased cost and risk at this stage of research. The goal of this Request for Proposals (RFP) is to increase the number of innovative treatments tested in humans for Alzheimer's disease, related dementias, and cognitive aging.

055304	Drug Development Program	Alzheimer's Drug Discovery Foundation		08-May-2020	600,000 USD
--------	--	---------------------------------------	--	-------------	-------------

Contact Name	Alessio Travaglia, PhD, Scientific Program Officer
Contact Telephone	212-901-7998
Contact Email	atravaglia@alzdiscovery.org
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	08-May-2020 , 10-Jul-2020 [LOI/Pre-App], 07-Aug-2020 , 09-Oct-2020 [LOI/Pre-App], 06-Nov-2020
Synopsis	The focus of this request for proposals is to develop therapeutics for Alzheimer's disease and related dementias. This RFP focuses on building preclinical evidence in animal models and on advancing lead molecules to the clinical candidate selection stage. The proposed studies should have a high probability of reaching IND-enabling studies within

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

two years.

059708	ADDF-Harrington Scholar Program	Alzheimer's Drug Discovery Foundation		31-Jul-2020	600,000 USD
--------	---	---------------------------------------	--	-------------	-------------

Contact Name	
Contact Telephone	212-901-8000
Contact Email	grants@alzdiscovery.org
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	31-Jul-2020
Synopsis	The ADDF-Harrington Scholar Program seeks to accelerate translation of innovative research with potential to prevent, treat, or cure Alzheimer's disease. It provides award recipients with both research funding and committed project support by a team of pharmaceutical industry experts.

059477	Neuromarkers and CSF Biomarker Development Program	Alzheimer's Drug Discovery Foundation		08-May-2020	Not Specified
--------	--	---------------------------------------	--	-------------	---------------

Contact Name	Meriel Owen, PhD, Scientific Program Officer
Contact Telephone	212-901-7992
Contact Email	mowen@alzdiscovery.org
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	08-May-2020 , 10-Jul-2020 [LOI/Pre-App], 07-Aug-2020 , 09-Oct-2020 [LOI/Pre-App], 06-Nov-2020
Synopsis	Given the pathological heterogeneity of Alzheimer's disease and related dementias, new biomarkers are needed to more accurately characterize specific underlying pathophysiology. This RFP seeks to support the development of CSF and neuroimaging biomarkers for multiple contexts of use (see below) that include but are not limited to: Clearly demonstrate target engagement for novel therapeutics The development of biomarkers that can serve as measures of target engagement for novel targets such as neuroinflammation features (e.g. microglial activity, cytokine production,

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>astrocytic activity), synaptic damage, metabolic activity, mitochondrial dysfunction, vascular health and epigenetic changes, among others, are of particular interest. High priority will be given to projects developing biomarkers that can be used in combination with therapies currently in development and serve as companion biomarkers. Detect signs of disease earlier and monitor progression We are seeking programs developing sensitive biomarkers that can detect disease earlier than currently available tests. This includes biomarkers that can predict and monitor conversion from cognitively healthy to mild cognitive impairment (MCI) or MCI to Alzheimer's disease. We also seek prognostic markers that can predict rates of cognitive decline. More accurately diagnose and distinguish between dementia subtypes Many types of dementias can present with similar clinical features, and patients often show overlapping pathologies. At present, it is challenging to distinguish between dementia subtypes. Biomarkers that can distinguish between subtypes and stratify patients in clinical trials are of high priority.</p>				
061078	Request For Proposal: Prevention Beyond The Pipeline	Alzheimer's Drug Discovery Foundation		08-May-2020	Not Specified
	<p>Contact Name Yuko Hara, PhD, Assistant Director, Aging and Alzheimer's Prevention Contact Telephone 212-901-7991 Contact Email yhara@alzdiscovery.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 08-May-2020 , 10-Jul-2020 , 07-Aug-2020 , 09-Oct-2020 [LOI/Pre-App], 06-Nov-2020 Synopsis The ADDF seeks to support prevention drug discovery not covered by most research funders or their current RFPs.</p>				
081154	Korb-Exford Dry Eye Career Development Grant	American Academy of Optometry		01-Jul-2020	25,000 USD
	<p>Contact Name Jennifer Rubin, Grants and Awards Manager Contact Telephone 321-319-4872 Contact Email AAOAwards@aoptom.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 01-Jul-2020</p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The Korb-Exford Dry Eye Career Development Grant is designed to support an individual to further their knowledge in the broad area of dry eye.			
081146	Allergan Foundation Research Grant	American Academy of Optometry		15-Jul-2020	60,000 USD
	Contact Name	Jennifer Rubin, Grants and Awards Manager			
	Contact Telephone	321-319-4872			
	Contact Email	AAOAwards@aoptom.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Jul-2020			
	Synopsis	The Allergan Foundation Research Grant is awarded to support talented optometry and vision science faculty and researchers in innovative research in the area of glaucoma or the anterior segment. One, one-year award, of \$60,000, plus a \$750 travel grant for the Principal Investigator and up to three co-investigators on the project to attend the next annual meeting of the American Academy of Optometry.			
081854	Award for Outstanding Achievement in Basic Cancer Research	American Association for Cancer Research		31-Jul-2020	Not Specified
	Contact Name	Ms. Linda Stokes			
	Contact Telephone	215-446-7128			
	Contact Email	linda.stokes@aacr.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	31-Jul-2020			
	Synopsis	The AACR established the Award for Outstanding Achievement in Basic Cancer Research to recognize an early career investigator on the basis of their meritorious achievements in basic cancer research.			
084443	Minorities in Cancer Research Jane Cooke Wright Lectureship	American Association for Cancer Research		31-Jul-2020	Not Specified

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name | Ms. Linda Stokes
Contact Telephone | 215-446-7128
Contact Email | linda.stokes@aacr.org
Sponsor Website | [Link to sponsor website](#)
Program URL | [Link to program URL](#)
Deadline Dates (ALL) | 31-Jul-2020
Synopsis | The AACR-Minorities in Cancer Research Jane Cooke Wright Lectureship is intended to recognize an outstanding scientist who has made meritorious contributions to the field of cancer research and who has, through leadership or by example, furthered the advancement of minority investigators in cancer research.

053872	AACR Team Science Award	American Association for Cancer Research		31-Jul-2020	Not Specified
--------	---	--	--	-------------	---------------

Contact Name |
Contact Telephone | 215-446-7128
Contact Email | awards@aacr.org
Sponsor Website | [Link to sponsor website](#)
Program URL | [Link to program URL](#)
Deadline Dates (ALL) | 31-Jul-2020
Synopsis | The AACR Team Science Award was established by the American Association for Cancer Research and Eli Lilly and Company to acknowledge and catalyze the growing importance of interdisciplinary teams to the understanding of cancer and/or the translation of research discoveries into clinical cancer applications. The team selected to receive the AACR Team Science Award will collectively be awarded a prize and recognized during the AACR Annual Meeting 2021, at which time all representative institutions will be cited for their contributions to fostering team science.

028774	ACVP/AAVLD Diagnostic Pathology Travel Award	American College of Veterinary Pathologists		01-Jul-2020	1,000 USD
--------	--	---	--	-------------	-----------

Contact Name | Jane Shepard

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Telephone 608-443-2466
 Contact Email meetings@acvp.org
 Sponsor Website [Link to sponsor website](#)
 Program URL [Link to program URL](#)
 Deadline Dates (ALL) 01-Jul-2020
 Synopsis The American College of Veterinary Pathologists (ACVP) and the American Association of Veterinary Laboratory Diagnosticians (AAVLD) encourage trainees in veterinary pathology to participate in the Annual Meetings of both organizations. The ACVP/AAVLD Diagnostic Pathology Travel Award is available to graduate students and/or residents in veterinary pathology for travel to and participation in the Annual Meeting of the AAVLD.

084035	Excellence in Aerospace Standardization Award	American Institute of Aeronautics & Astronautics		01-Jul-2020	Not Specified
--------	---	--	--	-------------	---------------

Contact Name Patricia A. Carr, Honors and Award Manager
 Contact Telephone 800-639-2422
 Contact Email patriciac@aiaa.org
 Sponsor Website [Link to sponsor website](#)
 Program URL [Link to program URL](#)
 Deadline Dates (ALL) 01-Jul-2020
 Synopsis The Excellence in Aerospace Standardization Award is presented to recognize substantive contributions by individuals that advance the health of the aerospace community by enabling cooperation, competition, and growth through the standardization process.

023279	Short-Term Research/Training Fellowship	Asian Pacific Society of Respirology		31-Jul-2020	Not Specified
--------	---	--------------------------------------	--	-------------	---------------

Contact Name
 Contact Telephone +81-3-5684-3370
 Contact Email apsrinfo@theapsr.org



Non Federal Funding Opportunities: July 2020

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Sponsor Website [Link to sponsor website](#)
 Program URL [Link to program URL](#)
 Deadline Dates (ALL) 31-Jul-2020 , 30-Nov-2020
 Synopsis The APSR is funding a scholarship programme with the aims of: promoting science and research in respiratory medicine in the APSR region; supporting the exchange in the APSR region of young scientists and clinicians actively involved in respiratory medicine; and contributing to the development of research and science of respiratory medicine in the APSR region.

079141	Exceptional Project Grants	Breast Cancer Alliance, Inc.		24-Jul-2020	100,000 USD
--------	--	------------------------------	--	-------------	-------------

Contact Name
 Contact Telephone 203-861-0014
 Contact Email researchgrants@breastcanceralliance.org
 Sponsor Website [Link to sponsor website](#)
 Program URL [Link to program URL](#)
 Deadline Dates (ALL) 24-Jul-2020
 Synopsis Breast Cancer Alliance (BCA) offers Exceptional Project Grants to recognize creative, unique and innovative research. Clinical doctors and research scientists whose primary focus is breast cancer are invited to apply. This is a one year grant for a total of \$100,000.

059797	Young Investigator Grant Program	Breast Cancer Alliance, Inc.		24-Jul-2020	125,000 USD
--------	--	------------------------------	--	-------------	-------------

Contact Name
 Contact Telephone 203-861-0014
 Contact Email researchgrants@breastcanceralliance.org
 Sponsor Website [Link to sponsor website](#)
 Program URL [Link to program URL](#)

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	24-Jul-2020			
	Synopsis	To encourage a commitment to breast cancer research, the Breast Cancer Alliance invites clinical doctors and research scientists whose primary focus is breast cancer research, and who are in the early stages of their career, to apply for funding for the Young Investigator Grant.			
025620	Thomas C Chalmers Award	Cochrane Collaboration		11-Jul-2020	500 USD
	Contact Name				
	Contact Telephone				
	Contact Email	abstracts@cochrane.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	11-Jul-2020			
	Synopsis	The Cochrane Collaboration gives an award at each Cochrane Colloquium to the principal author of both the best oral and the best poster presentation addressing methodological issues related to systematic reviews given by an early career investigator. The presentations must demonstrate originality of thought, high quality science, relevance to the advancement of the science of systematic reviews, and clarity of presentation.			
059521	Grants Program	Conservation, Food and Health Foundation		01-Jul-2020 [LOI/Pre-App]	20,000 USD
	Contact Name	Prentice Zinn			
	Contact Telephone	617-391-3091			
	Contact Email	pzinn@gmafoundations.com			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jul-2020 [LOI/Pre-App], 01-Sep-2020			
	Synopsis	The Conservation, Food and Health Foundation seeks to protect natural resources, improve the production and distribution of food, and promote public health in Asia, Africa, Latin America, and the Middle East. The foundation			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

helps build the capacity of organizations and coalitions with grants that support research or improve the learning and generation of local solutions to complex problems. The foundation supports projects that demonstrate local leadership and promote professional development in the conservation, agricultural, and health sciences; develop the capacity of local organizations; and address a particular problem or question in the field. It prefers to support projects that address under-funded issues and geographic areas.

032505	CGS/ProQuest Distinguished Dissertation Award --Biological Sciences	Council of Graduate Schools		02-Jul-2020	2,000 USD
--------	---	-----------------------------	--	-------------	-----------

Contact Name	Anna M. Naranjo
Contact Telephone	202-223-3791
Contact Email	anaranjo@cgs.nche.edu
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	02-Jul-2020
Synopsis	The CGS/ProQuest Distinguished Dissertation Awards are made each year to individuals who, in the opinion of the award committee, have completed dissertations representing original work that makes an unusually significant contribution to the discipline. Two awards are given annually in two different broad areas (mathematics, physical sciences and engineering; and social sciences; and the biological sciences; and humanities and fine arts). The 2020 fields of competition are: Mathematics, Physical Sciences, Engineering and Social Sciences.

039877	CGS/ProQuest Distinguished Dissertation Award --Mathematics, Physical Sciences and Engineering	Council of Graduate Schools		02-Jul-2020	2,000 USD
--------	--	-----------------------------	--	-------------	-----------

Contact Name	Anna M. Naranjo
Contact Telephone	202-223-3791
Contact Email	anaranjo@cgs.nche.edu
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	02-Jul-2020

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis CGS invites applications for the CGS/ProQuest Distinguished Dissertation Award, made annually to individuals who, in the opinion of the award committee, have completed dissertations representing original work that makes an unusually significant contribution to the discipline. Two awards are given annually in two different broad areas (mathematics, physical sciences and engineering; and social sciences; and the biological sciences; and humanities and fine arts). Individuals must be nominated for these awards by a member institution.

000055	Research Fellowship Awards	Crohn's & Colitis Foundation of America		05-May-2020 [LOI/Pre-App]	174,750 USD
--------	--	---	--	------------------------------	----------------

Contact Name Orlando Green
Contact Telephone 646-943-7501
Contact Email ogreen@crohnscolitisfoundation.org
Sponsor Website [Link to sponsor website](#)
Program URL [Link to program URL](#)
Deadline Dates (ALL) 05-May-2020 [LOI/Pre-App], 20-Jul-2020
Synopsis The Crohn's & Colitis Foundation's Research Fellowship Awards are intended to support individuals in the post-doctoral phase of their career, to develop skills related to basic and/or clinical investigation in the field of inflammatory bowel disease (IBD), or Crohn's disease and ulcerative colitis.

001440	Career Development Awards	Crohn's & Colitis Foundation of America		05-May-2020 [LOI/Pre-App]	270,000 USD
--------	---	---	--	------------------------------	----------------

Contact Name
Contact Telephone 646-943-7501
Contact Email mmbesch@crohnscolitisfoundation.org
Sponsor Website [Link to sponsor website](#)
Program URL [Link to program URL](#)
Deadline Dates (ALL) 05-May-2020 [LOI/Pre-App], 20-Jul-2020
Synopsis The goal of the Career Development Award (CDA) is to encourage a career of independent basic and/or clinical

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		investigation in the area of Crohn's disease and ulcerative colitis research.			
083322	Crohn's & Colitis Foundation/NASPGHAN IBD Young Investigator Award	Crohn's & Colitis Foundation of America		05-May-2020 [LOI/Pre-App]	Not Specified
	Contact Name				
	Contact Telephone	646-943-7505			
	Contact Email	grant@crohnscolitisfoundation.org			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-May-2020 [LOI/Pre-App], 20-Jul-2020 , 05-Nov-2020 [LOI/Pre-App], 28-Jan-2021			
	Synopsis	This three-year grant, in partnership with the NASPGHAN Foundation and the Crohn's & Colitis Foundation, is available to research fellows or junior faculty. Applications must propose original clinical, translational, epidemiological, or basic scientific research related to pediatric inflammatory bowel disease.			
063869	Litwin IBD Pioneers Initiative	Crohn's & Colitis Foundation of America		20-May-2020 [LOI/Pre-App]	Not Specified
	Contact Name				
	Contact Telephone	646-943-7505			
	Contact Email	grant@crohnscolitisfoundation.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	20-May-2020 [LOI/Pre-App], 20-Jul-2020			
	Synopsis	The Litwin IBD Pioneers Initiative supports innovative clinical and translational research projects with the potential to impact the treatment of IBD patients in the near future. The program encourages novel research into the diagnosis, identification of clinically relevant subsets, treatments, and cures for inflammatory bowel diseases (IBD) and funds innovative pilot research so that scientists can test their initial ideas and generate preliminary data.			
033065	Clinical Pilot and Feasibility Awards	Cystic Fibrosis Foundation		17-Jul-2020	Not

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Specified

Contact Name	
Contact Telephone	301-841-2614
Contact Email	grants@cff.org
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	17-Jul-2020
Synopsis	Clinical Research Awards are offered to provide support for investigator-initiated clinical research projects that have the potential to make an important contribution to the CF Foundation's mission. Research projects may address diagnosis, treatment, management of disease or symptom, or the pathophysiology of CF using clinical observational/interventional), translational or epidemiologic study approaches. Applicants must demonstrate access to sufficient numbers of CF patients and appropriate controls.

061719	Seedcorn Funding Programme	Cystinosis Ireland		31-Jul-2020	10,000 USD
--------	--	--------------------	--	-------------	------------

Contact Name	
Contact Telephone	01 828 0483
Contact Email	research@cystinosis.ie
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	31-Jul-2020
Synopsis	The Cystinosis Seedcorn Funding Programme aims to provide researchers with the opportunity to generate solid preliminary data which would contribute to a sustainable, longer-term application for funding. Funding is available to research institutions worldwide.

092281	Damon Runyon-Rachleff Innovation Award	Damon Runyon Cancer Research Foundation		01-Jul-2020	400,000 USD
--------	--	---	--	-------------	-------------

Contact Name	
--------------	--

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone 212-455-0520 Contact Email awards@damonrunyon.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 01-Jul-2020 Synopsis The Damon Runyon-Rachleff Innovation Award is designed to provide support for the next generation of exceptionally creative thinkers with “high-risk/high-reward” ideas that have the potential to significantly impact our understanding of and/or approaches to the prevention, diagnosis or treatment of cancer. The Stage 1 award will be for two years, \$200,000 per year (\$400,000 total) with the opportunity for up to two additional years of funding (up to four years total for \$800,000). Stage 2 support for years three and four will be granted to those awardees who demonstrate progress on their proposed research during years one and two of the award.				
004329	Grants Program		Drown (Joseph) Foundation	15-Jul-2020	Not Specified
	Contact Name Alyssa Santino, Program Officer Contact Telephone 310-277-4488 x100 Contact Email alyssa@jdrown.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 15-Jul-2020 , 15-Oct-2020 Synopsis The Joseph Drown Foundation provides support in the areas of education; community, health and social services; medical and scientific research; arts and humanities; and special projects. Tax-exempt organizations, primarily in the state of California, are eligible. The Foundation makes grants for both operating support and program support, but does not make multi-year commitments. Organizations may receive funding up to four years, after which they must take a two-year hiatus.				
086707	Grant Program		EB Research Partnership (EBRP)	15-Jul-2020	Not Specified

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Name Contact Telephone 664-844-0902 Contact Email grants@ebresearch.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 15-Jul-2020 Synopsis EB Research Partnership (EBRP), a 501(c)(3) non-profit organization, seeks to award grant funding for research with the potential to lead directly to commercially feasible products and therapies for treating and/or curing Epidermolysis Bullosa (EB).				
057992	Simulation Research Grant		Emergency Medicine Residents' Association	15-Jul-2020	500 USD
	Contact Name Contact Telephone 972-550-0920 Contact Email awards@emra.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 15-Jul-2020 Synopsis The purpose of the EMRA Simulation Research Grant is to provide research funding to Emergency Medicine (EM) physician-in-training interested in completing simulation-based projects during residency/medical school.				
009737	ECCO Grants		European Crohn's and Colitis Organisation	31-Jul-2020	87,200 USD
	Contact Name Contact Telephone +43-01-710 2242-0 Contact Email ecco@ecco-ibd.eu Sponsor Website Link to sponsor website				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Program URL	Link to program URL
Deadline Dates (ALL)	31-Jul-2020
Synopsis	The European Crohn's and Colitis Organisation (ECCO) offers Research Grants to promote innovative scientific research in the area of Inflammatory Bowel Diseases (IBD) in Europe. ECCO Grants are designed to support IBD Research within the country of affiliation. Typically, research for ECCO Grant projects is undertaken in the own institution of the applicant. Target audience are young basic and/or clinical scientists not older than 40 years, or if above than being within 5 years after finishing GI training or PhD graduation. Up to eight ECCO Grants may be given each year.

057307	Research Grants	Fibrolamellar Cancer Foundation		01-Jul-2020	Not Specified
--------	---------------------------------	---------------------------------	--	-------------	---------------

Contact Name	
Contact Telephone	203-3400-7800
Contact Email	grants@fibrofoundation.org
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	01-Jul-2020 , 01-Jan-2021
Synopsis	The Fibrolamellar Cancer Foundation (FCF) is accepting proposals to support innovative research, leading to curative treatments for this aggressive teen/young adult liver cancer.

090145	Investigating Environmental Factors that Increase the Risk for Parkinson's Disease	Fox (Michael J.) Foundation for Parkinson's Research		14-May-2020 [LOI/Pre-App]	400,000 USD
--------	--	--	--	---------------------------	-------------

Contact Name	
Contact Telephone	800-708-7644
Contact Email	grants@michaelifox.org
Sponsor Website	Link to sponsor website
Program URL	Link to program URL

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 14-May-2020 [LOI/Pre-App], 22-Jul-2020</p> <p>Synopsis The purpose of this Request for Applications (RFA) is to investigate environmental exposures, such as chemicals or toxic emissions, that increase the risk of Parkinson's Disease (PD) and/or influence disease progression. While there are reports linking a variety of environmental factors with risk of PD, much remains unknown regarding the identification of specific environmental factors, their role in disease, and quantification of their contributions. A better understanding of such factors could lead to efforts to reduce or prevent such exposures in order to reduce the risk of PD.</p>				
076236	General Research Grants	Friedreich's Ataxia Research Alliance		15-Jul-2020 [LOI/Pre-App]	300,000 USD
	<p>Contact Name</p> <p>Contact Telephone 484-879-6160</p> <p>Contact Email info@curefa.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Jul-2020 [LOI/Pre-App], 15-Sep-2020</p> <p>Synopsis FARA supports research through funding competitive grants, promoting collaboration among scientists, advocating for public-private partnerships that support drug discovery, drug development and clinical research and hosting open forums for leading scientists to share their insights, ideas and challenges to advancing treatments for Friedreich's ataxia.</p>				
036255	Kyle Bryant Translational Research Award	Friedreich's Ataxia Research Alliance		15-May-2020 [LOI/Pre-App]	500,000 USD
	<p>Contact Name</p> <p>Contact Telephone 484-879-6160</p> <p>Contact Email grants@curefa.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Deadline Dates (ALL) 15-May-2020 [LOI/Pre-App], 15-Jul-2020

Synopsis The Kyle Bryant Translational Research Award is given to proposals focused on pre-clinical and clinical investigations that will advance treatments for Friedreich's Ataxia.

067688 [Gilead Sciences Research Scholars Program in Cystic Fibrosis](#)

Gilead Sciences

31-Jul-2020

Not Specified

Contact Name

Contact Telephone 919-534-7653

Contact Email gileadsciences@bcdme.com

Sponsor Website [Link to sponsor website](#)

Program URL [Link to program URL](#)

Deadline Dates (ALL) 31-Jul-2020

Synopsis The mission of the Gilead Sciences Research Scholars Program in Cystic Fibrosis is to support innovative research from emerging investigators around the world to advance scientific knowledge in areas of unmet medical needs and improve the lives of patients everywhere. Gilead Sciences, Inc. hopes that the research supported by these awards will enhance understanding of cystic fibrosis.

057289 [Mid-Career Research Award](#)

Hemostasis & Thrombosis Research Society, Inc.

20-Jul-2020

216,000 USD

Contact Name Dr. Terri Holzen

Contact Telephone 414-937-6569

Contact Email tholzen@versiti.org

Sponsor Website [Link to sponsor website](#)

Program URL [Link to program URL](#)

Deadline Dates (ALL) 20-Jul-2020

Synopsis The HTRS Mid-Career Research Award (MCRA) Program provides financial support for mid-career investigators pursuing clinical, translational, or basic science research projects in hemostasis and/or thrombosis. The

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

maximum 2019 MCRA over two years is \$216,000.

057155	Grants Program		Hofmann (Kent Richard) Foundation	31-Jul-2020 [LOI/Pre-App]	Not Specified
--------	--------------------------------	--	-----------------------------------	------------------------------	---------------

Contact Name	Eliza McAllister
Contact Telephone	917-573-0486
Contact Email	krhofmann@gmail.com
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	31-Jul-2020 [LOI/Pre-App], 28-Aug-2020
Synopsis	Kent Richard Hofmann Foundation, a private foundation dedicated to the fight against HIV and AIDS, invites applications from non-profit organizations, in support of: Care and direct services; Education; and Research.

081163	SWOG/Hope Foundation Impact Award		Hope Foundation for Cancer Research	01-Jul-2020 [LOI/Pre-App]	250,000 USD
--------	---	--	-------------------------------------	------------------------------	----------------

Contact Name	Johanna Horn
Contact Telephone	734-998-7150
Contact Email	jo@thehopefoundation.org
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	01-Jul-2020 [LOI/Pre-App], 01-Sep-2020
Synopsis	The SWOG/Hope Foundation Impact Award is a funding program that encourages novel and innovative SWOG research by supporting early and conceptual stages of these projects.

033209	HD Human Biology Project - HDSA Research Fellowship		Huntington's Disease Society of America, Inc.	22-May-2020 [LOI/Pre-App]	150,000 USD
--------	---	--	---	------------------------------	----------------

Contact Name | Dr. George Yohrling, Senior Director of Mission and Scientific Affairs

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone	212-242-1968			
	Contact Email	GYohrling@hdsa.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	22-May-2020 [LOI/Pre-App], 24-Jul-2020			
	Synopsis	The HD Human Biology Project provides support for investigator-initiated research directed to better understand the biology of Huntington's disease (HD) as it occurs in humans. The research projects and observations resulting from them should have the potential to directly impact the lives of patients or help guide future drug development for HD.			
030361	Conference Travel Awards		International Continenence Society	01-Jul-2020	1,240 USD
	Contact Name				
	Contact Telephone	+44 117 9444881			
	Contact Email	awards@ics.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jul-2020			
	Synopsis	The ICS aims to advance bladder and bowel science, promote multi-disciplinary continence care and encourage the development of continence services in less economically developed countries.			
019867	Milstein Young Investigator Award		International Cytokine and Interferon Society	15-May-2020	1,500 USD
	Contact Name	Joan Oefner, Managing Director			
	Contact Telephone	1-800-947-1960			
	Contact Email	joefner@cytokinesociety.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-May-2020 , 15-Jul-2020			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis Every year up to five awards are granted to International Cytokine and Interferon Society (ICIS) members who have received a Ph.D or M.D. within the previous 10 years and have made notable contributions to either basic or clinical research.

019869	Sidney & Joan Pestka Graduate and Post-Graduate Awards in Interferon & Cytokine Research	International Cytokine and Interferon Society		15-May-2020	7,500 USD
--------	--	---	--	-------------	-----------

Contact Name Joan Oefner, Managing Director
Contact Telephone 800-947-1960
Contact Email joefner@cytokinesociety.org
Sponsor Website [Link to sponsor website](#)
Program URL [Link to program URL](#)

Deadline Dates (ALL) 15-May-2020 , 15-Jul-2020

Synopsis The Sidney & Joan Pestka Graduate and Post-Graduate Awards are targeted to graduate students and post-doctoral fellows who have begun to make an impact in interferon and cytokine research.

020749	Primary Grants	International Mechanical Diagnosis and Therapy Research Foundation		01-Jul-2020	50,000 USD
--------	--------------------------------	--	--	-------------	------------

Contact Name
Contact Telephone
Contact Email info@imdtrf.org
Sponsor Website [Link to sponsor website](#)
Program URL [Link to program URL](#)

Deadline Dates (ALL) 01-Jul-2020

Synopsis This foundation is seeking grant applications to further research into the usefulness and limitations of Mechanical Diagnosis and Therapy (MDT). Consideration will be given to proposals examining basic and clinical sciences with the ultimate aim of improving the quality of care for musculoskeletal patients. New or experienced investigators are encouraged to apply. Preference will be given to proposals that include functional outcomes assessments. Proposals

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

will be subjected to a peer-review process and only the highest quality projects will receive funding. The Primary Grant mechanism will fund up to \$50,000 USD for a 2 year proposal. Proposals to this mechanism must be original projects. Pilot study proposals are encouraged.

093725	Research Fellowships		Internationales Forschungszentrum Kulturwissenschaften	05-Jul-2020	10,137 USD
--------	--------------------------------------	--	---	-------------	------------

Contact Name	
Contact Telephone	+43-1-504 11 26
Contact Email	ifk@ifk.ac.at
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	05-Jul-2020
Synopsis	The IFK's Research Fellowships are intended for postdoctoral researchers.

093722	Senior Fellowships		Internationales Forschungszentrum Kulturwissenschaften	01-Jul-2020	10,137 USD
--------	------------------------------------	--	---	-------------	------------

Contact Name	
Contact Telephone	+43-1-504 11 26
Contact Email	ifk@ifk.ac.at
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	01-Jul-2020
Synopsis	The IFK's Senior Fellowships are designed to support excellent scholars, who are well advanced in their academic careers.

081724	Therapeutic Area Contributions - Infectious Diseases Program		Janssen Pharmaceuticals, Inc.	31-May-2020	Not Specified
--------	--	--	-------------------------------	-------------	---------------

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Name Contact Telephone 908-218-6095 Contact Email Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 31-May-2020 , 31-Jul-2020 , 30-Sep-2020 , 15-Nov-2020 Synopsis The sponsor makes charitable contributions to support therapeutic area initiatives. Applications are evaluated competitively with emphasis given to innovative programs with measurable outcomes that address disparities or unmet needs. The Infectious Diseases area of interest supports the following disease states: Hepatitis B; HIV / AIDS; Respiratory Infections; and Vaccines.				
052803	Clinical Scholars Program	Johnson (Robert Wood) Foundation		09-Jul-2020	Not Specified
	Contact Name Melissa Green, MPH Contact Telephone 919-843-3304 Contact Email clinical.scholars@unc.edu Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 09-Jul-2020 Synopsis The Robert Wood Johnson Foundation (RWJF) offers a three-year fellowship for clinically active health care providers spanning a range of professions. The program offers providers the opportunity to build and develop the unique skills they need to lead communities and organizations toward a Culture of Health. Strong applicants include a team of innovative providers that will bring a knowledge of and experience in the art and science of health care services; a unique perspective as providers in health and health care systems; and an understanding of the special professional status and relationship with patients and communities.				
007466	Other Awards (Capital Funding, Equipment Grants, Clinical Support)	Kendall (Kay) Leukaemia Fund		15-Jul-2020	Not Specified

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name
Contact Telephone 020 7410 0330
Contact Email info@kklf.org.uk
Sponsor Website [Link to sponsor website](#)
Program URL [Link to program URL](#)
Deadline Dates (ALL) 15-Jul-2020
Synopsis The Kay Kendall Leukaemia Fund will award capital funding, equipment grants, and clinical care grants for research on aspects of leukaemia and for relevant studies on related haematological malignancies.

090535	Project Grants	Kendall (Kay) Leukaemia Fund		15-Jul-2020	Not Specified
--------	--------------------------------	------------------------------	--	-------------	---------------

Contact Name
Contact Telephone 020 7410 0330
Contact Email info@kklf.org.uk
Sponsor Website [Link to sponsor website](#)
Program URL [Link to program URL](#)
Deadline Dates (ALL) 15-Jul-2020
Synopsis The Kay Kendall Leukaemia Fund awards grants for research on aspects of leukaemia and for relevant studies on related haematological malignancies.

043095	Grants Program	Lloyd's Register Foundation		28-May-2020	Not Specified
--------	--------------------------------	-----------------------------	--	-------------	---------------

Contact Name
Contact Telephone +44 (0)20 7709 9166
Contact Email info@lrfoundation.org.uk
Sponsor Website [Link to sponsor website](#)

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Program URL [Link to program URL](#)
 Deadline Dates (ALL) 28-May-2020 , 24-Jun-2020 , 27-Jul-2020 , 27-Aug-2020 , 28-Sep-2020 , 28-Oct-2020 , 30-Nov-2020
 Synopsis Lloyd's Register Foundation awards grants to research and education organisations to achieve its mission: to secure, for the benefit of the community, high technical standards of design, manufacture, construction, maintenance, operation and performance for the purpose of enhancing the safety of life and property, at sea, and on land and in the air; and the advancement of public education including within the transportation industries and any other engineering and technological disciplines.

017361	Thoracic Pathology Fellowship	Memorial Sloan-Kettering Cancer Center	31-Jul-2020	Not Specified
--------	---	--	-------------	---------------

Contact Name Nicole Rinaldi
 Contact Telephone 212-639-7102
 Contact Email RinaldiN@mskcc.org
 Sponsor Website [Link to sponsor website](#)
 Program URL [Link to program URL](#)
 Deadline Dates (ALL) 31-Jul-2020
 Synopsis The Department of Pathology offers a Thoracic Pathology Fellowship Training Program. A clinical year is accredited by the Accreditation Council for Graduate Medical Education (ACGME). A second optional research year focuses on the molecular biology of thoracic disease.

058805	Investigator Studies Program (MISP) -- Surgery -- Anesthesia	Merck	19-Jun-2020	Not Specified
--------	--	-------	-------------	---------------

Contact Name Lisa Mount
 Contact Telephone 267-305-1258
 Contact Email lisa_mount@merck.com
 Sponsor Website [Link to sponsor website](#)
 Program URL [Link to program URL](#)

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Deadline Dates (ALL) 19-Jun-2020 , 02-Jul-2020 [LOI/Pre-App], 17-Aug-2020 , 01-Sep-2020 [LOI/Pre-App], 19-Oct-2020

Synopsis The Investigator Studies Program aims to advance science and improve patient care by supporting, through the provision of drug/vaccine and/or total/partial funding, high-quality research that is initiated, designed, implemented and sponsored by external investigators. Results will be generated and properly disseminated in peer-reviewed publications.

028525	Large Companion Animal (Horses and Llamas/Alpacas) - Established Investigator Grants	Morris Animal Foundation		08-Jul-2020	50,000 USD
--------	--	--------------------------	--	-------------	------------

Contact Name
Contact Telephone 303-790-2345
Contact Email grantapplications@morrisanimalfoundation.org
Sponsor Website [Link to sponsor website](#)
Program URL [Link to program URL](#)
Deadline Dates (ALL) 08-Jul-2020

Synopsis Morris Animal Foundation's Large Companion Animal (Horses and Llamas/Alpacas) Program invites proposals for Established Investigator Grants on topics relevant to large companion animal health and welfare.

058261	Fellows Award	MQ		03-Jul-2020	279,000 USD
--------	-------------------------------	----	--	-------------	-------------

Contact Name
Contact Telephone +44 (0)333 440 1220
Contact Email grants@mqmentalhealth.org
Sponsor Website [Link to sponsor website](#)
Program URL [Link to program URL](#)
Deadline Dates (ALL) 03-Jul-2020

Synopsis MQ: Transforming Mental Health is seeking talented researchers with bold ideas from across the globe, who aspire to be the next generation of leaders in mental health research. MQ Fellows Awards will provide funding of up to

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

£225,000 (GBP) for up to a period of three years.

073620	Maxwell Finland Award for Scientific Achievement	National Foundation for Infectious Diseases		15-Jul-2020	Not Specified
--------	--	---	--	-------------	---------------

Contact Name	
Contact Telephone	301-656-0003
Contact Email	info@nfid.org
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	15-Jul-2020
Synopsis	The Maxwell Finland Award for Scientific Achievement is presented annually by NFID to honor scientists who have made outstanding contributions to the understanding of infectious diseases and public health.

073621	Jimmy and Rosalynn Carter Humanitarian Award	National Foundation for Infectious Diseases		15-Jul-2020	Not Specified
--------	--	---	--	-------------	---------------

Contact Name	
Contact Telephone	301-656-0003
Contact Email	info@nfid.org
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	15-Jul-2020
Synopsis	The Jimmy and Rosalynn Carter Humanitarian Award is presented annually by NFID to honor individuals whose outstanding humanitarian efforts and achievements have contributed significantly to improving global public health through domestic and/or international activities. Priority is given to contributions in the area of infectious diseases.

063032	Junior Faculty Research Award -- Clinical Science	National Lipid Association		01-Jul-2020	70,000 USD
--------	---	----------------------------	--	-------------	------------

Contact Name

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone	904-998-0854			
	Contact Email				
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jul-2020			
	Synopsis	The purpose of the NLA Junior Faculty Research is to encourage scholarly advancement of Junior Faculty in the pursuit of a career related to hyperlipidemia and other lipid disorders in humans. The NLA will fund eligible institutions to provide \$70,000 per year in salary support for those actively involved in clinical and/or basic science that provides promise of developing new information in fields of study that could advance the diagnosis and management of lipid disorders such as biochemistry, physiology, or genetics as well as interventions that improve therapy. The institutions eligible shall be non profit and offer an environment that would logically support a young faculty member with appropriate equipment, space and experienced faculty for proposed studies. The proposal will identify a specific candidate with training and strong signs of early success in an appropriate area of research and with a plan for developing appropriate experiments or clinical studies.			
063030	Junior Faculty Research Award -- Basic Science	National Lipid Association		01-Jul-2020	70,000 USD
	Contact Name				
	Contact Telephone	904-998-0854			
	Contact Email				
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jul-2020			
	Synopsis	The purpose of the NLA Junior Faculty Research is to encourage scholarly advancement of Junior Faculty in the pursuit of a career related to hyperlipidemia and other lipid disorders in humans. The NLA will fund eligible institutions to provide \$70,000 per year in salary support for those actively involved in clinical and/or basic science that provides promise of developing new information in fields of study that could advance the diagnosis and management of lipid disorders such as biochemistry, physiology, or genetics as well as interventions that improve therapy. The institutions eligible shall be non profit and offer an environment that would logically support a young faculty member with			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

appropriate equipment, space and experienced faculty for proposed studies. The proposal will identify a specific candidate with training and strong signs of early success in an appropriate area of research and with a plan for developing appropriate experiments or clinical studies.

074733	Accelerator Award	Neuroendocrine Tumor Research Foundation		20-Jul-2020	1,200,000 USD
--------	-----------------------------------	--	--	-------------	---------------

Contact Name	
Contact Telephone	617-946-1780
Contact Email	grants@netrf.org
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	20-Jul-2020
Synopsis	The Neuroendocrine Tumor Research Foundation (NETRF) seeks investigators and teams with the tools to study neuroendocrine cancers in innovative and transformative ways. Awards of \$1.2 million are available.

093326	COVID-19 Relief & Response Campaign Grant	NORCAL Group Foundation		31-Jul-2020	10,000 USD
--------	---	-------------------------	--	-------------	------------

Contact Name	
Contact Telephone	
Contact Email	grants@norcalgroupfoundation.org
Sponsor Website	Link to sponsor website
Program URL	
Deadline Dates (ALL)	31-Jul-2020
Synopsis	The Foundation is providing special grants to charitable organizations focused on Virtual Telehealth, Caregiver Counseling or Protective Equipment in their fight against the impact of COVID-19.

084914	Hall Award for Clinically Innovative Research Paper by a Junior Investigator	Pediatric Infectious Diseases Society		15-Jul-2020	Not Specified
--------	--	---------------------------------------	--	-------------	---------------

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Name	Attn: Nominations and Awards Committee			
	Contact Telephone	703-299-6764			
	Contact Email	pids@idsociety.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Jul-2020			
	Synopsis	The Hall Award for Clinically Innovative Research Paper by a Junior Investigator will be presented annually by the Pediatric Infectious Diseases Society to a junior investigator who is the first author of a paper that best illustrates Dr. Caroline B. Hall's innovative approach to clinical research.			
089504	Medical Education Grants -- Local Level Educational Grants Program to Increase Awareness & Understanding of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)	Pfizer Pharmaceuticals		29-May-2020	20,000 USD
	Contact Name	Amanda Stein, Grant Officer			
	Contact Telephone	212-733-2323			
	Contact Email	amanda.j.stein@pfizer.com			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	29-May-2020 , 31-Jul-2020 , 30-Sep-2020 , 30-Oct-2020			
	Synopsis	Pfizer requests applications focused on improving the care of patients on the local level with Transthyretin Cardiomyopathy (ATTR-CM). Individual projects of up to \$20,000 will be considered.			
093013	Artificial Intelligence/Machine Learning Research in Hemophilia	Pfizer Pharmaceuticals		30-Jul-2020	450,000 USD
	Contact Name				
	Contact Telephone	212-733-2323			
	Contact Email	GMG@pfizer.com			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	30-Jul-2020			
	Synopsis	Projects that will be considered for Pfizer support will focus on Artificial Intelligence/Machine Learning.			
093414	NASH – Future of Non-invasive Diagnosis Technologies	Pfizer Pharmaceuticals		30-Jul-2020	250,000 USD
	Contact Name	Angelo Carter			
	Contact Telephone	212-733-2323			
	Contact Email	angelo.carter@pfizer.com			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	30-Jul-2020			
	Synopsis	It is the sponsor's intent to provide an independent grant(s) to an organization or organizations that will focus on the future of non-invasive diagnosis for nonalcoholic steatohepatitis (NASH).			
016536	Garite Mini-Sabbatical Grants	Pregnancy Foundation		01-Jul-2020	10,000 USD
	Contact Name				
	Contact Telephone	202-517-7068			
	Contact Email	foundation@smfm.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jul-2020			
	Synopsis	The Garite Mini-Sabbatical Grants allow recipients to gain or expand skills in clinical practice or research under the guidance of experts in the field of maternal-fetal medicine. The Foundation for SMFM awards up to \$10,000 in funding for mini-sabbatical grants each year to members of the Society for Maternal-Fetal Medicine (SMFM), including MFM fellows in ABOG-approved or DO-approved MFM fellowship programs.			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
077263	Medical Research Grant	Progeria Research Foundation		01-Jul-2020 [LOI/Pre-App]	75,000 USD
	Contact Name				
	Contact Telephone	978- 535-2594			
	Contact Email	researchgrants@progeriaresearch.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jul-2020 [LOI/Pre-App], 01-Oct-2020			
	Synopsis	The Progeria Research Foundation (PRF) is a driving force worldwide in finding treatments and the cure for Progeria and its aging-related disorders, including heart disease. Phase I awards are typically for 1-2 years at a maximum of \$75,000/year.			
058323	Microgrant Program	Rare Disease Foundation		31-Jul-2020	3,500 USD
	Contact Name				
	Contact Telephone	866-348-6677			
	Contact Email	research@rarediseasefoundation.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	31-Jul-2020			
	Synopsis	The Rare Disease Foundation, in collaboration with BCCHF, and Global Genes, provides microgrants to expedite exploration of new ideas for understanding rare diseases and improving patient care. Awards of up to \$5,000 will be available.			
070888	RPB Stein Innovation Awards	Research to Prevent Blindness		15-Jun-2020 [LOI/Pre-App]	300,000 USD
	Contact Name	Pattie Moran			
	Contact Telephone	646-892-9566			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email pmoran@rpbusa.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Jun-2020 [LOI/Pre-App], 01-Jul-2020</p> <p>Synopsis The RPB Stein Innovation (SI) Awards provide funds to two groups of researchers, both with a common goal of understanding the visual system and the diseases that compromise its function. These SI Awards are intended to provide seed money to proposed high-risk/high-gain vision science research which is innovative, cutting-edge, and demonstrates out-of-the-box thinking.</p>				
006942	Career Development Awards		Research to Prevent Blindness	15-Jun-2020 [LOI/Pre-App]	300,000 USD
	<p>Contact Name</p> <p>Contact Telephone 646-892-9566</p> <p>Contact Email pmoran@rpbusa.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Jun-2020 [LOI/Pre-App], 01-Jul-2020</p> <p>Synopsis The RPB Career Development Award helps recruit young MDs, PhDs, or PhDs to eye research and support promising junior ophthalmology faculty. The \$300,000 grant is payable for up to four (4) years.</p>				
006934	Unrestricted Grants		Research to Prevent Blindness	01-Jul-2020	115,000 USD
	<p>Contact Name Pattie Moran</p> <p>Contact Telephone 646-892-9566</p> <p>Contact Email pmoran@rpbusa.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Deadline Dates (ALL) 01-Jul-2020

Synopsis Unrestricted Grants provide opportunities for creative planning and maximum flexibility in developing and expanding eye research programs. These annual \$115,000 grants provide opportunities for creative planning that go beyond the scope of restricted project grants which scientists normally depend upon for their principal support.

006935	Challenge Grants		Research to Prevent Blindness	01-Jul-2020	300,000 USD
--------	----------------------------------	--	-------------------------------	-------------	-------------

Contact Name Pattie Moran

Contact Telephone 212-752-4333

Contact Email pmoran@rpbusa.org

Sponsor Website [Link to sponsor website](#)

Program URL [Link to program URL](#)

Deadline Dates (ALL) 01-Jul-2020

Synopsis Challenge Grants encourage the growth of newly-emerging eye research programs or recently-appointed department heads. The Challenge Grant is designed to enhance a department's environment and capability to conduct vision research, to facilitate collaborative studies of the visual system, and to attract researchers to the department

070892	RPB International Research Collaborators Award		Research to Prevent Blindness	15-Jun-2020	75,000 USD
--------	--	--	-------------------------------	-------------	------------

Contact Name Pattie Moran

Contact Telephone 646-892-9566

Contact Email pmoran@rpbusa.org

Sponsor Website [Link to sponsor website](#)

Program URL [Link to program URL](#)

Deadline Dates (ALL) 15-Jun-2020 , 01-Jul-2020

Synopsis The RPB International Research Collaborators Award promotes international collaborations through which collaborating researchers in the U.S. and outside the U.S. gain new knowledge and skills. These international collaborations have the potential to accelerate the development of treatments for blinding disorders, positively

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		affecting large populations worldwide for years to come. This award of up to \$75,000 is available to researchers from any institution of higher education in the United States. A three- to six-month stay in the other country is expected by each researcher, with a minimum stay of three months.			
046418	Science & SciLifeLab Prize for Young Scientists		Science	15-Jul-2020	30,000 USD
	Contact Name				
	Contact Telephone	202-326-6417			
	Contact Email	SciLifeLabPrize@aaas.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Jul-2020			
	Synopsis	The Science & SciLifeLab Prize for Young Scientists is awarded annually to one young scientist for outstanding life science research for which he/she was awarded a doctoral degree in the previous two years. The topic of the entrant's thesis research must be in one of the following categories: Cell and Molecular Biology; Genomics, Proteomics and Systems Biology; Ecology and Environment; Molecular Medicine.			
047482	Health Professions Education Research Investigator Award (HPE-RI)		Singapore Health & Biomedical Congress	03-Jul-2020	560 USD
	Contact Name				
	Contact Telephone				
	Contact Email	shbc_secretariat@nhg.com.sg			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	03-Jul-2020			
	Synopsis	The Singapore Health & Biomedical Congress (SHBC) provides awards for abstracts submitted for the SHBC Scientific Competition. The Health Professions Education Research Investigator Award (HPE-RI) is open to all conducting Health Professions education research in any local and overseas institutions.			
047483	Singapore Primary Care Research Award (SG-PCR)		Singapore Health & Biomedical Congress	03-Jul-2020	560 USD

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Name Contact Telephone Contact Email shbc_secretariat@nhg.com.sg Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 03-Jul-2020 Synopsis The Singapore Health & Biomedical Congress (SHBC) provides awards for abstracts submitted for the SHBC Scientific Competition. The Singapore Primary Care Research Award (SG-PCR) is open to any Doctor, Nurse and Allied health professional practicing in Primary Care.				
001413	Research Grants	St. Baldrick's Foundation		10-Jul-2020 [LOI/Pre-App]	Not Specified
	Contact Name Contact Telephone 626-792-8247 Contact Email Grants@StBaldricks.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 10-Jul-2020 [LOI/Pre-App], 28-Aug-2020 Synopsis These one-year grants are for specific research projects which are hypothesis-driven and may be laboratory, clinical or epidemiological research. While the average grant is \$100,000 or less, the proposed budget must be realistic for the project.				
001382	St. Baldrick's Scholars (Career Development Award)	St. Baldrick's Foundation		10-Jul-2020 [LOI/Pre-App]	330,000 USD
	Contact Name Laura Chung, Director of Grants Administration Contact Telephone 626-792-8247 x236 Contact Email Laura@StBaldricks.org				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	10-Jul-2020 [LOI/Pre-App], 28-Aug-2020			
	Synopsis	The St. Baldrick's Scholars program is a career development award aimed at helping develop the independent research of highly-qualified individuals still early in their careers (no more than seven years as a faculty member, post-fellowship). This is an early-career award. The Scholar award is intended to develop the independent pediatric cancer research careers of highly qualified investigators, not to support well established or senior investigators.			

067677	Grants Program	The Gibbs Family Foundation		01-Jul-2020 [LOI/Pre-App]	10,000 USD
--------	--------------------------------	-----------------------------	--	------------------------------	------------

	Contact Name				
	Contact Telephone	773-332-0323			
	Contact Email	info@thegibbsfamilyfoundation.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jul-2020 [LOI/Pre-App], 01-Oct-2020			
	Synopsis	The Gibbs Family Foundation seeks to expand its services to the community, in particular individuals at risk of contracting or developing rare diseases such as infectious diseases, certain cancers, and neurological conditions.			